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Accordingly, the projects summarized in this thesis sought to explore the activation of the 
innate and adaptive immunity and possibly overcome human glioma cells resistance to 
apoptosis as well as their escape from host immune surveillance. Work from other areas to 
which I also contributed has been omitted (see attached reference list). 
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Introductory remark 
 
In order to give this PhD thesis more structured contours, I decided to split it into various 
chapters by projects, each consisting of an introduction, a material and methods section, the 
results paragraph and a discussion. All references as well as a summary are provided at the 
end. The introductory paragraphs on glioma biology and immunology are intended to provide 
the background for the understanding of the work that follows. This format should enable 
readers who are interested in a specific part of the work outlined here to find all relevant 
information within a concise standard format. All sections represent the state-of-the-art when 
the respective project was prepared for publication and have been supplemented with the most 
relevant recent findings. 
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I. Introduction 
 
Glioma biology 
 
Prognosis, current treatment and perspectives 
Prognosis. Glioblastomas are primary brain tumors of unknown origin. Based on the cancer 
stem cell hypothesis by Singh et al. CD133-expressing stem cells generate later progenitor 
cells (CD133-) that give rise to the mature forms of brain cells like neurons, astrocytes and 
oligodendrocytes (Fig. 1.1.a), which are all CD133- (1). Neoplastic glioma clones (Fig. 1.1.b) 
are maintained exclusively by a rare fraction of cells with stem cell properties, expressing 
CD133, which possibly could recruit for the different grades of gliomas (2): pilocytic 
astrocytoma (grade I), diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III), and 
glioblastoma (grade IV). In 2004, the prognosis of glioblastoma patients remains poor, with 
less than 5% of patients living beyond 2 years after diagnosis. While tumor removal, 
irradiation, and chemotherapy have somewhat improved patient survival in the last 30 years, 
current treatment results are still unsatisfactory (3). The reason for this failure is inherent to 
the biological properties of malignant gliomas. Malignant glioma cells are highly infiltrative 
in the brain, which prevents total tumor resection; they are also intrinsically resistant to the 
doses of radiotherapeutic and  chemotherapeutic therapies that can be safely applied to the 
brain.  
 A 
B 
Fig. 1.1.A,B Brain-cell hierarchy. A. In the normal brain, stem cells, which express the CD133 
marker and are designated CD133+, can generate new stem cells by the process of self-renewal. 
They can also produce early progenitor cells (CD133+) and later progenitor cells (CD133-) that 
give rise to the mature forms of brain cells (neurons, astrocytes and oligodendrocytes, all CD133-). 
Unlike the stem cells, progenitor cells have limited ability to replicate. B. Singh et al. (1) have 
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identified cancer stem cells. Such cells could arise from CD133+ brain stem cells, when loss of 
normal constraints results in expansion of the abnormal stem cell pool, or from early CD133+ 
progenitor cells as a result of mutations that make these cells self-renewing. In either case, the 
cancer stem cells also generate abnormally differentiated CD133- progeny that cannot self-renew 
and thus cannot form new tumors. Figure modified from (1). 
Current treatment. On the positive side, major strides have been made in the last decade in 
Cell cycle control. Tumor cells display uncontrolled proliferation. Genetic alterations 
underli
Protooncogenes. Protooncogenes can be modified by genetic alterations into genes 
that p
understanding the genetic, immunologic and biologic mechanisms that underlie the initiation 
and malignant progression of gliomas. We have gained a much clearer understanding of the 
pathways leading to glioma development. These advances are already being exploited for the 
development of new treatment approaches targeting the key molecular effectors of these 
tumorigenic pathways, regaining tumor cell cycle control, inducing glioma cell death, 
antagonizing angiogenesis, and immunotherapies. 
e this disruption in cell cycle control. Activation of protooncogenes by mutational 
events can promote mitotic signalling while loss of tumor suppressors can remove regulatory 
checkpoints. Interference with oncogenic signalling and restoration of tumor suppressor 
function are two therapeutic approaches aiming at regaining cell cycle control. 
romote tumor formation (oncogenes). Protooncogenes are activated by several 
mechanisms, including overexpression caused by gene amplification, point mutations, 
modification of regulatory elements leading to increased transcription, and gene 
rearrangements. Protooncogene products can be growth factors or their receptors, like 
epidermal growth factor (EGF), EGF receptor (EGFR), signal transducing proteins (ras, 
phosphatidylinositol 3-kinase), transcription factors (myc, fos, jun), and suppressors of 
apoptosis B cell lymphoma/leukemia-2 (BCL-2), B cell lymphoma mutant, extra long (BCL-
XL). In gliomas (4), protooncogene activation occurs as the result of gene amplification with 
or without gene rearrangement. Examples include EGFR, murine double minute 2 
(MDM2),cyclin-dependent kinase 4 (CDK)4, CDK6, and the platelet-derived growth factor 
receptor-α. Persistent oncogenic signals can augment the proliferation of cells and render 
them resistant to irradiation (5) and apoptosis (6, 7). Because of these properties, EGFR (8, 9) 
and the tyrosine kinase signalling have become a major focus of antiproliferative therapy. 
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While many of these antiproliferative strategies have great potential, they are unlikely to 
succeed on their own because gliomas are genetically unstable and because of intertumor and 
intratumor heterogeneity. 
Tumor suppressor genes. Tumor suppressor genes hold their name because they are 
instrumental in protecting a cell from becoming transformed. Typically, these genes are lost in 
two steps, one allele is deleted and the other acquires an inactivating mutation. A number of 
target genes for these deletions have been identified: Phosphatase and tensin homolog deleted 
on chromosome ten (PTEN) (10q) (10-12) and others directly regulate the cell cycle (TP53, 
p16INK4A, p14ARF) (13-15). Therapeutic strategies aiming at restoring tumor suppressor 
function in gliomas have essentially focused on p53. Preclinical models have shown that 
restoration of p53 function in glioma cells using retroviral or adenoviral TP53 delivery 
induces cell cycle arrest and apoptosis (16). Other strategies are based on the restoration of 
p53 function  using small molecules such as CP-31398 stabilizes the active conformation of 
p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53 (17). 
 
Prodrug/suicide gene therapy. Gene-directed enzyme prodrug therapy is a two step 
therapeutic approach for cancer gene therapy. In the first step, the transgene is delivered into 
the tumor and expressed. In the second step a prodrug is administered and is selectively 
activated by the expressed enzyme. The first  system described was the thymidine kinase gene 
of the Herpes Simplex virus (HSV-TK) in combination with the prodrug Ganciclovir (GCV). 
The enzyme phosphorylates the prodrug to GCV triphosphate, an inhibitor of DNA synthesis 
that leads to cell death. Prodrug/suicide gene therapies lead to the killing of infected as well as 
nontransduced tumor cells. This useful feature, coined “bystander effect”, is believed to be 
mediated by the cell-to-cell transfer of phosphorylated ganciclovir through gap junctions as 
well as an immune response (18). Phase I/II clinical trials with the GCV/TK system showed 
low toxicity and preliminary indications of tumor response. Unfortunately, when efficacy was 
tested in newly diagnosed gliomas in a phase III randomized trial, no significant advantage 
over standard therapy was found(19). One of the limitations of the GCV/TK system is poor 
blood-brain barrier penetration of GCV and insufficient HSV-TK gene transduction of tumor 
cells. Local infusion of ganciclovir to the tumor area or the use of different prodrug/suicide 
gene systems (cyclophosphamide/cytochrome P450 2B1), in which the prodrug can cross the 
blood-brain barrier, are currently being developed (20, 21). 
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Apoptosis induction. Apoptosis induction is an attractive therapeutic approach that 
tries to trigger the natural mechanism of programmed cell death in tumor cells while sparing 
normal cells. This has been tried in different ways that all take advantage of the fact that 
tumor cells show a degree of apoptosis “priming” as the result of cell transformation. For 
example, glioma cells express death receptors of the tumor necrosis factor (TNF) receptor 
family while normal astrocytes do not. Their ligands include TNF-α, FasL and TRAIL. While 
all three can induce apoptosis in tumor cells, TRAIL shows the lowest toxicity to normal 
tissue, principally the liver (22, 23), and is therefore a promising new therapeutic agent for 
cancer (7). TRAIL induces apoptosis by binding to death receptors DR4 (TRAIL-R1) and 
DR5 (TRAIL-R2). These are type I transmembrane receptors containing an intracellular death 
domain (24) that is involved in the assembly of a death-inducing signal complex. This induces 
caspase-8 cleavage, activation of downstream effector caspases (caspase-3 and others), and 
leads to programmed cell death. Malignant glioma cells mostly express DR5 and are sensitive 
to TRAIL-induced apoptosis (25). While this is a novel and promising strategy to kill tumor 
cells, concerns regarding potential hepatotoxicity have so far prevented its testing in the 
clinic. 
Inhibition of angiogenesis. Tumor angiogenesis, the process by which a tumor attracts 
endothelial cells to form a tumor-specific vascular network, has raised considerable interest as 
a therapeutic target. The rationale is that as a consequence of every microvascular cell killed 
an additional 50 to 100 tumor cells will die because they depend on the vascular supply of 
oxygen and nutrients (26). Furthermore, it is believed that because vascular cells are 
nontransformed they will not easily develop resistance to anti-angiogenesis treatment like 
genetically instable tumor cells do. Angiogenesis is triggered by the release of angiogenic 
stimulators by the tumor cells. This can occur as the result of genetic alterations as well as 
through the activation of the physiologic response to hypoxia. Hypoxia, a reduction in partial 
oxygen pressure, is a characteristic feature of a growing tumor and results from both tumor 
outgrowth of pre-existing co-opted vascular supply and through tumor-induced normal 
vascular regression events. Hypoxia activates hypoxia-inducible factor, a transcription factor 
inducing the transcription of genes encoding angiogenic stimulators like the vascular 
endothelial growth factor (VEGF) family. Expression of VEGF is particularly evident in 
regions surrounding necrosis in gliomas where hypoxia is most severe (27). A great number 
of therapeutic strategies aim at inhibiting the pro-angiogenic forces operating in the tumor as 
well as modulating the expression of angiogenesis inhibitors. This is achieved through small 
molecular compounds or antibodies that block multiple stages of the neovascularization 
 18
process, the use of soluble endogenous inhibitors as well as gene therapy approaches. A large 
number of pharmacotherapeutic agents are tested in phase I and II clinical trials for the 
treatment of newly diagnosed or recurrent malignant gliomas, including agents that target the 
positive regulators of angiogenesis (28). Endogenous inhibitors of angiogenesis (IFN-γ, IL-
12, angiostatin, endostatin) are also evaluated in phase I/II trials for gliomas (29). 
Immunotherapy. The extensive spread of tumor cells in the brain presents a particular 
challenge. Surgical resectability is a major limitation and radiatiotherapy and chemotherapy 
have their limits in moderate efficacy and neurotoxicity. Therefore, immunotherapy has for a 
long time been particularly attractive as a “microsurgical tool” to eliminate single infiltrating 
cancer cells while sparing normal brain. This putative highly specific antitumor cytotoxicity  
depends on the identification of specific tumor antigens. While only a limited number of 
glioma-associated antigens were identified over the last 20 years (Table 1), the recent 
advances in screening for new brain tumor-associated antigens has been more successful. 
Besides the classical antibody based serological screening of cDNA expression libraries 
(SEREX) or screening for cytolytic T cell clones via eucaryotic expression of such libraries, 
several novel methods are available today (30). Our progress in the understanding of the 
molecular mediators of the immune response will also help overcome the well known but 
incompletely understood immune escape mechanisms used by tumors (31). Several routes of 
administration for immunologic medicine will have to be evaluated once identification of 
immunologically active glioma peptides has been achieved. Immunotherapy includes 
molecules, that can be antibodies or ssRNA, or cells like T cells or lymphokine activated 
killer cells, and activated tumor infiltrating lymphocytes. A number of antibodies coupled to 
radioisotopes or immunotoxins have been tested in clinical trials (32, 33). 
Active (vaccine) immunotherapy augments an existing or creates a new antitumor immune 
response in the host. These cancer “vaccine” approaches have initially focused on cytokine 
gene therapy (IL-2, IL-4, IL-12, GM-CSF and interferons) to generate or augment antitumor 
immunity (34-37). Many of the recent efforts have capitalized on our better understanding of 
the role of antigen-presenting cells in the initiation of the immune response. Professional 
antigen-presenting cells (dendritic, microglial, and Langerhans cells) will capture tumor 
antigens, process them, and present them on major histocompatibility complex molecules to T 
cell receptors. In addition, T cell activation requires a second stimulatory signal provided by 
co-stimulatory molecules (e.g., B7 or CD70 on antigen-presenting cells engaging CD28 or 
CD27 on T cells). Once properly activated, these T cells will launch a potent tumor-specific 
immune response. Recent approaches have attempted to prime dendritic cells with antigen in 
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vitro and to reinject these cells into the patient to activate a T cell response. This peripheral 
immunization has been shown to elicit immune responses against central nervous system 
tumors in vivo (38).  
 
Category of antigen   Antigen Clinical trials 
 
Unique mutant antigens (Ag) EGFRvIII 
Mutated ras 
 
Mutated p53 
Mutated p16 
Anti-EGFR MAb 
Farnesyltransferase 
inhibitors 
ONYX-015 
No 
 
Cancer-testis Ag melanoma-associated antigen 
(MAGE-1) 
MAGE-3 
B-melanoma antigen (BAGE) 
G-antigen (GAGE) 
IL-13R 
Sox6 
No 
 
No 
No 
No 
IL-13 PE38QQR 
No 
 
Tissue of origin-related Ag 
(differentiation antigens) 
gp100 
Tyrosinase 
Tyrosinase-related protein-1 
Tyrosinase-related protein-2  
MART-1 
No 
No 
No 
No 
No 
 
Normal proteins with selective 
or over-expression in brain 
cancer 
Wild-type EGFR 
Her-2/neu 
Tenascin 
gp240 
Proteoglycan chon. sulfate Ag 
SART-1 
Granulin 
Anti-EGFR Mab 
Herceptin 
MAb 81C6 
No 
No 
No 
No 
Table 1. Tumor-associated antigens in human gliomas 
 
 
Perspectives. The extensive development of central nervous system tumor research in the last 
decade may provide new clinical tools that will improve survival in patients with malignant 
gliomas. Current radiotherapy and chemotherapy regimens may have reached their limits in 
improving survival. Novel strategies for treating gliomas must be brought into clinical trials 
and will likely function best in combination with standard therapies. These advances are made 
possible by progress in the understanding of tumor genesis, tumor biology and immunology, 
including adaptive immunity as well as innate immunity, and their combination and the 
availability of novel tumor-antigens. 
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While this progress is clearly exciting, it is sobering to keep in mind the challenges that 
remain. Malignant gliomas are a very heterogeneous group of tumors, as is evidenced by the 
number and diversity of genetic mutations involved in their genesis. Genetic diversity is also 
found within a single tumor, probably a reflection of genetic instability, and likely contributes 
to the development of resistance to radiotherapy and chemotherapy by clonal evolution. 
Furthermore, the highly infiltrative nature of these tumors is a tremendous challenge and the 
main reason for tumor recurrence after surgery and focal radiotherapy. Because of this 
heterogeneity and propensity to therapeutic resistance, simultaneous targeting of multiple 
components essential to the tumor’s growth and survival will maximize the chances to control 
the disease. Therapies based on immune system activation, angiogenesis inhibition, 
restoration of cell cycle control, induction of programmed cell death, and others, combined 
with the standards of radiotherapy and chemotherapy may have a significant impact on the 
disease. A further advantage of such integrated therapeutic strategies may be reduced toxicity 
and possible synergistic effects. To make this possible, additional mechanisms need to be put 
in place to foster transition of exciting preclinical work into clinical trials. 
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Tumor immunology and immunotherapy 
 
Basic immunology 
The latin word munia can be translated as responsibilities or merits. As the roman senators 
were free of responsibilities, or later free of legal prosecution, their status was called 
immunitas (negation forming prefix, lat.: im). Nevertheless it was not a roman but a greek 
historian, namely Thukydides (460-400 B.C.) who first circumscribed immunological 
incidents during a siege in “The Peloponnesian War”. People who sufferd from “pestilencial 
plague” (with Perikles as its most famous victim, 500-429 B.C.) and survived did not fall ill 
again. He did not know that he described one of the major features of the adaptive immune 
system: immunological memory.   The immune system defends our body against infections. In 
the late 19th century Robert Koch proved that infectious diseases could be evocated from 
microorganisms, causing specific illnesses with a  particular etiopathology. There are three 
major columns of the immune system: physical and chemical barriers, the innate immune 
system and the adaptive immune system. The first line of active defense against 
microorganisms is called innate immunity. However, innate immunity is unable to protect 
against a reinfection, as immunological memory is unique to adaptive immunity based on the 
“clonal selection” of lymphocytes of an existing repertoire with a multiplicity of highly 
specific receptors. Thus the immune system is able to cope with nearly any foreign antigen, as 
antigen specific lymphocytes proliferate and differentiate to “effector cells”, which in turn 
destroy these pathogens. These immune defense mechanisms require different recognition 
systems and a broad variety of effector functions to search and destroy foreign pathogens. 
Adaptive immunity is also able to build up a repertoire of memory cells differentiated by 
clonal selection, each specific for a certain pathogen. This allows for a more rapid and 
effective  reaction during a reinfection.  
 
Innate Immunity 
Innate immunity can be defined as the components of the immune system with a constant 
specificity during an individual lifetime. The first component comprises a barrier function of 
the epithelia of the body (39), as linings and covering on all external and internal body 
surfaces pose a barrier to infection. The barriers can be divided into physical and chemical 
ones, which are dermis, mucosa, mucus and cilia for the physical barriers and hydrochloric 
acid (pH=1-2) and lysozyme (degrading bacterial murein), for the chemical barriers. 
Pathogens penetrating this epithelial defense are facing a stronghold of cells and molecules 
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confining and destroying pathogens. Most importantly tissue macrophages patrol on body 
boundaries while the complement system of proteins mediates the second line of defense in 
the interstitia and blood. Other important innate cell types are granulocytes, monocytes, mast 
cells, natural killer and γ:δ T cells. The latter have some effector function besides being 
assisted by antibodies or T cells. Innate immune cells recognize pathogen-associated 
molecular patterns (PAMP), i.e. structural motifs that are conserved on pathogenic 
microorganisms (lipopolysaccharide, mannose, bacterial cell wall) and absent from eukaryotic 
cells via pattern recognition receptors (PRR). Endocytic pattern recognition receptors 
(mannose or scavenger receptors) are found on the surface of phagocytes like macrophages or 
neutrophilic granulocytes, dendritic cells and natural killer (NK) cells. Their activation 
promotes the engulfment and destruction of microorganisms (40) and the release of cytokines. 
Signalling PRR include CD14 and the group of toll-like receptors (TLR). Importantly, 
expression of TLR is not restricted to innate immune cells (41) and will be addressed in detail 
in the next subchapter.  
 
 Toll-like receptors. The discovery of the TLR as sensors of microbial molecules 
transformed the views of discrimination between self and non-self, a key requirement of any 
immune system. It turns out that much of microbial recognition is served by only a handful of 
TLR. As evolutionary successful processes are conserved, the Toll gene is found in mice, 
sharks, nematodes and plants. Toll-like receptors are regarded as a link between innate und 
adaptive immunity because they recognize PAMP like LPS, unmethylated DNA or single-
stranded RNA and in addition are able to trigger immunological adaptive responses via 
dendritic cells (42). TLR are type I integral membrane glycoproteins. On the basis of 
considerable homology in the cytoplasmic region, they are members of a larger superfamily 
that includes the interleukin1 receptors (IL-1Rs). By contrast, the extracellular region of  TLR 
and IL-1Rs differs markedly: the extracellular region of TLR contains leucine-rich repeat 
(LRR) motifs, whereas the extracellular region of IL-1Rs contains three immunoglobulin-like 
domains (Fig. 1.2.a). 
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 Fig. 1.2.a TLR structure and signalling. Toll-like receptors (TLR) and interleukin-1 receptors 
(IL-1Rs) have a conserved cytoplasmic domain, known as the Toll/IL-1R (TIR) domain. The TIR 
domain is characterized by the presence of three highly homologous regions known as boxes 1, 2 
and 3. Despite the similarity of the cytoplasmic domains of these molecules, their extracellular 
regions differ markedly: TLR have tandem repeats of leucine-rich regions (known as leucine rich 
repeats, LRR) whereas IL-1Rs have three immunoglobulin (Ig)-like domains. Figure modified 
from (43). 
The subcellular localization of different TLR correlates to some extent with the molecular 
patterns of their ligands. TLR1, TLR2 and TLR4 are located on the cell surface and are 
recruited to phagosomes after activation by their respective ligands. By contrast, TLR3, TLR7 
and TLR9, all of which are involved in the recognition of nucleic acid-like structures, are not 
expressed on the cell surface (44-46). For example, TLR9 is expressed in the endoplasmic 
reticulum and recruited to endosomal/lysosomal compartments after stimulation with CpG-
containing DNA (47). Double-stranded ribonucleic acid (dsRNA) serves as a danger signal 
associated with viral infection and leads to stimulation of innate immune cells. In contrast, the 
immunostimulatory potential of single-stranded RNA (ssRNA) was poorly understood and 
innate immune receptors for ssRNA were unknown until Bauer et al. (48) reported that 
guanosine (G)- and uridine (U)-rich ssRNA oligonucleotides derived from human 
immunodeficiency virus-1 (HIV-1) stimulated DC and macrophages to secrete interferon-
alpha and proinflammatory as well as regulatory cytokines. By using Toll-like receptor 
(TLR)-deficient mice and genetic complementation, these authors showed that murine TLR7 
and human TLR8 mediate species-specific recognition of GU-rich ssRNA. After ligand 
binding, TLR/IL-1Rs dimerize and undergo the conformational change required for the 
recruitment of downstream signalling molecules. These include the adaptor molecule myeloid 
differentiation primary-response protein 88 (MyD88), IL-1R-associated kinases (IRAKs), 
transforming growth factor-β (TGF-β)-activated kinase (TAK1), TAK1-binding protein 1 
(TAB1), TAB2 and tumor necrosis factor (TNF)-receptor-associated factor 6 (TRAF6) (49, 
50). MyD88-deficient mice do not produce TNF or IL-6 when exposed to IL-1 or microbial 
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components that are recognized by TLR2, TLR4, TLR5, TLR7 or TLR9 (50, 51) . Thus, 
MyD88 is essential for responses against a broad range of microbial components. However, 
closer study of MyD88-deficient cells has revealed the  
 
 
 
Fig. 1.2.b.  Involvement of TIR domain-containing adaptors in TLR signalling pathways. The 
Toll/IL-1-receptor (TIR)-domain-containing adaptor molecule MyD88 mediates the TLR-
signalling pathway that activates IRAKs and, and leads to the activation of the IKK (inhibitor of 
nuclear factor-κB (IκB)-kinase) complex which consists of IKK-α, IKK- β and IKK-γ. This 
pathway is used by TLR1, TLR2, TLR4, TLR5, TLR6, TLR7 and TLR9 and releases NF-κB from 
its inhibitor. NF-κB then translocates to the nucleus and induces the expression of inflammatory 
cytokines. TIRAP, a second TIR-domain-containing adaptor protein, is involved in the MyD88-
independent pathway. The non-typical IKKs, IKK-ε and TBK1 mediate activation of IRF3 
downstream of TRIF. A fourth TIR-domain-containing adaptor, TRAM, is specific to the TLR4-
mediated, MyD88-independent/TRIF-dependent pathway. Modified from (43). 
 
existence of MyD88-dependent and -independent pathways, both of which mediate signalling 
in response to LPS. The MyD88-independent pathway was further characterized by 
determining the genes expressed in MyD88-deficient macrophages following exposure to LPS 
(52). A number of genes known to be interferon (IFN)-inducible genes were identified, such 
as glucocorticoid-attentuated response gene 16 (GARG16), immunoresponsive gene 1 (IRG1) 
and the gene encoding CXC-chemokine ligand 10. In addition to inducing the expression of 
IFN-inducible genes, the MyD88-independent pathway leads to the LPS-mediated maturation 
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of dendritic cells (53). When cultured with LPS, MyD88-deficient bone marrow-derived DC 
upregulate the cell surface expression of co-stimulatory molecules, such as CD40, CD80 and 
CD86 and induce the proliferation of T cells. In contrast, TLR4-deficient DC fail to mature in 
response to LPS, indicating that DC maturation proceeds in a MyD88-independent manner 
(53). The discovery of the MyD88-independent pathway led to the characterization of adaptor 
proteins: TIRAP (TIR-domain-containing adaptor protein; also known as MyD88-adaptor-like 
protein, MAL); TRIF (TIR-domain-containing adaptor protein inducing IFN-β; also known as 
TIR-domain-containing molecule 1, TICAM1); and TRAM (TRIF-related adaptor molecule; 
also known as TIR-domain-containing molecule 2, TICAM2) (Fig. 1.2.b). 
 
Induced-self and missing-self recognition. NK cells mediate cellular cytotoxicity and 
produce chemokines and inflammatory cytokines such as IFN-γ and TNF (54). They are 
important in attacking pathogen-infected cells, especially during the early phases of an 
infection. They are also efficient killers of tumor cells and are believed to be involved in 
tumor surveillance (55). The hypothesis that NK cells exert an immunoregulatory effect is 
supported by recent evidence of “crosstalk” with DC (56). Unlike B and T cells, receptor 
genes of NK cells do not undergo a variable-diversity-joining (VDJ) recombination or 
sequence diversification in somatic cells (57-59). NK cells use a multiple receptor recognition 
strategy whereby an individual NK cell can be triggered through various receptors 
independently or in combination, depending on the ligands presented by the target cell (58, 
60). Besides recognition of pathogen-encoded molecules, NK cells use the so called “induced-
self” recognition strategy, exemplified by the NK group 2D (NKG2D) receptor. NKG2D 
recognizes self proteins that are upregulated on the surface of most tumors and many infected 
cells. NKG2D, like Ly49H, is encoded in the NK gene complex and a lectin-like type 2 
transmembrane receptor (61). The receptor is expressed by all NK cells and by certain T cell 
subsets. The NKG2D ligands are type I transmembrane proteins encoded by the host genome: 
they include MHC class I chain-related A chain (MICA) or B chain (MICB) in humans (62) 
and a diverse family of ligands shared by human and mice called the retinoic acid early 
transcripts (RAET1) family, which includes Rae-1, H-60 and murine UL16-binding protein-
like transcript 1 (Mult1) (63-66) in mice and the UL16-binding protein (ULBP) or human 
Rae-1 proteins in humans (67). All the ligands are distant relatives of MHC class I molecules 
and adopt a MHC class I-like structure. However, none associate with β2-microglobulin and, 
with the exception of human MICA and MICB, most of the corresponding genes are located 
in a gene cluster separate from the MHC. The expression patterns of different NKG2D ligands 
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differ and are complex. In general, however, it seems that ligands are expressed poorly on the 
surface of normal cells but are often upregulated in tumor cells (68) or infected cells. Ligand 
mRNAs are upregulated in cells infected with cytomegalovirus (69). It seems that cells use 
intrinsic signals associated with tumorigenesis as well as extrinsic and/or intrinsic signals 
associated with infections to regulate expression of NKG2D ligands. Ligand expression by 
target cells provokes NK cells to attack and can enhance antigen-specific CD8+ T cell 
responses. In vivo, ligand expression by subcutaneously transferred tumor cells incites 
immune rejection of the tumor (70, 71). Thus, the ligand upregulation that occurs normally in 
tumorigenesis may activate immune responses that can in some cases eliminate the tumor 
cells or impede their growth or spread. In the case of certain human tumors evasion may take 
place by shedding of a soluble form of the MICA ligand into the circulation where it binds to 
NKG2D on lymphocytes and desensitizes the cells to subsequent stimulation via NKG2D 
(72). At least three other stimulatory receptors have been linked to NK-mediated lysis of 
tumor cells. NKp46, NKp44 and NKp30 are all members of the immunoglobulin superfamily 
(73-75). Not the induced- but the missing-self recognition was the first strategy for NK cells 
being discovered (76). The principle is that the NK cell is inhibited by receptors specific for 
proteins expressed on the surface of normal cells. Strong inhibitory interactions can even 
prevent the lysis of target cells that express ligands for stimulatory NK receptors. Loss of the 
self protein, which can occur as a result of infection or transformation, unleashes the NK cell 
to attack the target cell. It is likely that missing-self recognition operates only when the target 
cell also expresses ligands for stimulatory receptors expressed by NK cells. In this sense, 
missing-self recognition occurs in concert with various forms of stimulatory recognition, 
rather than as a completely independent form of recognition. The mechanism of missing-self 
recognition was elucidated by the discovery of MHC-recognizing inhibitory receptors, 
including Ly49 receptors (77), the killer immunoglobulin-like receptors (KIRs) (78, 79), the 
leukocyte immunoglobulin-like receptors (LIRs) (80, 81) and the CD94-NKG2 receptors (82-
84). The Ly49 and CD94-NKG2 receptors are lectin-like type II transmembrane proteins 
encoded in the NK gene complex whereas the KIR and LIR genes are immunoglobulin-like 
type I transmembrane proteins and are encoded in the leukocyte receptor gene complex. Ly49 
receptors have a prominent function in mouse NK cells but are not functionally expressed in 
humans whereas KIR and LIR are important in humans but not in mice. Genes encoding 
CD94-NKG2A are transcribed in both species. It seems that the activation state of NK cells is 
regulated by the equilibrium between the input received from stimulatory (NKp, NKG2D) and 
inhibitory (NKG2A, KIR) NK cell receptors (57). Cellular stress like viral infection or 
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malignant transformation induces MHC class I chain-related proteins A and B (MICA/B) and 
UL-16 binding proteins (ULBP1-4), all of which are absent from normal somatic cells. Some 
expression is found on intestinal epithelia, most likely due to the continuous presence of 
symbiotic bacteria on these tissues. Activation of the NKG2D receptor by these ligands (62, 
67) may overcome the inhibitory effect of “self recognition”. Activated NK cells would then 
induce apoptosis in the recognized target cell by releasing cytotoxic granules containing 
perforin and granzyme B and by upregulating death ligands (85-87). This NK cell response 
may therefore clear malignant cells before they can form a tumor (88).  
 
Adaptive Immunity 
The five major features of the adaptive immune system are specificity, diversity, memory, self 
restriction and the “self/non-self” discrimination. Adaptive immunity is mediated by B and T 
cells. Their receptors, BCR on B cells (with their secreted form Ig) and TCR on T cells, are 
able to adapt their specificity during their lifetime. Ig and TCR are highly variable molecules 
with a great variety in the variable (V)-region of the molecule which is binding the antigen. Ig 
are binding many chemically different antigens. α:β-TCR recognize peptide fragments of 
foreign proteins when presented by MHC molecules on cell surfaces. The stem cells of the 
innate and adaptive immune system originate in the bone marrow. 
In chicken a special gland, the bursa fabricii was eponymous for the B cells (in humans one 
can bear in mind “B cells” for “bone marrow”, as the “T lymphocytes” maturate in the 
“thymus”, although alike originating in the bone marrow). 
 
CD27/CD70 costimulation. Effective activation of T cells not only requires signals 
from TCR after its interaction with peptide-MHC complexes but also costimulatory signals. 
Costimulatory molecules affect the level of T cell activation by enhancing T cell receptor 
signalling (89) or providing additional signals that increase expansion of T cell populations 
and their responses. The best defined costimulatory signals are mediated by interactions 
between CD28 and B7 as well as ICOS and ICOSL (90) and between TNF receptor family 
members and their ligands (91), exemplified by CD27 and CD70, OX40 and OX40L and 4-
1BB and 4-1BBL (Fig. 1.3). 
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Fig. 1.3. Representation of the costimulatory ligands of the TNF family and their receptors. 
Ligands of the TNF family are homotrimeric type II transmembrane proteins with a carboxy-
terminal extracellular domain and an amino-terminal intracellular domain. The C-terminal 
extracellular domain, also known as the TNF homology domain, has 20-30% amino acid identity 
between the superfamily members. The TNF receptor family molecules are type I transmembrane 
monomers (extracellular N-terminus and intracellular C-terminus) and are thought to trimerize 
when interacting with their ligands. The receptors are characterized by cysteine rich repeats in the 
extracellular domain. Soluble forms of receptors have been identified. Modified from (92). 
The constitutive expression pattern of CD27 is at low-to-medium levels (93) whereas 
expression of OX40 and 4-1BB is inducible several hours after recognition of antigen (94, 
95). CD70 seems not to be constitutively expressed, neither by naïve T cells (96) nor by 
resting or immature APC (Table 1), but is inducible 24 hours to several days after activation, 
largely coinciding with the peak level of CD27 expression by T cells (97). Since CD27 is not 
fully expressed until after activation and since CD70 has to be induced, this interaction might 
indicate a second round of costimulation during the clonal expansion phase of T cell 
responses. 
 
Table 1. Expression characteristics of CD27 and CD70 molecules by T cells and APCs. 
Table modified from (92). 
Molecule T cells APC 
 Naïve Effector Memory Resting Activated 
CD27 ++ +++ ++/- - B 
CD70 - +++ - - B,DC,MΦ 
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CD27 is a costimulating receptor of mature T and B cell responses. Clinical data revealed that 
CD27 can be used as a marker for human lymphoid malignancies (98, 99). Several in vitro 
blocking studies have indicated that CD27 is also important in the initial stages of a T cell 
response: proliferation and cytokine secretion were inhibited when the CD27-CD70 
interaction is disrupted (100-102). T cells that lack CD27 initially divide normally, but then 
proliferate poorly 3 or more days after activation (103). This indicates that CD27 participates 
in promoting the initial expansion of the naive T cell population, by either early suppression 
of T cell death or by acting on the cell cycle to allow sustained division 2-3 days after 
activation. This is reinforced by in vivo studies of CD27-deficient mice, in which lower 
numbers of antigen-specific CD4+ and CD8+ T cells are seen at the peak of primary responses 
(days 4-8) and fewer memory T cells develop over 3 or more weeks (103). These observations 
have been supported by the analysis of mice that express a CD70 transgene in B cells (104), 
and from studies in which mice were immunized with CD70-transfected tumor cells (105, 
106). In the former, widespread expression of CD70 leads to increased numbers of 
memory/effector T cells and, in the latter, priming of tumor-reactive CD8+ and CD4+ T cells 
is augmented. However, definitive mechanistic studies are still lacking, and it is unclear 
exactly when and how CD27-CD70 interactions influence T cell priming. Because expression 
of CD27 is upregulated early after T cell activation, it might mainly deliver signals that 
maintain early proliferation, prior to the peak of the effector response. 
 
Immunosuppression by TGF-β. Secretion of TGF-β has been found in a variety of 
cancer types including malignant glioma, breast cancer, prostate cancer and leukemia. TGF-β 
is one of the most potent immunosuppressive cytokines yet characterized. It is capable of 
affecting the proliferation, activation and differentiation of cells participating in both the 
innate and acquired immune response. The proliferation of thymocytes, T cells, B cells, 
natural killer (NK) cells, monocytes and macrophages is inhibited by TGF-β. In addition to 
suppressing proliferation, TGF-β has been shown to induce apoptosis in B and T cells. Of 
particular importance is its effect on cytotoxic T lymphocytes (CTLs) which are probably 
required for anti-tumor immunity. TGF-β down-regulates many of the processes necessary for 
CTL activation. This is done by shifting the Th1-Th2 balance towards Th2, inhibiting Th1 
cytokines including IL-12, downregulating IL-2 receptors on T cells, inhibiting antigen 
presentation on MHC class II molecules and downregulating adhesion and costimulatory 
molecules. Inhibiting antigen presentation prevents T cells from recognizing the cancer cells 
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as foreign and downregulating adhesion molecules prevents T cells from even getting to the 
tumor site. If the T cells do manage to get to the tumor site and recognize the tumor, a lack of 
costimulation can cause the Th cells to become anergic instead of activated. Shifting the Th 
balance towards Th2 changes cytokines produced to ones such as IL-4 and IL-10 that 
mediated a humoral response appropriate for intercellular invaders, not cancer cells. Inhibiting 
Th1 cytokine production further prevents the appropriate, cell-mediated immune response 
from taking place. TGF-β activates a serin/threonine kinase complex that phosphorylates 
Smad2 and Smad3. Once activated, Smads accumulate in the nucleus and form transcriptional 
complexes with Smad4 and different DNA binding partners, coactivators, and corepressors. 
These genes target different genes, depending on their composition (107). Carcinoma and 
glioblastoma cells that avert TGF-β-mediated cytostasis may use this factor with impunity to 
exacerbate their own proliferative, invasive, and metastatic behavior (108). The TGF-β 
cytostatic program involves transcriptional activation of the cyclin-dependent kinase 
inhibitors p21Cip1 and p15Ink4b and repression of the growth-promoting transcription factors 
c-myc and Id1-Id3. Cooperatively, these gene responses mediate cell cycle arrest at G1. Many 
types of cancers have taken advantage of the regulatory role of cytokines to down-regulate 
appropriate immune responses targeted at destroying cancer cells. They do this by secreting 
immunosuppressive cytokines that induce generalized and specific inhibition of immune 
responses. Cancer patients often fail to mount sufficient or appropriate immune responses to 
their cancers. 
 
Experimental overwiew 
 
Restoring immune surveillance via CD70/CD27 interactions mediates glioma eradication 
The first part of the results section of this PhD thesis describes a novel strategy for the 
reinduction of immune surveillance via CD70/CD27 interactions against mouse glioma cells. 
In this context, delivery of co-activatory signals via CD70 was investigated. Showing the 
imbalance of effector cell formation by immunosuppressive properties of glioma cells, the in 
vitro micromilieu proved to be apoptotic for immune cells (109), whereas the stimulatory 
capacity of CD70 outweighed its potential to transmit apoptotic stimuli in vivo as outlined in 
chapter 2. Furthermore, in the presence of apoptotic tumor cells, CD70 may trigger 
protective anti-tumor memory against wildtype glioma cells inoculated intracranially in the 
immunocompetent SMA-560 VM/Dk mouse model. The present work also sought to 
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characterize the classes of cell types involved in this anti-tumor immunity, showing 
participation of NK cells in the innate phase of defense via CD1nu/nu mice, wheras during 
adaptive phases cytotoxic T cells seem to predominate. Another question was if TGF-β could 
interfere whilst tumor formation. This approach was addressed using a novel TGF-β-RI 
kinase inhibitor, SD-208, which abrogates TGF-β signalling (110). Cormary et al. have also 
shown strong anti-tumor effects in  a mouse model using a soluble form of CD70 (111) 
evading the need of a genetic approach to transduce the whole tumor. This is relevant since 
gliomas are thought to relapse from transmigrated single cells. 
 
ssRNA generates potent danger signals and elicits immunological memory 
Bacterial DNA (112) or its synthetic version, CpG ODN (OligoDeoxyNucleotide) generate 
danger signals through Toll-like-receptor (TLR) 9 in the context of vaccinations and 
immunotherapies. In vitro, CpG ODN trigger a strong activation of human plasmacytoid DC 
and B cells. In vivo, intra-tumor injection of CpG ODN in mice results in tumor regression 
(113). This immunity is mediated by the release of Th1-type cytokines, the production of 
antibodies, and the induction of CTL and T helper cells. On the other hand, CpG ODN are 
very stable and trigger severe side effects in mice (114). Such uncontrolled overstimulation 
may prevent the generalization of CpG ODN as a immune stimulatory tool. Like DNA, RNA 
has also been shown to generate potent danger signals dependening on TLR-signalling. 
Unlike CpG ODN, ssRNA is very sensitive to degradation by ubiquitous RNases and must be 
protected in vitro by encapsulation in liposomes (48, 115), condensation to a cationic peptide 
(Scheel et.al., unpublished data) or chemical modification by phosphothioate (ORN) 
backbones (42) to show immune stimulatory potency. ssRNAs are recognized by TLR7 and -
8 (48). TLR7 is expressed in mice in the cytosole of DC. In humans, TLR7 is expressed in the 
cytosole of PDC, B cells, monocytes (41) and eosinophils (13), TLR8 mainly in the cytosole 
of monocytes (41). TLR7 and 8 are not only expressed on different cell types, but also trigger 
different responses. The activation of cells by ssRNA is MyD88-dependent (42) whereas 
stimulation with dsRNA is partially MyD88-independent (Hilf et al., submitted). Thus, 
although the adjuvant and immunotherapeutic capacities of dsRNA were reported earlier, it is 
of interest to study the immune stimulatory properties of ssRNA. Ultimately, the interesting 
characteristics of these two types of RNA molecules may be combined in a potent RNA-only 
adjuvant or therapeutic tool. Based on this rationale ssRNA was used to generate an anti-
tumor treatment in mice and compared to CpG-DNA (chapter 3). Our promising pre-clinical 
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evaluation of ssRNA as an anti-tumor treatment is currently being translated from the 
laboratory to the clinic. 
 
TGF-β as a principal target for immunotherapy of malignant gliomas 
The strongest mediator of glioma-induced immunosuppression is TGF-β. TGF-β2 was named 
“glioblastoma-derived immunosuppressive factor” when it was discovered by Fontana et al. 
in 1987 (116, 117). TGF-β is the cytokine with the strongest known immunosuppressive 
activity. The direct effects of TGF-β on immune effector cells are well-documented (118) and 
have been further characterized in our group using the novel receptor kinase inhibitor SD-208 
(chapter 4). TGF-β is synthesized as a pre-pro-TGF-β polypeptide that contains a signalling 
peptide (pre) (residues 1-29), the pro-region (residues 30-278) and the mature TGF-β moiety 
(residues 279-390) (119). Activation to the mature 12.5 kDa TGF-β1, that needs to dimerize to 
exert its biological effects, depends on the action of subtilisin-like proprotein convertases such 
as furin, as shown for purified proteins obtained from cell culture supernatants in a cell-free 
system (120). Subtilisin-like proprotein convertases such as furin are thought to mediate TGF-
β processing. In chapter 5 we report that human malignant glioma cell lines express furin 
mRNA and protein, exhibit furin-like protease (FLP) activity and release active furin into the 
cell culture supernatant. FLP activity is not modulated by exogenous TGF-β or by 
neutralizing TGF-β antibodies. Exposure of LN-18 and T98G glioma cell lines to the furin 
inhibitor, dec-RVKR-cmk, inhibits processing of the TGF-β1 and TGF-β2 precursor 
molecules and consequently the release of mature bioactive TGF-β molecules. Ectopic 
expression of PDX, a synthetic antitrypsin analog with antifurin activity, in the glioma cells 
inhibits FLP activity, TGF-β processing and TGF-β release. Thus, subtilisin-like proprotein 
convertases may represent a novel target for the immunotherapy of malignant glioma and 
other cancers or pathological conditions characterized by enhanced TGF-β bioactivity 
 
MICA/NKG2D-mediated immunogene therapy of experimental gliomas 
The failure of conventional cancer therapy renders glioblastoma an attractive target for 
immunotherapy. Tumor cells expressing ligands of the activating immunoreceptor NKG2D 
stimulate tumor immunity mediated by NK and CD8+ T cells. Chapter 6 reports that human 
glioma cells express the NKG2D ligands MICA, MICB and members of the ULBP family 
constitutively. However, glioma cells resist NK cell cytolysis due to high MHC class I antigen 
expression. We investigated if plasmid-mediated or adenovirus-mediated (Ad-MICA) 
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overexpression of MICA enhances glioma cell sensitivity to NK and T cell responses in vitro. 
Furthermore we analyzed if the growth of subcutaneous and intracerebral LN-229 human 
glioma cell xenografts in nude mice and of SMA-560 gliomas in syngeneic VMDk mice is 
affected by MICA expression. Glioma cells forming progressive tumors after implantation of 
stably MICA-transfected human LN-229 cells have lost MICA expression, indicating a strong 
selection against MICA expression in vivo. Rejection of MICA-expressing SMA-560 cells in 
VMDk mice results in protective immunity to a subsequent challenge with wild-type tumor 
cells. Finally, the growth of syngeneic intracerebral SMA-560 tumors is inhibited by the 
peripheral vaccination with Ad-MICA-infected irradiated tumor cells, and vaccination results 
in the immune cell activation in the NK and T cell compartments in vivo. These data 
commend MICA immunogene therapy as a novel experimental treatment for human 
malignant gliomas. By targeting TGF-β (chapters 4 and 5) the relief of glioma-induced 
immunosuppression could be combined with the active induction of NK and T cell responses 
against cancer cells.  
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II. CD70/CD27 interactions and the immune response to malignant glioma: balancing 
immune effector formation 
A related manuscript has been submitted to Journal of Immunology, 2005 January 
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Introduction 
 
The protein encoded by the CD70 gene (121) is a type II transmembrane protein 
physiologically expressed on mature DC and activated T and B cells, but not on resting 
lymphocytes. CD70 belongs to the tumor necrosis factor family. Its receptor, CD27 
(TNFRSF7) (122), a type I glycoprotein and member of the TNF receptor family, is 
expressed constitutively by T and NK cells and acquired by B cells after activation (123). 
CD27 counteracts apoptosis in primed T cells and thereby promotes the accumulation of 
cytolytic effector cells as well as T cell memory (124, 125). Deliberate constitutive CD70 
expression on B cells in transgenic mice thus allows the rejection of poorly immunogenic 
tumors (125). CD70/CD27 interactions also play a role in regulating B cell expansion and 
consequent plasma cell formation (126, 127), and the cytotoxic function of NK cells (124). 
Soluble CD70-secreting cells induce T cell-mediated inhibition of wild-type tumor growth 
(111) in immunocompetent mice. In a RMA-S tumor model (128), CD70/CD27 interactions 
provide a key link between innate NK-mediated and adaptive T cell tumor rejection. 
However, chronic stimulation of CD27 in CD70 transgenic mice results in a progressive 
conversion of naïve T cells into effector-memory cells. This has no effect on immunity 
towards a challenge with vaccinia virus, but leads to progressive B (104) and T cell 
depletion, rendering the mice susceptible to opportunistic infections (129). 
Immune stimulatory signals transduced via CD27 are mediated by the adaptor proteins 
TRAF2 and TRAF5 (130) and result in the activation of NF-κB and MAPK8/JNK. In 
addition, Siva, a pro-apoptotic protein, can bind to the cytoplasmic tail of CD27 and has been 
implicated in apoptosis induction via CD27. Mouse Siva-1 and Siva-2 both bind to CD27 but 
differentially transmit apoptotic signals. The shorter alternate splice form Siva-2 has no death 
domain homology region (131) and thus cannot induce apoptosis.  
The major focus of our previous studies was the immune privilege created by human 
glioblastoma cells which involves the release of soluble factors such as TGF-β, IL-10 and 
prostaglandins, as well as cell surface molecules such as CD95L and HLA-G (132-134). A 
cDNA array analysis of irradiated glioma cells led to the identification of CD70 as an 
aberrantly expressed molecule in glioma cells. 
Unexpectedly, in contrast to the presumed role of CD70/CD27 interactions in lymphoid cell 
survival, CD70 expressed on glioma cells induced immune cell apoptosis rather than immune 
stimulation (109). The present work illustrates that CD70 expressed on glioma cells exhibits 
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opposing immune inhibitory and activating properties in vitro, but clearly overwhelming 
immune activating properties in mouse glioma models in vivo. 
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Materials and methods 
 
Reagents and cell lines. Purified polyclonal anti-mCD70 Abs (3B9, 6D9) and polyclonal 
anti-mCD70 F(ab’)2 fragments (3B9, 6D9) were a kind gift of R.A.W. van Lier (Amsterdam, 
The Netherlands). Mouse IL-2 and IL-10 and human TGF-β2 were from Peprotech (London, 
UK). Concanavalin A and camptothecin (CPT) were from Sigma-Aldrich Chemie 
(Taufkirchen, Germany). zVAD-fmk was from Bachem (Weil am Rhein, Germany). The 
flow cytometry reagents including FITC-labeled AnxV were from Pharmingen unless 
indicated otherwise. [methyl-3H] thymidine (925 GBq/mmol) and 51Cr (Sodium 
chromate/18.5 GBq/mg) were from Amersham Biosciences (Freiburg, Germany). SMA-560 
cells (135) were kindly provided by D.D. Bigner (Durham, NC), GL-261 cells by X.O. 
Breakefield (Boston, MA). The cells were grown in DMEM supplemented with 10% heat-
inactivated FCS (Biochrom KG, Berlin, Germany), 2 mM L-glutamine (Gibco Life 
Technologies, Paisley, UK), 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco). To 
generate glioma cell lines expressing CD70, a mouse CD70 cDNA (InvivoGen, San Diego, 
CA) was cloned into pIRES2-hygro (Clontech, Palo Alto, CA) to yield pIRES-mCD70. 
pIRES-mCD70 was transfected into SMA-560 or GL-261 cells by lipofection with 
FuGENE6 (Roche, Mannheim, Germany). The cells were subsequently screened for 
expression of mouse CD70 by flow cytometry using the FR70 mAb. Pan-specific TGF-β-
neutralizing antibody was purchased from R&D (Wiesbaden, Germany). SD-208 was kindly 
provided by SCIOS (Fremont, CA) (110). 
Animal experiments. C57BL/6 mice and CD1nu/nu mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany). Inbred VM/Dk mice were obtained from the TSE 
Resource Centre (Berkshire, UK). The generation of CD27-/- mice has been described (10). 
They were backcrossed for eight generations to a C57BL/6 background. The experiments 
were performed according to the German animal protection law. For the intracranial glioma 
model, groups of 5-6 mice aged 6-12 weeks were anesthetized and placed in a stereotaxic 
fixation device (Stoelting, Wood Dale, IL). A burr hole was drilled in the skull 2 mm lateral 
to the bregma. The needle of a Hamilton syringe (Darmstadt, Germany) was introduced to a 
depth of 3 mm. Five x 103 SMA-560 cells or 2 x 104 GL-261 cells resuspended in a volume 
of 2 µl PBS were injected into the right striatum. The mice were observed twice daily and, in 
the survival experiments, sacrificed when developing neurological symptoms, or sacrificed as 
indicated in the other experiments. For the s.c. glioma model, groups of 5 mice were injected 
106 glioma cells suspended in 0.1 ml PBS into the right flank. The mice were examined 
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regularly for tumor growth using a metric caliper and killed when tumors reached a diameter 
of more than 12 mm diameter. SD-208 was administered by oral gavage twice every second 
day (15 mg/kg) from day 3-7 post inoculation (110). 
Flow cytometry. The adherent glioma cells were detached nonenzymatically using cell 
dissociation solution (Sigma). Cell cycle analysis was performed using fixed and ethanol 
(70%)-permeabilized B, T and NK cells. RNA was digested with RNase A (Gibco). DNA 
was stained with PI (50 µg/ml). B, T and NK cell apoptosis was also analyzed by AnxV 
staining for phosphatidylserine translocated to the outer cell membrane. Fluorescence was 
measured in a Becton Dickinson FACSCalibur. SFI were calculated by dividing mean 
fluorescence obtained with specific antibody by mean fluorescence obtained with control 
antibody. 
Isolation of NK, B and T cells. Spleen cells from VM/Dk and C57BL/6 mice were depleted 
of erythrocytes by hypoosmolaric (NH4Cl 1.66% (w/v)) treatment for 5 min. T and B cells 
were isolated by negative selection using mouse Lineage Panel (Pharmingen, San Diego, 
CA) monoclonal biotinylated antibodies and streptavidin MicroBeads with the corresponding 
column system (Miltenyi Biotech, Bergisch Gladbach, Germany) to avoid nonspecific 
activation. Purity of T and B cells was > 95% CD3ε+ or B220+ by flow cytometry. 
Splenocytes, T, B and DX5+-purified NK cells were cultured in RPMI 1640 medium 
supplemented with 10% heat-inactivated FCS and 2 mM L-glutamine. For coculture 
experiments, purified splenocytes, B, T or NK cells (106/well) were cultured with SMA-560 
CD70 or hygro cells (105/well) in 24 well plates for 24-72 h.  
RT-PCR. Total RNA was extracted using the RNeasy RNA purification system (Qiagen, 
Hilden, Germany). RT-PCR for the detection of CD70 mRNA expression was performed 
according to standard procedures. The following mouse CD70 specific primers were used 
with an annealing temperature of 50.5 °C: 5´-GTAGCGGACTACT CAGTAAG-3´ (119-
138), 5´-CAAGGGCATATCCACTGAAC-3´ (587-568), yielding a 469 bp product. 
QPCR. Gene expression was measured in the ABI PRISM 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA). Primers (B&G Biotech, Freiburg, Germany) were 
selected with the Husar Genius software (DKFZ, Heidelberg, Germany) to span exon-intron 
junctions to prevent amplification of genomic DNA and to obtain amplicons of <150 bp to 
enhance efficiency of PCR amplification whenever possible. The sequences of the primers 
were as follows: mouse Siva-1: 5’-GGCCTAT AGAGATCACATATCGAG-3’(153-176), 
5’-CCTTCTGAGGCCTGAGCTTG-3’ (311-292), yielding a 159 bp product, mouse Siva-2: 
5’-GGTCTTCGGCCTTCCC AGG-3’ (111-129), 5’-CTCAGGCTTCAAACATAGCACAG-
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3’ (334-312), yielding a 224 bp product. Product specificity of each PCR product was further 
confirmed by agarose gel electrophoresis or by dissociation curve analysis. Amplification of 
specimens and serial dilutions of the amplicon standards were carried out in a total volume of 
15 µl using  2x SYBR Green Master Mix (Applied Biosystems) and primers at optimized 
concentrations. Standard curves were generated for each gene and the amplification was 90-
100% efficient as determined by the slopes of the standard curves. Relative quantification of 
gene expression was done using the comparative ∆∆CT method. 18S rRNA was used as 
housekeeping gene. 
Cytotoxicity assay. Mouse NK cells were prepared from splenocytes of VM/Dk,  C57BL/6 
or C57BL/6 CD27-/- mice and cultured with mouse IL-2 (5000 U/ml) for at least 10 d before 
use. Glioma cell targets (104/well) were labeled using 51Cr (50 µCi, 90 min) and incubated 
with effector cells at E:T ratios of 5-40. The maximum 51Cr release was determined by the 
addition of NP40 (1%). After 4 h the supernatants were transferred to a Luma-Plate TM-96 
(Packard, Dreieich, Germany) and measured in a Wallac 1450 Microbeta Plus Liquid 
Scintillation Counter (Turku, Finland). The percentage of 51Cr release was calculated as 
follows: 100 x [experimental release – spontaneous release]/[maximum release – 
spontaneous release]. 
Immunohistochemistry. Glioma or mouse brain cryosections (0.7 mm) were prepared at 
days 5 or 12 after s.c. glioma cell inoculation, fixed in acetone and blocked with 2% normal 
rabbit serum and 2% BSA. Tissue sections were stained with antibodies (1:50) to CD70 
(FR70), CD8 (53-6.7), Ly49G2 (detecting NK cells) and CD11b (M1/70, detecting 
macrophages and microglial cells) (BD Pharmingen, Heidelberg, Germany). A biotinylated 
anti-rat secondary antibody (Zymed, San Francisco, CA) was used at 1:150. Avidin 
conjugate (ABC-Elite Kit Vector, Wiesbaden, Germany) was added, and the staining was 
developed with diaminobenzidine. Mouse spleen (Ly49G2, CD11b and CD8) and thymus 
(CD70) served as positive controls. Cells were counted in high power fields (x 40 in an area 
of 400µm x 400µm). 
Statistical analysis. The experiments were performed at least three times. Significance was 
tested by Student´s t-test. P values are derived from two-tailedyt-tests.
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Results 
 
Balancing effector lymphocyte formation via CD70/CD27 interaction: increased 
immune cell apoptosis in vitro but enhanced tumor cell immunogenicity. The glioma cell 
line SMA-560 was derived from a SMA syngeneic in VM/Dk mice and does not express 
CD70 constitutively. To assess the biological effects of CD70 expression by glioma cells in a 
syngeneic tumor model, we cloned mouse CD70 into pIRES and generated stably transfected 
polyclonal SMA-560 sublines expressing high levels of mouse CD70 (Fig. 2.1.A,B). The 
ectopic expression of CD70 in SMA-560 cells had no effect on doubling time and 
clonogenicity in vitro (data not shown). Further, mouse GL-261 glioma cells, which are 
syngeneic to C57BL/6 mice, were transfected with the pIRES-CD70 plasmid. The 
overexpression of CD70 in the polyclonal glioma sublines reached a SFI of 7.1 in SMA-560 
and 6.9 in GL-261 cells. 
 
 
Fig. 2.1.A,B CD70 expression in mouse glioma cells. A,B. SMA-560 or GL-261 cells were 
transfected with pIRES-hygro (open histogram) or pIRES-mCD70 (black histogram) and assessed 
for transgene expression by flow cytometry using CD70 (FR70) antibody (A) and RT-PCR (B). 
 
 
To confirm our previous finding that CD70 expressed on glioma cells induces T cell 
apoptosis in alloreactivity assays (109), we characterized the fate of various negatively 
selected immune cell populations cocultured with syngeneic SMA-560 hygro or CD70 cells. 
There was a significant increase in the proportion of apoptotic splenocytes, T, B and NK 
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cells defined by PI flow cytometry for hypodiploid cells (Fig. 2.1.C,D) or by AnxV staining 
(data not shown) in cocultures containing SMA-560 CD70 cells compared with SMA-560 
hygro cells. The pro-apoptotic effect of CD70 appeared to depend on caspase activation since 
the broad-spectrum caspase inhibitor zVAD-fmk  was protective (Fig. 2.1.D). 
 
 
 
 
Fig. 2.1.C,D  CD70 promotes immune cell apoptosis. Syngeneic VM/Dk splenocytes, B, T or 
NK cells were co-cultured with SMA-560 hygro or CD70 cells in the absence or presence of 
zVAD-fmk (100 µM) for 72 h. Exposure to CPT (4 µM) for 6 h served as a positive control. 
Immune cells were fixed, permeabilized and stained with PI. Representative flow cytometry 
profiles for T cells are shown in C, depicting an increase in cell death from 14% to 32% in 
cocultures with hygro vs. CD70 cells. In D, data for splenocytes, B, T or NK cells are expressed as 
percentages of cells with hypodiploid DNA content (sub G0/G1 fraction). 
 
 
CD27-dependent apoptosis has been proposed to require the pro-apoptotic adaptor protein 
Siva-1 whereas its truncated form Siva-2 is thought to block apoptosis (131, 136). In 
cocultures with CD70-transfected glioma cells, an almost complete loss of Siva-1 mRNA as 
well as an increase in Siva-2 mRNA expression were observed (Fig. 2.1.E), suggesting that 
splenocytes surviving the coculture with CD70-positive glioma cells are selected for 
resistance to pro-apoptotic CD27 signalling or adapt to the CD70 challenge or both. This 
adaptation required cell-cell contact, and thus probably CD70/CD27 interactions, since it was 
not mimicked by glioma cell supernatant. Of note, a weaker alteration of the respective Siva-
1 and Siva-2 levels was also observed in T cells cocultured with control-transfected CD70-
negative cells which may reflect an adaptation to CD27-independent pro-apoptotic pathways 
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involving Siva-1 (137-139). Moreover, no changes in Siva-1 or Siva-2 mRNA expression 
were noted in response to IL-2 or TGF-β (data not shown). 
 
 
 
Fig. 2.1.E. CD70 modulates Siva expression. Syngeneic splenocytes were cocultured with SMA-
560 hygro (open bars) or CD70 (gray bars) cells for 72 h. Siva-1 and Siva-2 mRNA expression 
was assessed by QPCR and is expressed relative to untreated splenocytes (**p<0.01, t-test, CD70 
vs. hygro, n=3). 
 
T cell apoptosis induced by coculture with SMA-560 hygro or CD70 cells (Fig. 2.1.C) was 
inhibited by exogenous IL-2 in a concentration-dependent manner (Fig. 2.1.F). 
Fig. 2.1.F. IL-2 and TGF-β contribute to the apoptotic milieu in vitro. Cocultures (48 h) of 
syngeneic T cells and SMA-560 hygro (open bars) or CD70 (grey bars) cells were supplemented 
with zVAD-fmk (100 µM), mouse IL-2 (25 or 1000 U/ml), SD-208 (0.1 µM), TGF- β mAb (10 
µg/ml), isotype control mAb (10 µg/ml) or CPT (4 µM). 
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Further, apoptosis was facilitated by endogenous TGF-β since either exposure to neutralizing 
TGF-β mAb or to the TGF-β receptor I kinase antagonist, SD-208, reduced apoptosis. 
Appropriate control experiments showed that the ectopic expression of CD70 in SMA-560 or 
GL-261 glioma cells did not affect the expression of TGF-β1 or TGF-β2 mRNA as assessed 
by QPCR (data not shown). Altogether, these data corroborate in a syngeneic mouse system 
previous data from alloreactivity assays in the human system (109). However, in apparent 
contrast to the immune paralytic effects of CD70 expressed on glioma cells summarized in 
(Fig. 2.1.C-F), NK cells nevertheless lysed SMA-560 CD70 cells significantly better than 
SMA-560 hygro cells. NK lytic activity was abolished by a neutralizing CD70 antibody 
F(ab’)2 fragment, but not by an isotype F(ab’)2 fragment (Fig. 2.1.G). 
 
Fig. 2.1.G. CD70 enhances tumor cell immunogenicity. The cytotoxicity of syngeneic VM/Dk 
DX5+-selected (10 d, 5000 U/ml IL-2) NK cells was tested against 51Cr-labeled SMA-560 hygro 
(open) or CD70 cells (black) in the presence of control F(ab’)2 fragment (triangles) or CD70 
F(ab’)2 fragment (diamonds) (clone 3B9, 10 µg/ml). 
 
CD70 inhibits the growth of SMA-560 gliomas in CD1nu/nu mice. Athymic CD1nu/nu mice 
are deficient in T and B cells and therefore a suitable model to assess the role of NK cells in 
the response to tumor allo- or xenografts. The growth of s.c. SMA-560 gliomas expressing 
CD70 was significantly delayed compared with gliomas formed by hygro control cells (Fig. 
2.2.A). Similarly, there was a delay in the development of neurological symptoms and thus 
an increase in overall survival in CD1nu/nu mice inoculated i.c. with CD70-expressing SMA-
560 glioma cells (Fig. 2.2.B). 
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Fig. 2.2.A,B CD70 delays the growth of s.c. and i.c. SMA-560 gliomas in nude mice. A. 106 
SMA-560 hygro (open circles) or CD70 (black squares) cells were inoculated s.c. into CD1nu/nu 
mice. Tumor growth was examined every second day with a caliper. Data are expressed as mean 
diameters and SEM (n=5). B. 5 x 103 SMA-560 hygro (open circles) or CD70 cells (black squares) 
were inoculated i.c. into CD1nu/nu mice. The mice were monitored for survival. 
 
The mean survival was prolonged from 23.2±2.5 days (median 25) in control animals to 
30.4±2.6 days (median 29) in animals carrying CD70-expressing tumors. The survival rate at 
27 days was 100% in the latter, but 0% in the control mice. Maintenance of transgene 
expression in vivo was ascertained by immunocytochemistry on day 5 (Fig. 2.2.C-F). These 
data strongly suggest that CD27-expressing NK cells of CD1nu/nu mice interact with CD70 
expressed on glioma cells in vivo, that NK cells gain access to glioma-bearing mouse brain 
and that the CD70-mediated increase in NK cell susceptibility probably outweighed the pro-
apoptotic effect on immune cells in vivo in mice. 
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 Fig. 2.2.C-F. CD70 expression was assessed by immunocytochemistry using CD70 (FR70) 
 
D70 mediates tumor regression in immunocompetent VM/Dk mice. We next explored 
 
antibody on day 5 (size bar in F: 40 µm): s.c. SMA-560 CD70 (C) or hygro (D). Thymus 
stained with specific antibody served as a positive control (E), staining with isotype control 
antibody was the negative control (F). 
C
the immune response to CD70-expressing SMA-560 gliomas in immunocompetent syngeneic 
VM/Dk mice. SMA-560 hygro cells inoculated s.c. formed rapidly growing tumors whereas 
CD70-expressing SMA-560 gliomas showed a delayed growth which peaked around day 12, 
followed by tumor regression evolving over a few days (Fig. 2.3.A). Previous work has 
demonstrated that immune responses to glioma cells are counteracted by large quantities of 
TGF-β released by glioma cells (140, 141). Here we observed that tumor formation by 
CD70-expressing glioma cells was abrogated when the animals bearing CD70-expressing 
gliomas were treated with the TGF-β RI kinase antagonist, SD-208. SD-208 also delayed the 
growth of s.c. SMA-560 hygro tumors. Moreover, VM/Dk mice challenged i.c. with CD70-
expressing SMA-560 cells never developed neurological symptoms, and their survival was 
100% with a median observation of more than 60 days. In contrast, control animals 
experienced a median survival time of 18.8±1.2 days (Fig. 2.3.B). 
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 Fig. 2.3.A,B CD70 promotes the rejection of s.c. and i.c. SMA-560 gliomas in syngeneic mice. 
3
 
munocytochemistry confirmed persistent transgene expression in CD70-transfected SMA-
the establishment of tumor-specific memory. 
 
A. 106 SMA-560 hygro or CD70 cells were inoculated s.c. into VM/Dk mice. The mice were 
treated with vehicle or SD-208 (15 mg/kg) on Days 3, 5 and 7 twice a day. Tumor growth was 
examined every second day with a caliper. Data are expressed as mean diameters and SEM (n=5). 
B. 5 x 10  SMA-560 hygro or CD70 cells were inoculated i.c. into VM/Dk mice. The mice were 
monitored for survival. 
Im
560 glioma cells whereas control tumors were negative (Fig. 2.3.C, D). Tumor-free s.c. 
challenged mice were rechallenged i.c. with 5 x 103 wild-type SMA-560 glioma cells and 
remained symptom-free for more than 60 days (Fig. 2.3.E, F). Thus CD70 expression on 
tumor cells apparently allowed for the recruitment of a tumor-specific T cell repertoire and 
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 SMA-560 CD70 
challenged mice. CD70 expression was assessed by immunocytochemistry in s.c. SMA-560 
ice (n=3) were (re)challenged 60 days later i.c. with 5 x 103 SMA-560 wild-
type glioma cells ((E), representative brain sections at day 12, arrow denotes tumor in control 
animal, (F), survival curve). 
 
 
ouse CD70 gene transfer promotes immune cell infiltration in the SMA-560 syngeneic 
ouse glioma model. The infiltration of the experimental gliomas by immune cells was 
Fig. 2.3.C-F. In vivo CD70 expression and wt i.c. rechallenge of s.c.
CD70 (C) or hygro (D) tumors on day 5 (size bar: 40 µm). E,F. SMA-560 CD70 s.c. surviving or 
untreated control m
M
m
examined in s.c. tumors at day 12 after tumor inoculation using specific mAb for NK cells 
(Ly49G2), macrophages/microglia (CD11b) or T cells (CD8). A similar extent of NK cell 
infiltration was observed in CD70-negative and CD70-positive tumors of CD1nu/nu and 
VM/Dk mice (Fig. 2.4.A-D, Table 1). There also was no difference in the extent of 
macrophage infiltration between SMA-560 hygro or CD70 tumors in either s.c. mouse model 
(Fig. 2.4.G-J). However, there was a significant increase in CD8 T cells in SMA-560 CD70 
compared with hygro tumors in VM/Dk mice (Fig. 2.4.M, N, Table 1). 
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Fig. 2.4.A-P. Immune cell infiltration in CD70-negative and CD70-transfected SMA-560 
tumors in the s.c. VM/Dk syngeneic mouse glioma model. SMA-560 hygro (left column) or 
CD70 (middle column) tumors grown in the right flank of CD1nu/nu (A,B,G,H) or VM/Dk 
(C,D,E,F,I,J,K,L,M,N,O,P) mice were assessed for infiltrating Ly49G+ NK cells (A-D), 
macrophages (G-J) or CD8+ T cells (M and N) on day 12. Spleen served as a positive control (+) 
with specific antibody and negative control (-) with isotype antibody (right column) (size bar: 40 
µm). 
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 isruption of the CD27 gene in C57BL/6 mice nullifies CD70-mediated anti-tumor 
 Table 1. Patterns of immune infiltration in control and CD70   
s.c. SMA - 560 tumors on day 1
SMA-560 hygro 8.0± 1.0  NK cells  
SMA-560 CD70 9.5± 2.5  
SMA-560 hygro 17.0± 3.0  
CD1nu/nu  
Macrophages 
SMA-560 CD70 16.0± 4.0  
SMA-560 hygro 7.0± 1.0  NK cells  
SMA-560 CD70 3.5± 1.5  
SMA-560 hygro 36.0± 3.0  Macrophages 
SMA-560 CD70 41.0± 3.0  
SMA-560 hygro 0.5± 0.5  
VM/Dk  
T cells  
SMA-560 CD70 26.5± 1.5 ∗  
  
1 Data are expressed as mean percentages and S.E.M. of labeled cells  
within a high power field ( ∗ p< 0.05, t-test)
 
 
D
responses. To demonstrate the unique requirement for CD70/CD27 interactions mediating 
tumor rejection as shown in Fig. 2.2. and Fig. 2.3., we reproduced the observations made in 
the VM/Dk model using the GL-261 glioma cell line in syngeneic C57BL/6 mice. Like 
SMA-560 cells, GL261 cells did not express CD70 constitutively, but expressed high levels 
after pIRES-CD70 transfection (Fig. 2.1.A). Similar to SMA-560 cells, CD70 enhanced the 
susceptibility of GL-261 to NK cell lysis. In contrast, there was no difference in the lytic 
activity of NK cells from CD27-/- mice against GL-261 CD70 or hygro cells (Fig. 2.5.A). 
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 Fig. 2.5.A. CD70-mediated tumor regression requires CD27 interaction. A. The cytotoxicity 
+
-/- 51
 
urther, immunocompetent C57BL/6 mice challenged s.c. with GL-261 hygro cells 
 
 
of syngeneic C57BL/6 DX5 -selected (10 d, 5000 U/ml IL-2) NK cells from wild-type (circles, 
dashed lines) or congeneic CD27  C57BL/6 mice (squares, solid lines) was tested against Cr-
labeled GL-261 hygro (open symbols) or CD70 cells (filled symbols). 
F
developed large tumors whereas CD70-expressing GL-261 gliomas regressed within 15 days 
(Fig. 2.5.B). In contrast, CD27-/- mice developed large s.c. tumors irrespective of whether 
CD70 was expressed or not (Fig. 2.5.B). Finally, C57BL/6 mice challenged i.c. with CD70-
expressing GL-261 cells developed neurological symptoms, but 50% of the mice survived. In 
contrast, control animals experienced a median survival time of 38.5±2.5 days (Fig. 2.5.C). 
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 Fig. 2.5.B,C.  CD70 promotes the rejection of s.c. and partially i.c. GL-261 gliomas in 
6
4
 
syngeneic mice. 10  GL-261 hygro or CD70 cells were inoculated s.c. into wild-type (circles) or 
CD27-/- (squares) C57BL/6 mice. Growth was assessed by determining mean diameters and SEM 
(n=5). C. 2 x 10  GL-261 hygro or CD70 cells were inoculated i.c. into C57BL/6 mice which were 
then monitored for survival. 
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Discussion 
 
Glioblastoma is a paradigmatic type of cancer which exerts multiple effects, mostly 
inhibitory, on various aspects of immune cell function. Among the growing list of molecules 
with potential immune inhibitory function expressed by glioma cells, we previously 
identified CD70, the ligand for CD27 (109). Although CD70/CD27 interactions in the 
lymphoid system support expansion and differentiation by promoting survival (127), CD70 
expressed on human glioma cells strongly inhibited alloreactivity and promoted apoptosis in 
the immune compartment in vitro (109). The induction of immune cell apoptosis via 
CD70/CD27 interactions was confirmed in syngeneic glioma mouse models here when CD70 
was expressed in the mouse glioma cell lines SMA-560 and GL-261 (Fig. 2.1.C-F, data not 
shown). 
Interestingly, mRNA levels of the pro-apoptotic adaptor molecule Siva-1 and its anti-
apoptotic counterpart Siva-2 changed in splenocytes challenged with CD70-positive tumor 
cells. The minor effects observed for SMA-560 hygro cells, which are necessarily CD70-
independent, may be due to changes in transcription mediated by p53 or E2F1 (137) or 
interactions of Siva and Bcl-2 family proteins (138). The massive induction of Siva-2 and the 
almost complete loss of Siva-1 (Fig. 2.1.E) may represent a mechanism by which mouse 
splenocytes adapt to chronic stimulation via CD27 and escape from CD70-mediated 
apoptosis. Fig. 2.1.F demonstrates that immune cell apoptosis evolving in cocultures with 
glioma cells is a complex process regulated at several levels, including CD70/CD27 
interactions. Thus, IL-2 inhibits apoptosis whereas TGF-β promotes apoptosis, both in the 
absence and presence of CD70. In conclusion, one might assume that the net effect of CD70 
expressed on glioma cells acting on CD27 expressed on immune cells in vivo might depend 
on the absence or presence of further immune activating or inhibitory signals operating in 
microenvironment of human gliomas. 
In fact, despite the confirmation of immune cell apoptosis mediated by CD70 in the mouse 
system (Fig. 2.1.C-F), SMA-560 CD70 glioma cells were lysed significantly better by NK 
cells than control cells (Fig. 2.1.G). We therefore set out to determine which of these 
opposing effects of CD70 expressed on glioma cells would dominate in vivo. To this end, we 
used three different model systems of s.c. and i.c. glioma growth: (i) SMA-560 gliomas 
grown in nude mice, (ii) SMA-560 gliomas grown in syngeneic VM/Dk mice and (iii) GL-
261 gliomas grown in wild-type and CD27-/- syngeneic C57BL/6 mice. 
 53
The growth delay of s.c. and i.c. CD70-expressing gliomas in nude mice suggests a role for 
CD27 expressed on NK cells as a pathway of immune surveillance (Fig. 2.2). This is because 
CD1nu/nu mice possess innate immunity only since they are athymic and therefore devoid of T 
and B cells. Enhanced tumor rejection mediated by NK cells may reflect the ability of CD70 
to stimulate the lytic activity of NK cells by increasing proliferation and IFN-γ production 
(142) as well as effector and target conjugate formation (124). Consequently, CD70-
transfected tumor cells are cleared more efficiently than control transfectants. 
Compared with the nude mice model, the syngeneic model provided evidence for cures and 
immunological memory when CD70 was expressed, attributing a key role to T cell-mediated 
immunity in rejecting CD70-expressing gliomas (Fig. 2.3). There was no significant 
difference in macrophage infiltration, but a CD70-dependent increase in CD8 T cell 
infiltration (Table 1). The growth inhibition presumably mediated by NK cells in nude mice 
together with the cures achieved in immunocompetent mice are fully consistent with a role 
for CD70 in the cooperation between NK and T cell immunity (128). 
We have previously demonstrated the pivotal role of TGF-β as an immune inhibitory 
molecule and therefore promising molecular target in glioblastoma (110, 140, 141, 143). 
Here we observed an additive effect of CD70-mediated immune stimulation and the 
abrogation of TGF-β signalling, mediated by the TGF-β receptor I kinase antagonist, SD-208 
(Fig. 2.3.A). These results are consistent with a central role for glioma-derived TGF-β in the 
priming phase of cytotoxic T lymphocytes or in the potential to suppress innate immunity or 
both. Alternatively, TGF-β may play a role in the initial seeding of gliomas in the host tissue, 
given its role in invasion and angiogenesis (144). 
The net immune stimulatory effect of CD70 expressed on glioma cells was then confirmed in 
another syngeneic model, GL-261 glioma cells grown in C57/BL6 mice (Fig. 2.5) which had 
the advantage that CD27-/- mice were available (145) to confirm the specificity of the 
observations made in the VM/Dk model (Fig. 2.3, 2.4). In fact, the disruption of CD27 
expression nullified the immune stimulatory properties of CD70 gene transfer in GL-261 
glioma cells (Fig. 2.5.A, B).  
The expression of CD70 in human glioblastomas (109) which ultimately kill their host 
clearly shows that the suppressed immune system of human glioma patients cannot  eliminate 
CD70-expressing glioma cells. Nevertheless, the present study shows that CD70, a cell 
surface protein and ligand for the TNF receptor-related CD27 protein, which was identified 
as a radio-inducible gene in glioma cells (109), has the potential to mediate strong immune 
responses in several in vivo glioma models, suggesting that CD70/CD27-interactions could 
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be exploited in the context of future strategies of active immunotherapy for glioblastoma, 
notably those relying on the antagonism of TGF-β and the reinforcement of IL-2-dependent 
immune activation. 
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III. Anti-tumor immunity induced by injections of immune stimulatory RNA in tumor-
bearing mice 
A related manuscript is under preparation for submission in Cancer Research 
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the ambitious clinical phase I study. 
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Introduction  
 
Glioblastomas are the most common malignant intrinsic brain tumors in adults (146). Despite 
surgery, radiation therapy and chemotherapy, affected patients experience a median survival 
of only 12 months. Although they express a variety of antigens (147), glioblastomas do not 
seem to be recognized by the immune system. A reason for this apparent immune ignorance 
may be that glioma cells induce active immunosuppression through the release of TGF-β  
(148, 149).  Immunological ignorance may be a frequent phenomenon in tumor patients. In 
situ immunostimulation is a method to overcome immunosuppression and to signal tumor 
cells to the immune system. This phenomenon was observed more than 100 years ago when 
W. Coley injected bacterial products at the tumor site. Coley found that this treatment was 
associated to protection against sarcoma in more than 10% of patients (150). The injected 
prokaryotic components are now known to be immune stimulatory due to danger signals such 
as unmethylated CpG motifs in bacterial DNA, endotoxins and flagellin. A danger signal in 
the context of vaccinations and immunotherapies appears to be bacterial DNA (112) or its 
synthetic version, CpG ODN (OligoDeoxyNucleotide). By mimicking the conserved immune 
stimulatory feature of bacterial genomic DNA, CpG ODN activate immune cells through 
Toll-like-receptor (TLR) 9. In vitro, CpG ODN trigger a strong activation of human 
plasmacytoid DC and B cells. In vivo, intra-tumor injection of CpG ODN in mice results in 
tumor regression (113). This immunotherapy activates a local immunity that kills tumor cells 
and triggers a systemic immunity. This preventing the formation of metastases and providing 
long-term anti-tumor immune memory. This immunity is mediated by the release of Th1-type 
cytokines, the production of antibodies and the induction of CTL and T helper cells. Still, the 
transfer of the pre-clinical results to the clinic may be limited by the different pattern of TLR9 
expression in mouse and human immune cells. More importantly, CpG ODN are very stable 
and trigger severe side effects in mice (114). Such uncontrolled overstimulation may prevent 
the clinical value of CpG ODN as a immune stimulatory tool. 
Other danger signals originating from viruses include double-stranded RNA or stabilized 
single-stranded RNA (ssRNA). Like DNA, RNA has also been shown to be a potent danger 
signal dependent on TLR-signalling. Unlike CpG ODN, ssRNA is very sensitive to 
degradation by ubiquitous RNases and must be protected in vitro by encapsulation in 
liposomes (48, 115), condensation to a cationic peptide (Scheel et.al., unpublished data) or 
chemical modifications (phosphorothioate ORN) (42) to show immune stimulatory potency. 
Protamine-stabilised mRNA can readily activate human immune cells whereas 
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phosphorothioate ORN must be encapsulated in liposomes to be immune stimulatory in vitro 
for human cells. ssRNAs are recognized by TLR7 and -8 (48). TLR7 is expressed in mice in 
the cytosole of DC. In humans, TLR7 is expressed in the cytosole of PDC, B cells, monocytes 
(41) and eosinophils (13), TLR8 mainly in the cytosole of monocytes (41). TLR7 and 8 are 
not only expressed on different cell types, they also trigger different responses. The activation 
of cells by ssRNA is MyD88 dependent (42) whereas stimulation with dsRNA is partially 
MyD88-independent (Hilf et.al., submitted). Thus, although the adjuvant and 
immunotherapeutic capacities of dsRNA were reported earlier, it is of interest to study the 
immune stimulatory properties of ssRNA. Ultimately, the interesting characteristics of these 
two types of RNA molecules may be combined in a potent RNA-only adjuvant or therapeutic 
tool. 
Here, we investigated the possibility to use ssRNA as an anti-tumor treatment in mice and 
compare it to CpG-DNA. We found that intratumor or subcutaneous injections of ssRNA are 
as potent as injections of CpG-DNA as an anti-tumor immunotherapy. As opposed to CpG-
DNA, repeated ssRNA injections were not associated with side effects such as splenomegaly. 
This pre-clinical evaluation of ssRNA as an anti-tumor treatment is currently being translated 
from the laboratory to the clinic. 
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Material and methods 
 
Mouse strains and animal experiments. Inbread VM/Dk mice were obtained from the TSE 
Research Centre (Berkshire, UK). The experiments were performed according to the German 
animal protection law. For the subcutaneous glioma model, groups of 5 mice aged 6-12 weeks 
were injected s.c. in the right flank with 106 SMA-560 cells resuspended in a volume of 100 
µl PBS. The mice were observed daily and, in the survival experiments, sacrificed when 
developing neurological symptoms, or sacrificed as indicated in the other experiments. The 
mice were examined every second day for tumor growth using a metric caliper and killed 
when tumors reached ≥ 12 mm diameter. Treatment started on day 3 post inoculation. 50 µl 
PBS containing 25 µg RNA alone, protamine-condensed RNA or CpG-DNA 1826 were 
injected in the vicinity of the tumor or into the contralateral flank every other day. 
Cell lines. SMA-560 cells (135) were kindly provided by D.D. Bigner (Durham, NC). The 
cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% 
heat-inactivated fetal calf serum (FCS) (Biochrom KG), 2 mM L-glutamine (Gibco Life 
Technologies), 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco). The cells were 
routinely screened for mycoplasma contamination. 
RNA and oligonucleotides. Nucleic acids were produced by CureVac. For the production of 
messenger RNA, linearized DNA templates containing the β-galactosidase gene under a 
phage promoter were transcribed for two hours using the T7 or the SP6 RNA polymerase 
(CureVac). Then, DNase (CureVac) was added to the reaction and after 30 min at 37°C, the 
RNA was precipitated by LiCl and washed with ethanol 75%. The RNA pellet was 
resuspended in water, quantified by OD260, extracted by phenol/chloroform and re-
precipitated by ethanol/ammonium acetate. After a wash of the pellet with ethanol 75%, the 
RNA was re-suspended in water at 1 mg/ml, checked on a formaldehyde/agarose gel, 
aliquoted and stored at -20°C until utilization. Protamine-protected RNA was produced by 
mixing 1 mg/ml RNA with an equal volume of a 1 mg/ml solution of protamine sulfate (Leo 
Pharma, Ballerup, Denmark). The content of endotoxins in the preparations was tested using 
the Limulus Amebocyte Lysate (LAL) assay (Cambrex Bio Science, East Rutherford, NJ) 
being consistently below 10 IU/mg RNA. Injection preparations were supplemented with 10x 
PBS to a concentration of 500µg/ml RNA in 1x PBS. CpG ODN was synthesized by CureVac 
following standard protocols. In all ODN the phosphate group was substituted by a 
phosphorothioate group desensitizing the nucleic acid backbone against RNase degradation. 
The sequence used was 1826 5’-TCCATGACGTTCCTGACGTT-3’.  
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Stimulation of splenocytes. Splenocytes of BALB/c mice were isolated. After red blood cell 
lysis, cells were incubated in 96-well U-bottom plates at 2 x 105 cells/well in 200 µl of 
medium RPMI with 10% heat inactivated FCS (both from PAA, Wien, Austria), 2 mM L-
Glutamine (Bio Whittaker), 10 µg/ml Streptomycin, 10 U/ml Penicillin (PEN-STREP, Bio 
Whittaker) with protamine-condensed mRNA at 10 µg/ml for 16 h. Cells were stained with 
CD 86 PE and B220 FITC (BD Pharmingen) and analyzed by flow cytometry with a 
FACSCalibur (Becton Dickinson, Heidelberg, Germany). 
Cytokine ELISA. Seventeen hours after addition of the particular stimulus, 100 µl of the 
splenocyte (DC) supernatant was removed. ELISA plates (Nunc, Maxisorb) were coated 
overnight with capture antibody in binding buffer (NaN3 0.02%, Na2CO3 15 mM, NaHCO3 15 
mM, pH 9.7), blocked for one hour with PBS containing 1% BSA, and then incubated with 
100 µl of DC supernatant for 4 hours at 37°C, 7.5% CO2 in a humidified atmosphere. 
Biotinylated antibody (BD Pharmingen) at a concentration of 0.5 µg/ml in blocking solution 
was added after 4 washing steps with PBS 0.05% Tween and incubated for 2 hours at room 
temperature. HRP-Streptavidin (BD Pharmingen) was diluted 1:1000 in blocking solution and 
added in the wells (100µl/well). After three washing steps, 100 µl ABTS (300 mg/l 2,2’-
Azino-bis-(3-ethylbenzthiazoline-6)-sulfonic acid (Sigma) in 0.1 M citric acid, pH 4.35) per 
well were added, and the levels of cytokines were quantified by OD405 and calculated 
according to a standard curve made in the ELISA by titrating amounts of recombinant 
cytokines (BD Pharmingen).  
ELISPOT. For ex vivo ELISPOT the ELISPOT plates were coated over night with IFN-γ 
antibody in coating buffer at 4°C. After 2 h of blocking at 37°C and 3 washing steps with 
serum-containing medium, splenocytes of the mice were taken and counted after red blood 
cell lysis by Gey’s solution (7.0 g/l NH4Cl, 0.37 g/l KCl , 0.3 g/l Na2HPO4.12H2O, 0.024 g/l 
KH2PO4, 1.0 g/l glucose, 10.0 mg/l phenol red, 8.4 mg/l MgCl2.6H2O, 7.0 mg/l MgSO4.7H2O, 
6.8 mg/l CaCl2 and 45 mg/l NaHCO3). Different cell numbers were then coincubated in 
ELISPOT plate (Millipore) with 5000 irradiated (28 Gy) SMA-560 cells per well. After 24 h 
incubation at 37°C and 6 washing steps with PBS Tween 0.05% the second antibody was 
added at 1 µg/ml in PBS Tween containing 1% BSA. Incubation was performed at 37°C for 2 
h. 
Immunohistochemistry. Glioma cryosections (8 µm) were prepared after the mice were 
sacrificed. For staining , they were fixed in PFA and blocked with 2% normal rabbit serum, 
2% BSA using the biotin blocking system (Dako Cytomation, Hamburg, Germany). Tissue 
sections were stained with antibodies (1:50) to CD8 (53-6.7) and CD11b (M1/70, detecting 
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macrophages and microglial cells) and NK cells (Ly49G2) (BD Pharmingen). A biotinylated 
anti-rat secondary antibody (Zymed) was used at 1:150. Avidin (Vector Labs) conjugate was 
added, and the staining was developed with diaminobenzidine (Vector Labs). Mouse spleens 
served as positive controls, normal mouse brain as a negative control. 
Crystal violet staining. The SMA-560 cells were seeded in 96 well plates at 104 cells/well 
and allowed to attach for 24 h. Protamin-condensed β-Gal mRNA at different concentrations 
was added in fresh serum-free medium for 24 h, camptothecin served as a positive control (4 
µM for 6 h). After staining with crystal violet for 15 minutes at room temperature, unspecific 
staining was washed away with H2O. Viable cell counts were obtained by crystal violet 
staining analysed by absorption at λ=550 nm. 
Statistical analysis. The experiments reported herein were usually performed at least three 
times with similar results. Significance was tested by Student´s t-test. P values are derived 
from two-tailed t-tests. 
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 Results 
 
BMDC and B cells are activated by stabilized mRNA. Synthetic ssRNA oligonucleotides 
stabilized by a phosphorothioate backbone have immune stimulating properties in mice (115). 
Condensation of in vitro transcribed mRNA to the cationic peptide protamine is another 
method to generate stabilized ssRNA capable of stimulating mouse DC (Scheel et.al., 
unpublished data). In order to check whether protamine-mRNA stimulates other cell types 
than DC in mice, we incubated splenocytes for 16 h with protamine-condensed mRNA at 
10µg/ml. This results in the production of IL-6 (Fig. 3.1.A) and IL-12 (data not shown). After 
2 days of culture, B220+ splenocytes (B cells) were evaluated for the up-regulation of CD86. 
The baseline CD86 expression detected at the surface of B cells cultured in medium without 
additional molecules or in the presence of protamine, is strong up-regulated when splenocytes 
are cultured in the presence of poly I:C, CpG-DNA or protamine-condensed mRNA (Fig. 
3.1.B). Thus, protamine-mRNA complexes not only activate myeloid mouse DC but also 
stimulate B cells in fresh mouse spleen. 
 A B
 
Fig. 3.1.A,B. Activation of mouse splenocytes. A. Release of IL-6 by BMDC after 16 h co-
culture with poly I:C, CpG-DNA, protamine, uncapped β-Gal mRNA or protamine-condensed 
uncapped β-Gal mRNA. Cytokine release was measured by ELISA. B. Up-regulation of CD86 on 
B220-positive cells. Splenocytes were co-incubated for 16 h with poly I:C, CpG-DNA, protamine, 
uncapped pp65 mRNA or protamine-condensed pp65 mRNA. The surface expression CD86 was 
measured by flow cytometry following multicolour staining: B220 FITC and CD86 PE. 
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Stabilized mRNA exhibits anti-tumor properties comparable to CpG-DNA. Since danger 
signals such as CpG-DNA or poly I:C are potent in situ immune stimulatory molecules, we 
were interested to see whether ssRNA injected into solid tumors induces tumor regression. 
Mice were inoculated with 106 SMA-560 glioma cells subcutaneously (s.c.) in the right flank. 
The treatment involvedinjections into the tumor of 50 µg RNA alone, 50 µg protamine alone, 
50 µg mRNA condensed to 50 µg protamine or 50 µg CpG ODN 1826. One group of tumor-
implanted mice were injected s.c. with 50 µg mRNA condensed to 50 µg protamine into the 
non-tumor-bearing flank. The treatment was started on day 3 after tumor inoculation and 
performed every second day. Each group consisted of 5 mice. 
In all mice tumors grew rapidly and were palpable 3 days after implantation. Mice had to be 
sacrified when tumor sizes reached more than 12 mm in diameter. Injection of mRNA alone 
or protamine-protected mRNA into the tumor led to a noticeable delay in tumor growth, as 
did the injection of CpG-DNA (Fig. 3.2). 
 
Time [days after inoculation] 
 
Fig. 3.2. Course of tumor development. Mice were inoculated with 106 SMA-560 glioma cells 
s.c. in the flank and injected every other day with β-Gal mRNA, protamin-condensed β-Gal 
mRNA, CpG-DNA or protamine into the tumor (i.t.) or into the opposite flank (o.s.). Tumor size 
was measured every second day using a metric caliper. Tumor volume is given in mm3. 
 
 
Interestingly the same effect on tumor growth could be observed when the protamine-
condensed mRNA was injected into the contralateral flank. Two of 5 mice in the CpG ODN-
treated group were tumor-free after 21 days, and 1 of 5 mice in the group injected with 
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mRNA protamine into the tumor and into the other flank. In the group treated with mRNA 
alone, tumor growth was delayed but not impeded whereas protamine alone treated mice 
experienced aggressive tumor growth and had to be sacrificed. 
 
Intratumoral injection of stabilized mRNA leads to memory immune response. At the 
end of the experiment all mice that were tumor-free (two in the CpG treated group, one each 
in the mRNA protamine intra tumor and contralaterally injected group) were re-challenged 
with an injection of 106 glioma cells into the opposite flank. As a control, 2 mice that had not 
received tumor cells in the first round of the experiment were inoculated with 106 tumor cells 
in the right flank. The tumor size was measured every second day and mice were sacrificed 
when tumor sizes reached more than 12 mm in diameter. Whereas the control mice developed 
fast growing tumors and had to be sacrificed, none of the mice that had recovered from the 
primary tumor challenge showed any palpable tumors (Fig. 3.3). Mice were observed for 60 
days after re-challenge and remained tumor-free. Thus, immunotherapy of solid tumors with 
mRNA may trigger long-term anti-tumor immunity.  
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Fig. 3.3. Rechallenge of tumor-free mice. 4 weeks after the beginning of the treatment, the mice 
that were by then tumor-free were again inoculated with 106 SMA-560 glioma cells s.c. in the 
other flank. Tumor size was measured using a metric caliper every second day. 
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No tumor-specific, IFN-γ-producing cells are detectable in the spleen. We performed 
immunomonitoring studies using the spleens of the tumor challenged mice. In an ELISPOT 
assay, fresh splenocytes were mixed with SMA-560 cells (Fig. 3.4.). Although the average 
number of spots may grossly correlate with the clinical outcome, in several animals, the 
detected immune response was lower in cured mice compared to mice with progressive 
disease.  
 
 
 
N
um
be
r o
f s
po
ts
 [n
]
 
Fig. 3.4. IFN-γ ELISPOT of splenocytes. After the mice were sacrificed, splenocytes were 
coincubated overnight in an ELISPOT plate with SMA-560 cells as targets. IFN-γ release was 
measured by ELISPOT. The number of spots given is the mean of three experiments . 
 
Intratumoral injection of stabilized mRNA leads to a specific immune response and 
tumor infiltrating cells. We tested whether immune cells infiltrated regressing or progressing 
tumors in mice treated with CpG-DNA, stabilized mRNA or protamine alone. When the mice 
were sacrificed, tumors were surgically removed and cryopreserved. Cryosections of tumors 
treated with CpG-DNA (A), protamine-condensed mRNA (B) and protamine (C) were stained 
with antibodies against cytotoxic T cells (CD8) (Fig. 3.5) and NK cells (Ly49G2) (data not 
shown). Spleen sections of healthy mice were used as positive control. In all regressive 
tumors (injected with CpG ODN or protamine-condensed mRNA) an infiltration of CD8+ 
cells was observed. Few NK cells were also detected. Progressive as well as regressive tumors 
contained many CD11b positive cells (data not shown). 
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Fig. 3.5.A-C. Antibody staining of tumor sections. Glioma cryosections were 
Protamine-condensed mRNA is nontoxic. One of the well-known side effects induced by 
stained with CD8 antibody (53-6.7) and examined by light microscopy to analyse 
infiltrating cells (200X, Axioplan II Carl Zeiss). A. CpG-treated tumor. B. 
Protamine mRNA-treated tumor. C. Protamine-treated tumor. 
 
repeated CpG injections is uncontrolled B cell proliferation evidenced by enlarged spleens. 
To screen for splenomegaly, spleens from treated tumor-implanted mice were weighed. As 
shown in Fig. 3.6.A, the spleen weight of mice treated with protamine-condensed mRNA 
remained normal, i.e. similar to the one of controlled mice (untreated, not shown, or 
protamine-injected mice). In contrast, the spleens of the mice that received CpG ODN were 
approximately 3-fold larger than these of protamine or protamine-mRNA treated mice. Thus, 
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whereas repeated injections of CpG ODN induce splenomegaly, this is not the case for 
repeated injections of protamine-mRNA.  
To investigate a possible direct toxicity of stabilized mRNA on tumor cells, we also 
performed an in vitro toxicity experiment. The tumor cells were co-incubated with different 
concentrations of protamine-condensed mRNA, stained with crystal violet and retention of 
crystal violet by viable cells was measured by absorption. There was no direct toxicity even at 
high mRNA-protamine concentrations (Fig. 3.6.B). Thus, stabilized mRNA does not induce a 
direct lysis of tumor cells but rather, according to experiments shown in Fig. 3.3 and 3.4 
triggers an anti-tumor immune response that is responsible for tumor regression in vivo.  
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Fig. 3.6.A,B. Toxicity assays with protamin-condensed mRNA. A. Spleen weight after tumor 
treatment. After the end of the experiment, the spleens of the mice were taken and weighed. 
Weight is given in grams. B. In vitro toxicity of protamine. SMA-560 cells were co-incubated 
with different concentrations of uncapped β-Gal mRNA condensed with protamine or 
camptothecin. After 24 h, viable cell counts were obtained by crystal violet staining. The cytotoxic 
agent camptothecin was used as a positive control. 
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Discussion 
 
Our data show that that the injection of protamine-stabilized mRNA into solid tumors results 
in a growth arrest, regression or in 20% of the cases to a complete remission of the tumors. It 
is likely, that this effect is due to several mechanisms. ssRNA (48, 151, 152) as well as 
dsRNA (153) may serve as a danger signal which leads to the activation of various cell types 
via TLR. Thus, the presence of a danger signal at the tumor site triggers DC to incorporate 
tumor antigens, migrate to regional lymph nodes and present them to T cells. Furthermore, 
protamine-stabilized mRNA  activates DC and B cells in mice (42), which release cytokines 
and upregulate costimulatory molecules. The local release of IL-6 and IL-12 by mouse DC in 
turn leads to a recruitment of T cells to the site of the tumor (Fig. 3.5.). Besides, the presence 
of cytokines can have a direct effect on the tumor. Kishima et al. showed, that the injection of 
IL-12 i.p. in glioma-bearing mice can lead to tumor eradication and gliomas in rats that are 
injected peripherally with IL-12 along with irradiated tumor cells promote an  immunological 
rejection of flank 9L gliomas (154). The fact that a rechallenge in cured mice did not lead to 
development of a tumor and that invasion of CD8+ cells was seen in tumor sections of RNA-
treated mice strongly indicates that the treatment of tumors with protamine-complexed RNA 
triggers a specific immune response against tumor cells. The sequence of the RNA may have 
no effect on the activity of the treatment, since 2 different sequences of mRNA and 
additionally a Phosphorothioate RNA Oligonucleotide which all had the same activity (data 
not shown). The stabilized RNA itself had no direct toxic effect on the tumor cells in in vitro 
assays.  
Structural similarities of imidazoquinoline which activates TLR7 and TLR8 (155) and nucleic 
acids suggest that nucleic acids might be the natural ligand for these TLR and indeed, short 
ssRNA derived from HIV-1 stimulate mouse DC via TLR7 and human DC via TLR8 (10). 
Also, ssRNA viruses are recognized via TLR7 by pDC and B cells (14) and lead to the 
production of cytokines and activation of costimulatory molecules. 
Since that the TLR 7,8 and 9 form a subfamily according to genomic structure and sequence 
homology (156, 157), it is not unexpected that ssRNA, the natural ligand for TLR 7 and 8 has 
a similar effect on tumor growth as the TLR9 ligand, CpG-DNA, that is a strong anti-tumor 
agent.  
Regarding the severe side effects that have been observed after treatment with CpG-DNA (8), 
stabilized mRNA could be an alternative, being as potent in stimulating a specific immune 
response against the tumor, but exhibiting fewer side effects due to its much shorter half life. 
 68
mRNA can be a vaccine either loaded on DC (158) or by direct injection (159) and give rise 
to a specific immune response. We propose that mRNA can be used as a tumor treatment with 
a double effect, functioning as a danger signal and coding for tumor antigens at the same time.  
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IV. SD-208, a novel TGF-beta receptor I kinase inhibitor, inhibits growth and 
invasiveness and enhances immunogenicity of murine and human glioma 
cells in vitro and in vivo 
A related manuscript has been published in Cancer Research, 2004 Nov 1;64(21):7954-61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This project was a collaborative effort of Scios Inc., Fremont, CA and our laboratory. Scios 
scientists (Ramona Almirez, Ruban Mangadu, Yu-Wang Liu, Alison Murphy, Darren H. 
Wong and Linda S. Higgins) developed the drug and characterized it for receptor kinase 
specificity and bioavailability. In our laboratory, most experiments were carried out by Dr. 
Martin Uhl. My contribution involved animal experiments, mainly intracranial and 
subcutaneous inoculation, survival screening and oral gavage as well as functional 
immunological assays. 
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Introduction 
 
Human glioblastoma patients experience a median survival of little more than one year 
with the standard treatment of surgery, radiotherapy and nitrosourea-based 
chemotherapy (160). For many years immunotherapy has been explored as an 
alternative approach for these tumors because human glioma patients exhibit specific 
deficits in their cellular immune response ex vivo (161) and because human glioma cells 
are paradigmatic for the property of cancer cells to express immunosuppressive 
molecules. These include soluble factors such as TGF-β (148), prostaglandins (162) or 
IL-10 (163), as well as cell surface molecules such as CD70 (109)or HLA-G (134). 
Among these, TGF-β has attracted most interest (132), resulting in experimental 
therapeutic approaches using antisense strategies (164), gene transfer of TGF-β 
antagonists such as decorin (165), inhibition of TGF-β-processing proteases of the furin 
family (141) or drugs such as tranilast (166). The undesirable effects of TGF-β in 
malignant glioma are not restricted to the induction of immunosuppression in the host, 
but include a critical role of TGF-β in migration and invasion (167). We here examine a 
novel therapeutic principle of TGF-β antagonism in malignant glioma, defined by SD-
208, a pharmacological agent which blocks TGF-βRI signalling, similar to SB-505124, 
an inhibitor of activin-like kinase receptors 4, 5 (=TGF-βRI) and 7 (168). 
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Materials and methods 
 
Materials and cell lines. PHA was from Biochrom (Berlin, Germany). [Methyl-3H]-
thymidine was obtained from Amersham (Braunschweig, Germany). 51Cr was 
purchased from New England Nuclear (Boston, MA). Human recombinant TGF-β1, 
TGF-β2 and mouse IL-2 were obtained from Peprotech (London, UK). Neutralizing 
pan-anti-TGF-β antibody was purchased from R&D (Wiesbaden, Germany). Specific 
ELISA kits (R&D) were used for the detection of human and murine TGF-β. The 
human malignant glioma cell line LN-308 was kindly provided by N. de Tribolet 
(Lausanne, Switzerland). The murine glioma line SMA-560 was a kind gift of D.D. 
Bigner (Durham, NC). CCL64 mink lung epithelial cells were obtained from the 
American Type Culture Collection (Rockville, MD). 
Cell culture. The glioma cells and CCL64 cells were maintained in DMEM 
supplemented with 2 mM L-glutamine (Gibco Life Technologies, Paisley, UK), 10% 
FCS (Biochrom) and penicillin (100 IU/ml)/streptomycin (100 µg/ml) (Gibco). Growth 
and viability of the glioma cells were examined by crystal violet staining, LDH release 
(Roche, Mannheim, Germany) and trypan blue dye exclusion assays. For crystal violet 
staining, the cell culture medium was removed and surviving cells were stained with 
0.5% crystal violet in 20% methanol for 10 min. The plates were washed extensively 
under running tap water, air-dried and optical density values were read in an ELISA 
reader at 550 nm wave length. Human PBMC were isolated from healthy donors by 
density gradient centrifugation (Biocoll, Biochrom). Monocytes were depleted by 
adhesion and differential centrifugation to obtain PBL. To obtain purified T cells, 
PBMC were depleted of B cells and monocytes using LymphoKwik TTM reagent (One 
Lambda, Canoga Park, CA). The purity of this population was > 97% verified by flow 
cytometry using anti-human CD3-PE antibody (Becton Dickinson, Heidelberg, 
Germany). Human polyclonal NK cell populations were obtained by culturing PBL on 
irradiated RPMI 8866 feeder cells for 10 days (169). Murine NK cells were prepared 
from splenocytes from VM/Dk mice by positive selection using DX5 monoclonal 
antibody-coupled magnetic beads with the corresponding column system (Miltenyi 
Biotech, Bergisch Gladbach, Germany) and cultured with mouse IL-2 (5000 U/ml) for 
at least 10 days before use. The human polyclonal NK cell cultures, PBL, T cells and 
mouse NK cells were grown in RPMI 1640 supplemented with 10% FCS, 2 mM L-
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glutamine, 1 mM sodium pyruvate, 50 µM β-mercaptoethanol and penicillin (100 
IU/ml)/streptomycin (100 µg/ml). 
Characterization of SD-208. SD-208 is a TGF-βRI kinase inhibitor developed by 
Scios Inc. (Fremont, CA). To assess the specificity of SD-208 for TGF-βRI, various 
kinase activities were assayed by measuring the incorporation of radiolabeled ATP into 
a peptide or protein substrate. The reactions were performed in 96 well plates and 
included the relevant kinase, substrate, ATP and appropriate co-factors. The reactions 
were incubated and then stopped by the addition of phosphoric acid. Substrate was 
captured onto a phosphocellulose filter which was washed free of unreacted ATP. The 
counts incorporated were determined by counting on a microplate scintillation counter 
(TopCount, Perkin Elmer Corporation, Bosten, MA). The ability of SD-208 to inhibit 
the respective kinase was determined by comparing counts incorporated in the presence 
of compound to those incorporated in the absence of compound. 
TGF-β bioassay. The levels of bioactive TGF-β were determined using the CCL64 
bioassay. Briefly, 104 CCL64 cells were adhered to 96 well plates for 24 h and then 
exposed to recombinant TGF-β1, TGF-β2 or glioma cell culture SN diluted in complete 
medium for 72 h. Growth was assessed by crystal violet staining at 72 h. Glioma cell 
SN were harvested from subconfluent cultures maintained for 48 h in serum-free 
medium and heat-treated (5 min, 85°C) to activate latent TGF-β (141). 
Proliferation. Glioma cells were cultured in the absence or presence of SD-208 (1 µM) 
for 48 h. The cells were pulsed for the last 24 h with [methyl-3H]-thymidine (0.5 µCi), 
harvested (Tomtec, Hamden, CT), and incorporated radioactivity was determined in a 
Liquid Scintillation Counter (Wallac). 
Flow cytometry. The adherent glioma cells were detached nonenzymatically using cell 
dissociation solution (Sigma, Taufkirchen, Germany). Cell cycle analysis of glioma or 
immune effector cells was performed on fixed and 70% ethanol-permeabilized glioma or 
immune effector cells. RNA was digested with RNase A (Life Technologies, Inc.). DNA 
was stained with propidium iodide (50 µg/ml). Fluorescence was measured in a Becton 
Dickinson FACScalibur (Heidelberg, Germany). 
TGF-β reporter assays. Intracellular TGF- β signalling was assessed by reporter 
assays using pGL2 3TP-Luc (170) or pGL3 SBE-2 Luc (171) reporter gene plasmids 
kindly provided by J. Massagué (New York, NY) and B. Vogelstein (Baltimore, MD). 
The pGL2 3TP-Luc construct contains a synthetic promoter composed of a TGF-β-
responsive plasminogen activator inhibitor 1 promoter fragment inserted downstream of 
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three phorbol ester-responsive elements. The pGL3 SBE-2-Luc reporter contains two 
copies of the Smad-binding element GTCTAGAC. LN-308 and SMA-560 cells were 
transfected using FuGene (Roche). At 24 h after transfection the cells were pretreated in 
serum-containing medium with SD-208 for 12 h (1 µM). TGF-β1 (5 ng/ml) was then 
added for another 16 h. The cells were lysed and transferred to a LumiNuncTM plate 
(Nunc, Roskilde, Denmark) and luminescence was measured in a LumimatPlus (EG&G 
Berthold, Pforzheim, Germany), using Luciferase assay substrate (Promega, Mannheim, 
Germany). For T cell assays, 5 x 106 freshly isolated PBL were co-transfected with 4.5 
µg pGL2-3TP-Luc or pGL3-SBE-2 Luc reporter gene plasmid and 0.5 µg pRL-CMV 
(Promega), using the NucleofectorTM device and the cell type-specific human T cell 
nucleofectorTM kit (Amaxa, Cologne, Germany). IL-2 (50 U/ml) was added 4 h after 
nucleofection and the cells were pretreated with SD-208 for 1 h before TGF-β1 (5 
ng/ml) was added for another 16 h. The respective activities of firefly and renilla 
reniformis luciferase were determined sequentially using the firelite dual luminescence 
reporter gene assay (Perkin-Elmer, Rodgau-Jügesheim, Germany). Counts obtained 
from the measurement of firefly luciferase were normalized with respect to pRL-CMV. 
Immunoblot analysis. p-Smad2 levels in glioma cells were analyzed by immunoblot 
using 20 µg protein per lane on 12% SDS polyacrylamide gels. PBMC were analysed 
using 100 µg per lane and 10% gels. After transfer to a polyvinylidene difluoride 
membrane (Amersham), the blots were blocked in PBS containing 5% skim milk and 
0.05% Tween 20 and incubated overnight at 4°C with p-Smad2 antibody (2 µg/ml) (Cell 
Signaling Technology, Beverly, MA). Visualization of protein bands was accomplished 
using horseradish peroxidase-coupled secondary antibody (Sigma) and enhanced 
chemiluminescence (Amersham). Total Smad2/3 levels were assessed using a specific 
Smad2/3 antibody (1 µg/ml) (Becton Dickinson). 
Matrigel invasion assay (Boyden Chamber). Invasion of glioma cells was measured 
by the invasion of 10,000 cells through Matrigel-coated transwell inserts (Becton 
Dickinson). Briefly, transwell inserts with 8 µm pore size were coated with Matrigel 
and preincubated SMA-560 cells were applied to the upper wells and allowed to 
transmigrate through the membrane towards conditioned medium derived from NIH-
3T3 fibroblasts which was added to the lower wells. Migrated cells on the lower side of 
the membrane were fixed, stained in toluidine blue solution (Sigma) and counted in 5 
microscopic high power fields using a microgrid. 
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Spheroid collagen invasion assay. Multicellular SMA-560 glioma cell spheroids were 
cultured in 25 cm2 culture flasks base-coated with 1% Noble Agar (Difco Laboratories, 
Detroit, MI). Briefly, 4 x 105 cells were suspended in 10 ml medium, seeded onto 1% 
agar plates and cultured until spheroids had formed. Spheroids of about 200 µm 
diameter were selected for the experiments. Preincubated spheroids were seeded into 
collagen I and fibronectin containing wells. Spheroid radius, which is determined by the 
invasion of single cells into the matrix (172), was analyzed by morphometry using the 
MCID digitalization system (IMAGING Research, Ontario, Canada) at 24, 48 and 72 h. 
Alloproliferation. HLA-A2-mismatched human PBL (105/well) were cocultured with 
104 irradiated (30 Gy) LN-308 glioma cells in 96 well plates in triplicates for 5 days. 
Some cocultures received PHA (5 µg/ml). The cells were pulsed for the last 24 h with 
[methyl-3H]-thymidine (0.5 µCi), harvested (Tomtec), and incorporated radioactivity 
was determined in a Liquid Scintillation Counter (Wallac). 
Lysis assay. HLA-A2-mismatched PBL or T cells (107/25 cm2 flask) were cocultured 
with 106 irradiated (30 Gy) LN-308 glioma cells for 5 days. Glioma cell targets were 
labeled using 51Cr (50 µCi, 90 min) and incubated (104/well) with effector PBL 
harvested from the cocultures at E:T ratios of 100:1 to 3:1. The maximum 51Cr release 
was determined by addition of NP40 (1%) (Sigma). After 4 h the SN were transferred to 
a Luma-Plate TM-96 (Packard, Dreieich, Germany) and measured. The percentage of 
51Cr release was calculated as follows: 100 x [experimental release – spontaneous 
release]/[maximum release – spontaneous release].  
Cytokine release. IFN-γ, TNF-α and IL-10 release by immune effector cells was 
assessed by ELISPOT assay in multiscreen-HA 96 well plates (Millipore, Eschborn, 
Germany) coated with corresponding anti-human capture antibodies (Becton 
Dickinson). Briefly, 5 x 104 glioma cells were cocultured for 24 h with 105, 2.5 x 105 or 
5 x 105 HLA-A2-mismatched, prestimulated (5 days) PBL. The cells were removed 
using double-distilled water and captured cytokines were visualized using biotinylated 
antibodies and streptavidin-alkaline phosphatase (Becton Dickinson). Spots were 
counted on an ELISPOT reader system (AID, Straßberg, Germany). 
Ex vivo p-Smad2/3 ELISA. Male mice (BALB/c, Jackson Labs, Barharbor, ME) were 
studied in 6 groups of 8 animals each. For each drug group, a single volume of SD-208 
was administered by oral gavage 1 h prior to dosing with TGF-β1 (R&D Systems, 
Minneapolis, MN) diluted in 100 µl 0.1% BSA / 4 mM HCL/PBS by i.v. injection. The 
mice were sacrificed by cervical dislocation 1 h later. Tissues were removed and lysed 
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in 20 mM Tris, pH 7.5, containing 1 mM EDTA, 0.5% TX-100, 0.5% NP-40, 150 mM 
NaCl and 1x protease inhibitor cocktail (Roche) and 1x phosphatase inhibitor cocktail 
set II (Calbiochem, San Diego, CA). Tissue was homogenized using an Ultra-turrax T8 
(Reyom Instruments, Brabcova, Czech Republic). Tissue homogenates were clarified by 
centrifugation and the supernatant fraction was collected. Protein concentrations were 
determined with a bicinchoninic acid protein assay (Pierce, Rockford, IL). The levels of 
p-Smad were determined by sandwich ELISA. Briefly, 96 well ELISA plates were 
coated with an anti-Smad2/3 monoclonal antibody (100 ng/well, Becton Dickinson) for 
18 h at 4°C. Excess antibody was removed and the wells were treated with blocking 
buffer (0.3% BSA/PBS) for 2 h at room temperature. Tissue lysates (125-150 µg total 
protein) were added to each well and incubated overnight at 4°C. Wells were rinsed 
before adding a polyclonal anti-p-Smad 2/3 antiserum diluted in 2% BSA/0.5% Tween-
20/PBS. Follwing a 2 h incubation at room temperature, the wells were washed and 
secondary antibody was applied (horseradish peroxidase-conjugated goat-anti-rabbit 
IgG, Southern Biotech, Birmingham, AL). After 1 h the wells were developed with 
TMB (Sigma). The plate was incubated 5-30 min before the reaction was stopped with 
0.5 N H2SO4 and read at 450 nm in a SpectraMax 250 plate reader (Molecular Devices, 
Sunnyvale, CA). 
Survival studies in vivo. VM/Dk mice were purchased from the TSE Research Center 
(Berkshire, UK). Mice of 6-12 weeks of age were used for the survival experiments. 
The experiments were performed according to the German animal protection law. 
Groups of 8 mice were anesthesized before all intracranial procedures and placed in a 
stereotaxic fixation device (Stoelting, Wood Dale, IL). A burr hole was drilled in the 
skull 2 mm lateral to the bregma. The needle of a Hamilton syringe (Hamilton, 
Darmstadt, Germany) was introduced to a depth of 3 mm. Five x 103 SMA-560 cells 
(135) resuspended in a volume of 2 µl PBS were injected into the right striatum. Three 
days later the mice were allowed to drink SD-208 at 1 mg/ml in deionized water. The 
mice were observed daily and, in the survival experiments, sacrified when developing 
neurological symptoms. 
Histology. Glioma-bearing mice were sacrificed 10 days after tumor implantation by 
cardiac puncture, perfused and post-fixed in 4% paraformaldehyde (Sigma) overnight. 
Five µm paraffin sections were cut at 150 µm intervals from each brain. The sections 
were deparaffinized, rehydrated and stained with hematoxylin and eosin (Harri’s, 
American Master Tech, Lodi, CA), rat anti-mouse monoclonal CD34 IgG2a (1:100, 
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CL8927AP, Cedarlane, Hornby, Canada), rabbit polyclonal anti-Ki67 (1:100, ab833-
500, Novus Biologicals, Littleton, CO), rabbit anti-mouse caspase 3 active (1:400, 
AF835, R&D), anti-mouse CD8 (1:50, 53-6.7, BD Biosciences, Heidelberg, Germany), 
anti-mouse CD11b (1:50, M1/70, BD Biosciences) or anti-Ly-49G2 (1:50, 4D11, BD 
Biosciences). Biotinylated secondary antibodies (1:150) Zymed, San Francisco, CA 
were used for detection. Streptavidine alkaline phosphatase (1:100) was added, and the 
staining was developed with naphtol as substrate and levamisole as inhibitor of 
endogeneous alkaline phosphatase (Fast Red Tablets, Roche). The negative control for 
CD34 was normal rat IgG2a (CBL605, Chemicon International, Temecula, CA). The 
negative control used for Ki67 and caspase 3 was normal rabbit IgG (SC-2027, Santa 
Cruz Biotechnology, Santa Cruz, CA). The negative control for CD8, Ly-49G and 
CD11b was rat IgG2a or rat IgG2b. Murine spleen served as a positive control, normal 
murine brain as a negative control in these assays. The total number of CD34+ 
microvessels was counted in an area of 0.63 mm2 corresponding to 2 high power fields 
in 2 non-consecutive sections in the tumor center of the tumor. To assess the percentage 
of proliferating cells, Ki67-positive nuclei were counted. At least 600 nuclei were 
counted in 4 high power fields in 2 non-consecutive sections in the tumor center. To 
assess the degree of apoptosis, caspase-3-positive cells were counted in the tumor center 
in 2 two non-consecutive sections.  
Ex vivo immune effector assays. Glioma-bearing mice were sacrificed 10 days after 
tumor cell injection. Splenocytes were isolated and used in 24 h IFN-γ ELISPOT assays 
as described above. Further, these cells were stimulated with IL-2 (5000 U/ml) for 10 
days to generate LAK cells which were used in 51Cr release assays against SMA-560 
glioma cells as targets. 
Statistical analysis. The experiments were usually performed at least three times with 
similar results. Significance was tested by Student´s t-test. P values are derived from 
two-tailed t-tests. 
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Results 
 
SD-208 is a functional TGF-β1 and TGF-β2 antagonist in vitro. The initial 
characterization of SD-208 in cell-free assays led to its identification as a potent 
inhibitor of TGF-βRI. SD-208 exhibited an in vitro specificity for TGF-βRI kinase of 
>100-fold compared with TGF-βRII kinase and at least 20-fold over members of a 
panel of related protein kinases (Table 1). 
 
Table 1. Specificity of SD-208 for TGF-βRI kinase activity1 
TGF-βRI  0.048 
TGF-βRII > 50 
Epidermal growth factor receptor 68% 
mutant Drosophila p38-α 0.867 
p38 kinase γ > 50 
c-jun N-terminal kinase > 50 
Extracellular signal-regulated kinase-2 > 50 
Mitogen-activated protein kinase-activated protein-2 87% 
Mitogen-activated protein kinase kinase 6 > 50 
Protein kinases A and C > 50 
Protein kinase D 70% 
1Data are expressed as EC50 [µM] or percentage inhibition at 5 µM SD-208 in cell-free systems 
in vitro. 
 
The differential patterns of release of TGF-β1/2 by human glioma cell lines have been 
reported (141). The TGF-β release by the cell lines examined here was ascertained by 
ELISA. The levels of TGF-β released into the supernatant were unaffected by SD-208 
within the concentration and time frame of the ensuing experiments (Fig. 4.1.A). 
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Fig. 4.1.A. Prevention of the growth inhibitory effects of recombinant and glioma-
derived TGF-β1 and TGF-β2 in the CCL64 bioassay by SD-208. A. Murine SMA-560 or 
human LN-308 glioma cells were evaluated for the release of TGF-β into the SN by 
ELISA. SN was generated in the absence (open bars) or presence (filled bars) of SD-208 (1 
µM) for 48 h. 
 
CCL64 mink lung epithelial cells are sensitive to the growth inhibitory effects of human 
TGF-β1 and TGF-β2 at EC50 concentrations of 0.5 ng/ml. The inhibitory effects of 
recombinant TGF-β as well as those of TGF-β-containing glioma cell SN were 
abrogated by specific TGF-β antibodies (141). The CCL64 bioassay was used here to 
verify the TGF-β-antagonistic properties of SD-208 (Fig. 4.1.B). SD-208 rescued the 
inhibition of growth mediated by TGF-β1 or TGF-β2 (10 ng/ml) or diluted SMA-560 
(not shown) or LN-308 glioma cell SN in a concentration-dependent manner, with an 
EC50 concentration of 0.1 µM (Fig. 4.1.C). When these bioassays were performed in the 
absence of serum in the CCL64 medium, the EC50 for SD-208 was 0.03 µM (data not 
shown), corresponding to the data in Table 1. 
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4.1.B,C. SD-208 abrogates bioactive TGF-β in CCL64 assays. B. CCL64 cells were 
exposed to human TGF-β1, TGF-β2 or LN-308 SN (1:2) in the absence or presence of SD-
208 (0.5 µM) and cell density was assessed 72 h later. Neutralizing pan-TGF-β and isotype 
control antibodies (10 µg/ml) were also included (*p<0.05, **p<0.01, t-test, relative to 
vehicle). C. CCL-64 cells were cultured with TGF-β1 (filled triangles), TGF-β2 (filled 
squares) (10 ng/ml) or heat-activated glioma cell SN (1:2) (open rhomboids) in the absence 
or presence of SD-208 for 72 h. Cell density was assessed by crystal violet assay (mean and 
SD, n=3). 
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SD-208 abrogates autocrine TGF-β-dependent signal transduction in glioma cells. 
We next examined the biological effects of SD-208 on murine and human glioma cells 
in vitro. The concentrations required to block the growth inhibitory effects of TGF-β in 
the CCL64 bioassay had no effect on the proliferation of either glioma cell line. SD-208 
did not reduce proliferation assessed by [methyl-3H]-thymidine incorporation or 
viability assessed by LDH release or trypan blue dye exclusion assays at concentrations 
up to 1 µM for 48 h in SMA-560 (Fig. 4.2.A) or LN-308 cells (data not shown). 
Further, neither exogeneous TGF-β nor neutralizing TGF-β antibodies had such an 
effect. Accordingly cell cycle analysis showed no difference in both cell lines after 
exposure to SD-208 for 48 h (Fig. 4.2.B,C). 
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Fig. 4.2.A-C. Absence of toxicity and abrogation of TGF-β signalling in glioma cells by SD-
208. A. SMA-560 cells were treated with SD-208, TGF-β1 (10 ng/ml), their combination (1 µM 
SD-208) or neutralizing TGF-β (1D11) or isotype control (13C4) antibodies (10 µg/ml) for 48 h. 
Proliferation was assessed by [methyl-3H] thymidine incorporation. B,C. Cell cycle analysis of 
untreated or SD-208 (1 µM, 48 h)-treated LN-308 (B) or SMA-560 cells (C) was performed using 
flow cytometry. The profiles overlap because SD-208 has no effect. 
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The inhibition of TGF-β signalling transduced by endogenous or exogenous TGF-β was 
ascertained by demonstrating that SD-208 interfered with Smad2 phosphorylation without 
altering total cellular Smad2/3 levels (Fig. 4.2.D). Similarly, two different reporter assays 
revealed a strong inhibition of TGF-β signalling when the glioma cells were treated with SD-
208 (Fig. 4.2.E). 
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Fig. 4.2.D,E. SD-208 abrogates TGF-β signalling via p-Smad2 and reduces TGF-β promoter 
activity. D. Lysates from untreated glioma cells or cells preexposed to SD-208 (1 µM) for 24 h or 
exposed to TGF-β2 (5 ng/ml) for 1 h or both were assessed for the levels of p-Smad2 or total 
Smad2/3. Note that the antibodies are specific for p-Smad2 and total Smad2 and 3, respectively. E. 
The cells were untreated (open bars) or treated with TGF-β1 (5 ng/ml, filled bars) for 16 h in the 
absence or presence of SD-208 at 0.1 or 1 µM and assessed for TGF-β reporter activity in serum-
containing medium. 
 
SD-208 inhibits constitutive and TGF-β-evoked migration and invasion. We next 
examined the biological effects of SD-208 on SMA-560 cells in two independent migration 
and invasion paradigms in vitro. SD-208 reduced the invasion of glioma cells from a spheroid 
into a three dimensional collagen I gel and also the transmigration of glioma cells in a Boyden 
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chamber assay. Moreover, the proinvasive effect of exogenous TGF-β was neutralized by SD-
208 in either assay (Fig. 4.3.A,B). 
 
Fig. 4.3.A,B. Inhibition of constitutive and TGF-β-induced invasion of glioma cells by SD-
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208. A. SMA-560 spheroids were untreated or treated with SD-208 (1 µM), TGF-β2 (5 ng/ml) or 
both for 24 h prior to placement into the collagen I gel and during the experiment and spheroid 
diameter was determined every 24 h. Data are expressed as mean radius in percent of the spheroid 
radius at 0 h set to 100% (n=3, *p<0.05, t-test, effect of SD-208; +p<0.05, t-test, effect of TGF-β2). 
The concentration of DMSO required to dissolve SD-208 had no effect in this assay. B. Invasion 
was analyzed with matrigel-coated membranes in a Boyden chemotaxis chamber assay applying 
104 SMA-560 cells, untreated or treated with SD-208 (1 µM), TGF-β2 (5 ng/ml) or both for 24 h 
prior to and during the experiment, in the upper chamber. Invaded cells were counted at 24 h. Data 
are expressed as mean cell counts (n=3, *p<0.05, t-test, effect of SD-208, p<0.05, t-test, effect of 
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SD-2 h the 
effects of SD-208 on TGF-β-mediated signalling in glioma cells (Fig. 4.2.D,E), immunoblot 
 
Fig. 4.4.A. SD  A. Flow cytometric cell 
cycle analysis of untreated (grey line) and SD-208 (1 µM, 48 h)-treated (black line) PBMC show 
 
Fig. 4.4.B bols) or PHA-
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resence of increasing concentrations of SD-208. Vehicle-treated PBMC were normalized to 
A
08 enhances allogeneic immune responses to glioma cells in vitro. Consistent wit
analysis and reporter assays also revealed a strong resistance to TGF-β signalling in the 
presence of SD-208 in immune cells (Fig. 4.4.C,D). Again, SD-208 did not affect cell cycle 
distribution, apoptosis or proliferation (Fig. 4.4.A,B). 
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Fig. 4.4.C,  PBMC were treated 
with TGF- r 30 min and then 
 to immunoblot analysis for Smad2 phosphorylation (upper panel). Total Smad2 
expression was assessed as a loading control (lower panel). D. PBL were untreated or pretreated 
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immune cell responses to cultured human glioma cells. When HLA-A2-mismatched PBL or 
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with SD-208 (0.1, 1 µM) for 1 h and then untreated (open bars) or treated with TGF-β1 (5 ng/ml) 
(filled bars) for 16 h and subjected to the firelite reporter assay. 
ext series of experiments was designed to examine whether SD-208 restores allog
p
lytic activity in a subsequent 4 h Cr release assay was significantly enhanced (Fig. 4.5.A). 
Similar effects were obtained using neutralizing TGF-β antibodies (10 µg/ml, added every 
two days) (data not shown). The release of IFN-γ by HLA-mismatched PBL was strongly 
inhibited when the priming had taken place in the presence of glioma cells. SD-208 restored 
the IFN-γ release to levels comparable to PBL pre-cultured in the absence of LN-308 cells 
(Fig. 4.5.B). Similar results were obtained for TNF-α (Fig. 4.5.C). In contrast, IL-10 release 
was stimulated after coculturing with LN-308 cells, and SD-208 reduced the release of IL-10 
by immune effector cells generated both from unstimulated and glioma cell-primed cultures 
(Fig. 4.5.D). The lytic activity of polyclonal NK cells against LN-308 targets was inhibited by 
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exogenous TGF-β, and TGF-β-mediated inhibition was relieved by SD-208 (Fig. 4.5.E). 
Similarly, LN-308 SN inhibited NK cell activity, and this inhibition was also blocked by SD-
208 (Fig. 4.5.F) or neutralizing TGF-β antibodies (data not shown). Note that while the 
absolute lytical activity was donor-specific, the effect of SD-208 was consistent through all 
experiments. 
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Fig. 4.5.A-F. Modulation of allogeneic anti-glioma immune responses by SD-208 involves 
TGF-β antagonism. A. The lytic activity of PBL (squares) or purified T cells (triangles) 
preincubated with irradiated LN-308 cells in the absence (open symbols) or presence (filled 
symbols) of SD-208 (1 µM) was determined in 51Cr release assays using LN-308 cells as targets 
(+p<0.05, t-test, effect of SD-208 on PBL; *p<0.05, t-test, effect of SD-208 on T cells). B-D. PBL 
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were cultured in the absence (left) or presence (right) of irradiated LN-308 cells for 5 days. The 
cultures contained SD-208 (1 µM) (filled bars) or not (open bars). Subsequently these effector 
cells were cocultured for 24 h with fresh non-irradiated LN-308 cells in the absence of SD-208. 
The release of IFN-γ (B), TNF-α (C) or IL-10 (D) was assessed by ELISPOT assay. Data are 
expressed as cytokine-producing cells per 5 x 105 effector cells (n=3, *p<0.05, t-test, effect of SD-
208). E,F. Polyclonal NK cell cultures were exposed to TGF-β1 (5 ng/ml) (E) or diluted (1:4) 
glioma cell SN (F) without or with SD-208 (1 µM) for 48 h and subsequently used as effectors in 
51Cr release assays using LN-308 cells as targets. SD-208 alone or TGF-β antibody alone had no 
effect on NK cell activity in these assays (data not shown, E: +p<0.05, effect of TGF-β; *p<0.05, 
effect of SD-208; F: +p<0.05, effect of glioma SN; *p<0.05, effect of SD-208). 
08 prolongs the survival of SMA-560 intracranial experimental glioma-bea
D-208 inhibited t
 
SD-2 ring 
syngeneic mice. To verify the bioavailability of orally administered SD-208, we ascertained 
that S mad2/3 in spleen and 
rain (Fig. 4.6.A,B). Note that exogenous TGF-β was a more potent inducer of Smad2/3 
he TGF-β-dependent in vivo phosphorylation of S
b
phosphorylation in spleen than brain, but that SD-208 was an equally effective antagonist of 
TGF-β in both tissues. The therapeutic effects of SD-208 administered via the drinking water 
(1 mg/ml) were assessed in the syngeneic SMA-560 mouse glioma paradigm. The 
development of neurological symptoms was delayed by SD-208-treated mice and the mean 
survival was prolonged to 25.1±6.5 days (median 23) compared with 18.6±2.1 days (median 
18) in vehicle-treated animals (Fig. 4.6.C) (p=0.004, t-test). The survival rate at 30 days was 
29% in SD-208-treated animals, but 0% in control animals. Preliminary evidence also 
indicated that SD-208 modulated the immune response of the glioma-bearing animals. 
ELISPOT assays for IFN-γ release by splenocytes harvested at day 7 after the initiation of 
SD-208 treatment revealed an increase over background in 3 of 5 SD-208-treated animals, but 
only in 1 of 5 control animals (data not shown). Further, LAK cells generated from the 
splenocytes of SD-208-treated animals showed an enhanced lytic activity against SMA-560 as 
targets (Fig. 4.6.D).  
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Fig. 4.6.A,B. SD-208 blocks TGF-β signalling in the brain and inhibits the growth of 
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syngeneic SMA-560 experimental gliomas in vivo. A,B. Non-tumor-bearing animals were 
untreated (open bars) or treated with 150 ng TGF-β1 i.v. (filled bars) at 1 h after oral 
exposure to SD-208 at increasing doses. The mice were sacrificed 1 h later and analyzed for 
Smad2/3 phosphorylation by ELISA in spleen (A) or brain (B) (*p<0.01, Bonferroni´s test, 
effect of SD-208 on TGF-β). 
H
day 10 showed a trend towards a lower tumor burden in SD-208-treated animals, but 
these changes were not significant (data not shown), consistent with the clinical course 
at day 10 shown in Fig. 4.6.C. Immunhistochemistry revealed no significant difference 
in blood vessel formation (CD34), tumor cell proliferation (Ki67) or apoptosis (active 
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caspase 3) between the gliomas of untreated and SD-208-treated animals (Table 2). 
There was little tumor infiltration by immune or inflammatory cells in the vehicle group 
as detected by HE staining. However, HE staining revealed major differences in the 
sizes and the histology of the gliomas of SD-208-treated animals: as indicated by the 
variable clinical course (Fig. 4.6.C), there appeared to be “non-responder” and 
“responder” animals. Animals with small tumors had stronger immune cell infiltration 
of their tumors than mice bearing larger tumors. Typical staining patterns for CD8 T 
cells, NK cells (Ly49G) and macrophages/neutrophils (CD11b) in a vehicle-treated, a 
SD-208-treated non-responder and a SD-208-treated responder animal are presented in 
Fig. 4.7. 
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Fig. 4.6.C,D. SD-208 promotes the rejection of i.c. SMA-560 gliomas in syngeneic mice. 
C. VM/Dk mice received an intracranial injection of 5 x 103 SMA-560 cells. Three days 
involving 7-8 animals per group were pooled. D. Animals were treated as in the survival 
experiments and sacrificed on day 10 to obtain splenocytes which were stimulated with IL-
2 for 10 days to generate LAK cells. Their lytic activity was measured by Cr release using 
SMA-560 as target cells (vehicle, open squares; SD-208, filled squares; *p<0.05, t-test, 
effect of SD-208). 
 
 
later SD-208 treatment was initiated, and survival was monitored. Two experiments 
51
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Fig. 4.7.A-L. Immune cell infiltration in SD-208-treated tumor-bearing mice. Gliomas 
from a vehicle-treated animal (A,D,G,J), a SD-208-treated non-responder animal (B,E,H,K) 
and a SD-208-treated responder animal (C,F,I,L) were stained with HE (A-C) or analysed 
by immunohistochemistry for NK cells (D-F), CD8 T cells (G-I) or macrophages (J-L) 
(magnification: A-C 5x, D-I 20x and J-L 10x. Size bar in C: 500 µm; in F and I: 100 µm; in 
L: 200 µm). 
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   Table 2 Immunolabeling for microvessels, proliferation and apoptosis in vivo1 
 Vehicle SD-208 
CD34 
149 ± 27 132 ± 28 
Ki67 
29 ± 7 26 ± 6 
Caspase 3  
13 ± 9 9 ± 7 
 
1Sections from 7 animals were analysed by immunochemistry as outlined in the Methods 
section. 
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Discussion 
 
Antagonizing the biological effects of TGF-β has become a very attractive experimental 
strategy to combat various types of cancer including malignant gliomas. Current 
rationales for anti-TGF-β strategies include its putative role in migration and invasion 
(167), metastasis (173) and tumor-associated immunosuppression (132, 174). All of the 
TGF-β-based therapeutic approaches evaluated in experimental gliomas so far appear to 
have limitations with regard to their transfer into the clinic. Antisense oligonucleotides 
pose severe problems in terms of delivery to the desired site of action. The same applies 
to gene therapy strategies based e.g. on the transfer of the decorin gene (165). Inhibition 
of furin-like proteases aiming at limiting TGF-β bioactivity at the level of TGF-β 
processing (141) may not be achieved with acceptable specificity at present since a 
whole variety of molecules require processing by such enzymes (175). More specificity 
may result from the use of soluble TGF-β receptor fragments which act to scavenge 
bioactive TGF-β before it may reach the target cell population (173, 174). However, this 
approach may find its limits in the complex pathways of storage and activation of TGF-
β. These considerations suggest that specific small molecules designed to protect cells 
from the actions of TGF-β at the level of receptor-dependent intracellular signal 
transduction are a particularly promising alternative for antagonizing TGF-β (168). 
Here we characterize the activity of one such candidate agent, SD-208, against murine 
and human glioma cells in vitro and in vivo. Human LN-308 cells were chosen because 
they are paradigmatic for their prominent TGF-β synthesis (148),(141) (Fig. 4.1.A). 
SMA-560 cells transplanted in syngeneic VM/Dk mice probably represent the best 
model for the immunotherapy of rodent gliomas (135). We show that SD-208 is a potent 
TGF-βRI kinase inhibitor (Table 1) which blocks the biological effects of TGF-β1 and 
TGF-β2 as well as glioma cell SN in the CCL64 mink lung epithelial assay (Fig. 
4.1.B,C). Since SD-208 did not modulate glioma cell proliferation at concentrations up 
to 1 µM (Fig. 4.2.A), we did not confirm a negative growth regulatory effect of TGF-β 
on SMA-560 cells (176). Smad2 phosphorylation is induced by TGF-β in a SD-208-
sensitive manner (Fig. 4.2.C), indicating that TGF-β signalling is not abrogated 
constitutively in glioma cells, but may not play a role in the modulation of glioma cell 
proliferation. Moreover, as expected (167), the antagonism of autocrine and paracrine 
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signalling by TGF-β in SD-208-treated glioma cells, as confirmed by reporter assay 
(Fig. 4.2.E) resulted in a potent inhibition of migration and invasion (Fig. 4.3). 
We then focused on the desired immune modulatory effect of SD-208 which should 
result in an enhanced immunogenicity of glioma cells as a consequence of reduced 
TGF-β bioactivity. As predicted, human PBL and purified T cells developed enhanced 
lytic activity against LN-308 glioma cell targets when prestimulated with glioma cells in 
the presence of SD-208 (Fig. 4.5.A). This was paralleled by an enhanced release of 
proinflammatory cytokines such as IFN-γ and TNF-α and a reduced release of the 
immunosuppressive cytokine IL-10 in SD-208-treated cells (Fig. 4.5.B-D). Similarly 
SD-208 restored the lytic activity of polyclonal NK cell cultures cocultured with TGF-β 
or LN-308 SN (Fig. 4.5.E,F). 
The strong reduction of Smad phosphorylation in the unlesioned mouse brain indicates 
that SD-208 may reach sufficient levels beyond the intact blood brain barrier to 
counteract the biological effects of tumor-derived TGF-β (Fig. 4.6.B). Accordingly, SD-
208 prolonged the median survival of SMA-560 glioma-bearing mice significantly (Fig. 
4.6.C). No dose-limiting toxicity was reached in these experiments, but higher doses 
could not be administered by the drinking water because of poor solubility of SD-208, 
suggesting that the therapeutic effect of SD-208 or related agents might even be 
improved in that glioma model. The therapeutic effect of SD-208 might be mediated by 
the inhibition of glioma cell migration and invasion (167) or the promotion of anti-
glioma immune responses (132) or both. An immune contribution is suggested by the 
histological analyses (Fig. 4.7) which delineated an interrelation between tumor 
shrinkage and the degree of immune cell infiltration. 
The present data strongly suggest a role for SD-208 or related molecules in the treatment 
of gliomas. Such a systemic treatment with TGF-βRI kinase inhibitors might well be 
combined with local approaches to limit the bioavailability of TGF-β, e.g., TGF-β 
antisense oligonucleotides which are already evaluated clinically. 
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V. Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells 
involves cytoplasmic and secreted furin-like proteases 
A related manuscript has been published in Journal of Immunology. 2001 Jun 
15;166(12):7238-43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of the work has been carried out by Dr. Jens Leitlein who is the first author of this 
project. I designed and performed the northern blot analysis, together with Dr. Robert 
Waltereit, and was involved in the overall conception of the immunoblot analysis and the 
TGF-β bioassays. 
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Introduction 
 
Deficient T cell function is commonly found in human patients with glioblastoma (177). This 
state of immunosuppression is attributed to the release of various soluble factors, notably 
transforming growth factor-β (TGF- β) type 2 (147). Consistent with a pivotal role of TGF-β 
in the growth of malignant gliomas, expression of TGF-β2 antisense mRNA in 9L (164) or in 
C6 rat gliomas (178) induced their regression. Similarly, gene transfer-mediated ectopic 
expression of the functional TGF-β antagonist, decorin, promoted the regression of rat C6 
gliomas (165). 
TGF-β is synthesized as a pre-pro-TGF-β polypeptide that contains a signalling peptide (pre) 
(residues 1-29), the pro-region (residues 30-278) and the mature TGF-β moiety (residues 
279-390) (119). Activation to the mature 12.5 kDa TGF-β 1, that needs to dimerize to exert 
its biological effects, depends on the action of subtilisin-like proprotein convertases such as 
furin, as shown for purified proteins obtained from cell culture supernatants in a cell-free 
system (120). In fact, it has been suggested that TGF-β promotes furin gene expression as 
part of an amplification cascade of its own activation in fibroblasts and rat hepatocytes (179, 
180). The subtilisin-like proprotein convertases of mammalian cells constitute a family of 
proprotein convertases related to bacterial subtilisins and yeast Kex2p which process 
multiple protein precursors, including growth factors, proteases of the coagulation and 
complement cascades, glycoproteins of viral envelopes and bacterial exotoxins at multibasic 
recognition sites (181-183). Furin seems to be universally expressed in mammalian cells and 
localizes mainly to the trans-Golgi network. 
In the present study, we examined the role of FLP in the processing of TGF-β in malignant 
glioma cells. Since TGF-β2 is the predominant isoform of TGF-β secreted by human 
malignant glioma cells and since TGF-β2 has the same cleavable consensus site for furin (R-
X-R/K-R) as TGF-β1, we were specifically interested in examining whether human glioma 
cells express furin and whether inhibition of furin may result in the inhibition of the 
processing of both isotypes of TGF-β in intact glioma cells. 
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Materials and methods 
 
Reagents. The synthetic furin inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethylketone 
(dec-RVKR-cmk), as well as the furin substrate for the fluorescence assays, N-t-
butoxycarbonyl-Arg-Val-Arg-Arg-7-amido-4-methylcoumarine (boc-RVRR-amc), were 
purchased from Bachem (Heidelberg, Germany). [Methyl-3H]thymidine and 5‘-[α-
32P]desoxycytidine triphosphate were from Amersham (Braunschweig, Germany). The 
following antibodies were purchased: rabbit polyclonal antibody to TGF-β1 from Promega 
(Mannheim, Germany), rabbit polyclonal antibody to TGF-β2 from Santa Cruz (Santa Cruz, 
CA). Anti-furin antiserum was raised as previously described (184). Human recombinant 
TGF-β1 and TGF-β2 were purchased from Roche (Mannheim, Germany). ELISA assays for 
total TGF-β1 and TGF-β2 were obtained from R&D (Minneapolis, MN). 
Cell culture. sv-FHAS is a SV40 large T-antigen immortalized fetal human astrocytic cell 
line that was generously provided by A. Muruganandam and D. Stanimirovic (Institute of 
Biological Sciences, National Research Council of Canada, Ottawa, Canada). The human 
glioma cell lines were kindly provided by Dr. N. de Tribolet (Lausanne, Switzerland) and 
maintained in DMEM supplemented with 10% FCS and penicillin (100 IU/ml)/streptomycin 
(100 µg/ml) (185). Transfections were carried out by electroporation (7), using a PDX 
expression plasmid (186) and a human furin expression plasmid kindly provided by J. 
Creemers (187). 
TGF-β bioassay. Levels of bioactive TGF-β were determined using a modification of the 
CCL64 bioassay (165). Briefly, 5000 CCL64 cells were adhered to 96 well plates for 24 h. 
After removal of regular medium, the cells were exposed to cell culture supernatants diluted 
in serum-free medium for 56 h and then labeled with [methyl-3H]-thymidine (1 µCi/well) for 
additional 16 h. Cell culture supernatants were obtained by seeding 106 cells in a 25 cm² 
culture flask. After 24 h, the cells were washed with PBS and then incubated with serum-free 
medium. After further 48 h, the conditioned medium was harvested, cell debris was removed 
by centrifugation, and the supernatant stored at -20°C. Cell counts obtained at the end of 
supernatant generation were used to normalize the supernatants for cell culture density. 
Latent TGF-β was activated by heating of the supernatants to 85°C for 5 min (188). 
RT-PCR. RT-PCR for the detection of furin mRNA expression was performed according to 
standard procedures. The following primer sequences were used: furin sense (nucleotides 
corresponding to NotI site printed in italics plus nucleotides -7 to 11 containing the ATG), 
5’-TTTTTTG-CGGCCG-C-CCCCCCATGGAGCTGAA-3’; furin antisense (nucleotides 
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EcoRI in italics plus 428-409), 5’-TTTTGAATTCGTGTAGCCCTGCGCCCAGGC-3’; 35 
cycles, 40 sec/94°C, 60 sec/56°C, 60 sec/72°C; β-actin sense (nucleotides 409-429), 5‘-
TGTTTGAGACCTTCAACACCC-3‘; β-actin antisense (nucleotides 937-918), 5‘-
AGCACTGTGTTGGCGTACAG-3‘; 35 cycles, 40 sec/94°C, 60 sec/53°C, 60 sec/72°C; 
PDX sense (nucleotides 552-571 of the α1-antitrypsin mRNA), 5‘-CGTGGAGA 
AGGGTACTCAAG-3‘, PDX antisense (nucleotides 1164-1145 of the α1-antitrypsin mRNA 
but with the last two nucleotides complementary to the changes made to generate PDX, in 
italics) (17), 5‘-GACCTCGGGGGGGATAGATC-3‘, 30 cycles, 45 sec/94°C, 45 sec/60°C, 
60 sec/72°C. 
Northern blot analysis. Total RNA was isolated using the RNeasy kit (Qiagen, Hilden, 
Germany). Four micrograms of total RNA per lane were separated on 1.2% agarose gels and 
blotted onto nylon membranes (Amersham). The filters were hybridized according to 
standard procedures with ³²P-labelled full-length human cDNA probes for furin (189), kindly 
provided by V. van de Ven (Leuven, Belgium), TGF-β1 (190) and TGF-β2 (117), generous 
gifts of A. Fontana (Zürich, Switzerland). All blots were re-hybridized with a β-actin probe 
(191). Autoradiography signals were quantified with a phosphor-imager (Fuji BasReader 
1500, Raytest, Staubenhardt, Germany), and the signals of interest were normalized against 
β-actin expression. 
Immunoblot analysis. The levels of TGF-β and furin protein expression were assessed by 
immunoblot analysis. The general procedure has been described (192). Briefly, cells were 
lysed in 50 mM TRIS-HCl (pH 8) containing 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 2 
µg/ml aprotinin, 10 µg/ml leupeptin and 100 µg/ml phenylmethylsulfonylfluoride (PMSF). 
For the detection of TGF-β in the supernatant, serum-free supernatants were concentrated 
(because of the low protein production of some of the cell lines) with the Centriplus 
centrifugal filter device YM-3 (3,000 Da cut-off) (Millipore, Eschborn, Germany). This 
concentrated supernatant was also used for the immunoblot detection of furin in the 
supernatant. The furin antiserum was used at a dilution of 1:1000 in TS-TMBSA (TRIS-HCl, 
pH 7.5, 10 mM; NaCl 150 mM; Tween 20 0.1%; skim milk 5%; BSA 2%; sodium azide 
0.01%), the antibodies to TGF-β1 and TGF-β2 were used at 1:2000 and 1:3000. Anti-rabbit 
IgG (Santa Cruz, CA) at a dilution of 1:3500 in PBS/0.05% Tween-20/1.3% skim milk was 
used as a secondary antibody to detect TGF-β, anti-mouse IgG (Amersham, Braunschweig, 
Germany) diluted 1:2000 was used to detect furin. Labeling was visualized using enhanced 
chemiluminescence (ECL system, Amersham). Equal protein loading was ascertained by 
Ponceau S staining for all blots. 
 97
FLP activity. To determine cellular FLP activity, 15,000 cells were adhered to 96 well plates 
for 24 h. Growth medium was replaced by 50 µl of DMEM without phenol red, but 
containing 0.25% Triton X-100 for permeabilization and boc-RVRR-amc (100 µM) as a 
substrate. Because of the stable FLP activity over a range of 48 h in that assay, the data 
shown were measured at 4 h after substrate addition. Fluorescence was measured at 380 nm 
excitation and 460 nm emission wavelengths. The data were normalized to cell density by 
parallel staining of another 96 well plate with crystal violet. For the determination of FLP 
activity in the supernatant, cells were grown in a 75 cm² culture flask. At nearly confluent 
stage, normal growth medium was changed to 7 ml of DMEM without phenol red. The 
supernatant was harvested 48 h later, cleared of cell debris by centrifugation and stored until 
further use at –20°C. The assay was performed with 0.25% Triton X-100 and 100 µM 
substrate in a total volume of 100 µl. The data were normalized to the protein concentration 
in the supernatant. 
Statistical analysis. All experiments reported herein were performed at least three times with 
similar results. A correlation between various sets of data was examined by linear correlation 
analysis as outlined below. 
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Results 
 
Human malignant glioma cells express furin and exhibit FLP activity. To assess whether 
glioma cells express furin, RNA was prepared from 12 different human malignant glioma 
cell lines and analysed for furin mRNA by Northern blot (Fig. 5.1.A). A 4.2 kB furin mRNA 
species was detected in all cell lines. The highest levels of furin mRNA were detected in 
U138MG, LN-428, U373MG and LN-308 cells. Low levels were detected in U87MG, T98G 
and LN-319 cells. RT-PCR confirmed that all glioma cell lines expressed furin mRNA (data 
not shown). 
Next, we determined the levels of furin protein by immunoblot analysis. The 98 kD form is 
thought to be the major form of furin (183). Cleavage of furin in the cystein-rich region is 
thought to result in a minor 60 kD form (193). Furin protein was detected in soluble protein 
lysates from all cell lines at differing levels. Both the 98 kD and 60 kD forms of furin were 
detected. Rather low levels of furin protein were visualized in the sv-FHAS nonneoplastic 
astrocyte cell line (Fig. 5.1.B). Overall, mRNA and protein levels appeared to correlate. For 
instance, LN-308, the cell line showing the highest mRNA expression, also yields the 
strongest protein signal on the immunoblot. 
FLP activity was determined by measuring conversion of a fluorigenic substrate, boc-RVRR-
amc (Fig. 5.1.C). Overall, there was little variation in FLP activity among the cell lines. FLP 
activity correlated less well with mRNA and protein levels, suggesting that the enzyme assay 
does not only detect furin activity but also the activity of related furin-like proteases which 
are probably expressed by glioma cells. Of note, the astrocytic cell line sv-FHAS exhibited 
lower FLP activity than each of the glioma cell lines, consistent with the low levels of furin 
protein (Fig. 5.1.B). 
Since furin has been reported to be regulated by TGF-β in fibroblasts and rat hepatocytes (10, 
11), we examined whether exogenous TGF-β1 or TGF-β2 modulate FLP activity. LN-18 or 
T98G exposed to either isoform of TGF-β for 4 or 24 h failed to exhibit a significant change 
in FLP activity. Moreover, neutralizing TGF-β antibodies failed to modulate FLP activity in 
these cells (data not shown), suggesting that endogenous TGF-β does not modulate FLP 
activity. 
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Fig. 5.1.A-C. Furin expression and FLP activity in human malignant glioma cells. A. Furin 
mRNA expression was examined by Northern blot analysis. A 4.2 kB furin mRNA species was 
detected in all cell lines. Equal loading was confirmed by Northern blot analysis for β-actin. B. 
Cellular furin protein levels were determined by immunoblot analysis. The putative furin band 
was identified by transient transfection of LN-229 cells with a furin expression plasmid (data not 
shown). C. FLP activity was determined by monitoring boc-RVRR-amc cleavage. Data are 
expressed as mean relative decrease or increase and SEM of activity in percentages of the mean 
values for all cell lines for each single assay (n=6). 
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Fig. 8.2.A-C. TGF-β expression and
bioactivity in malignant glioma cells. A.
TGF-β1 and TGF-β2 mRNA expression
were examined by Northern blot. Equal
loading was ascertained by rehybridization
of the filters to β-actin. B,C. Levels of
TGF-β1 and TGF-β2 in cellular lysates and
total secreted protein were assessed by
immunoblot. The 12.5 kD TGF-β1 and
TGF-β2 forms were not detected in the
cellular lysates. 5 ng recombinant human
TGF-β1 or TGF-β2 served as a positive
control.  
 
 
TGF-β synthesis and release by glioma cells. TGF-β1 and TGF-β2 mRNA and protein 
expression and TGF-β bioactivity were assessed in the same panel of glioma cell lines. 
Northern blot analysis revealed that most glioma cell lines expressed a 5.1 kB mRNA for 
TGF-β1 and TGF-β2 (Fig. 5.2.A). Immunoblot analysis was performed with total cellular 
soluble protein lysates and with supernatant protein (Fig. 5.2.B,C). Cellular lysates contained 
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comparable levels of 55 kD TGF-β 1 but greatly differing levels of 55 kD TGF-β2. The 12.5 
kD active fragment was not detected in the cellular lysate (Fig. 5.2.B,C). Both the 55 kD and 
the 12.5 kD fragments for TGF-β1 and TGF-β2 were detected in the supernatant of both cell 
lines. These data suggest that TGF-β is mainly released as the 55 kD form and further 
processed following release. Appropriate control experiments were performed to assure that 
the TGF-β1 antibody did not recognize human recombinant TGF-β2, and vice versa (data not 
shown). The levels of TGF-β1 and TGF-β2 in the supernatant were also quantified by ELISA 
(Fig. 5.2.D) and by CCL64 bioassay which determines both TGF-β1 and TGF-β2 but allows 
to differentiate latent and active TGF-β (Fig. 5.2.E). Overall, there was fairly good 
correlation between the levels of mRNA and protein expression determined by the different 
methods. For instance, U87MG, D247MG and LN-229 cells, which showed very low TGF-
β2 mRNA expression on Northern blot analysis, also showed correspondingly low levels of 
TGF-β2 protein on immunoblot analysis or in the ELISA. Statistical analysis revealed that the 
levels of active TGF-β determined by bioassay correlated with the sum of TGF-β1 and TGF-
β2 levels in the ELISA (r=0.716, p=0.009), and the levels of total TGF-β in the bioassay with 
TGF-β1 and TGF-β2 levels in the ELISA as well (r=0.675, p=0.016). There was no clearcut 
correlation between furin mRNA and protein levels (Fig. 5.1) and the activation of TGF-β 
(Fig. 5.2), suggesting that furin is not the only mediator of TGF-β processing in glioma cells. 
However, some of the data fit rather well, e.g., the very efficient processing of TGF-β1 and 
 
TGF-β2 in LN-308 cells which are strongly furin-positive. 
Fig. 5.2.D. TGF-β ELISA. Levels of total TGF-β1 (black bars) and TGF-β2 (open bars) were 
measured by ELISA. Data are expressed in pg/ml, mean of duplicate values, per 106 cells, 
released in 48 h. 
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Fig. 5. l (open bars) TGF-β 
were m rnatant required for 
50 tion of CCL64 cells for native (black bars) and heat-activated (open bars) 
supernatants. 
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GF-β is not detected in the cell lysate, but in the supernatant, and since (iii) high levels of 
fluorescent FLP activity assay in parallel with (standard) and without cellular 
permeabilization (see Methods). These experiments revealed that the FLP activity of 
nonpermeabilized cells did not exceed 10% of the activity measured in permeabilized cells, 
consistant with previous studies which indicate that some furin is exposed at the cell surface 
(194-196). Yet, the residual 10% may also originate from minor penetration during the assay 
We thus went on to the test the hypothesis that furin is released into the supernatant to 
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a cells release furin into the cell culture supernatant. Since (i) furin is thought t
red for the processing of 55 kD TGF-β to active 12.5 kD TGF-β, since (ii) the 12.5
T
55 kD TGF-β are released into the cell culture supernatant where 12.5 kD is also detected, 
we concluded that significant TGF-β processing must take place in the cell culture 
supernatant or at the extracellular aspect of the cell membrane. First, to examine whether 
FLP activity localizes to the extracellular aspect of the cell membrane, we performed the 
of  the substrate into the cells or from furin release into the supernatant (see below). 
convert 55 kD TGF-  to 12.5 kD TGF- . Fig. 5.3.A shows that immunoreactive furin can be 
detected in the supernatant of most glioma cell lines. Particularly high levels were de
LN-308 cells, corresponding to the high intracellular levels of furin in these cells (Fig. 
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correlation of furin levels and FLP activity in the supernatant (Fig. 5.3). 
 
 
Fig. 5.3.A,B. re supernatants were assessed for 
immunoreactive furi VRR-amc cleavage (B) as in 
Fig. 5.1. 
 
LP activity is required for the processing of TGF-β in glioma cells. To assess whether 
rin-like enzymes mediate TGF-β processing in glioma cells, we monitored changes in 
TGF-  release induced by an inhibitor of furin, dec-RVKR-cmk. Fig. 5.4.A shows that dec-
RVK inhibited the formation of active (12.5 kDa) TGF-β1 and TGF-β2 in a 
oncentration-dependent manner. The loss of active TGF-β after exposure to the furin 
Furin release by cultured glioma cells. Cell cultu
n by immunoblot (A) or FLP activity by boc-R
F
fu
β
R-cmk 
c
inhibitor was confirmed at the level of ELISA (Fig. 5.4.B,C) and bioassay (Fig. 5.4.D). In 
parallel, there was an increase in the 55 kDa proform of TGF-β1 and TGF-β2 in the 
supernatant (Fig. 5.4.A). In contrast, the levels of intracellular 55 kDa pro-TGF-β were 
unaffected by inhibition of FLP activity (data not shown), confirming that most TGF-β 
conversion by furin takes place extracellularly. The inhibitor was equally effective in 
inhibiting TGF-β synthesis in the glioma cell lines which express both isoforms of TGF-β 
(Fig. 5.4) and in sv-FHAS astrocytes which express only TGF-β1 (data not shown). 
Altogether, these observations, notably the loss of 12.5 kD TGF-β and the relative increase 
of 55 kD TGF-β, support the hypothesis that released soluble furin plays a prominent role in 
the processing of TGF-β by glioma cells. 
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Fig. ss TGF-β  
T98 creasing c
The i use  
unpublished observation). Immunoblot analysis for TGF-β1 and TGF-β2 in the supernatant was 
performed as in Fig. 5.2.B-D. The glioma cells were exposed to increasing concentrations of dec-
 
PDX hetic 
serine protease inhibitor (serpin) designed to selectively inhibit furin (17). The LN-18 and 
T98G glioma cell lines were transfected with a PDX expression plasmid (17). PDX transgene 
xpression was verified by RT-PCR (Fig. 5.5.A). PDX-transfected glioma cell sublines 
 5.4.A-D. Furin-like proteases proce
G cells were untreated or treated with in
nhibitor was reapplied every 12 h beca
dec-RVKR-cmk [µM]
in malignant glioma cells. A. LN-18 or
oncentrations of dec-RVKR-cmk for 48 h. 
of its unstable nature ((34); W. Garten,
dec-RVKR-cmk [µM]
0 1 10 100
RVKR-cmk for 48 h as above. Supernatants were assessed for TGF-β1 (B) or TGF-β2 (C) by 
ELISA or total TGF-β by CCL64 bioassay (D). In D, supernantants were activated and diluted 
1:10. 
 gene transfer reduces glioma-associated TGF-β bioactivity. PDX is a synt
e
exhibited a minor, but significant reduction in cytoplasmic FLP activity (Fig. 5.5.B). 
However, although the reduction of FLP activity did not exceed 20%, there was strong 
inhibition of TGF-β processing, as assessed by the levels of 12.5 kD TGF-β in the 
supernatant (Fig. 5.5.C). Quantification of the immunoblots for 12.5 kD TGF-β revealed a 
reduction of TGF-β1 to less than 60% in T98G cells, and of TGF-β2 to less than 70% in LN-
18 and to less than 40% in T98G cells (Fig. 5.5.D). PDX transgene expression was not very 
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prominent in the glioma cell lines and was lost within few passages in vitro, suggesting 
strong selection pressure against furin inhibition in vitro (data not shown). 
 
 
Fig. 5.5.A-D. sing. A. Expression 
of the PDX t  FLP activity of PDX 
transfectants relative to neo control 
cells (*p<0.05, t-test). C. Immunoblot analysis for TGF-β1 and TGF-β2 in the supernatant was 
PDX gene transfer inhibits FLP activity and TGF-β proces
ransgene was confirmed by RT-PCR. B. Cytoplasmic
was assessed by boc-RVRR-amc cleavage and is expressed 
performed as in Fig. 5.2.D. The representative 12.5 kD TGF-β blot shown in C was quantified by 
densitometry. Signal intensity is expressed as percentage of PDX transfectants compared with neo 
controls. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Discussion 
 
TGF-β is a cytokine that is released by glioma cells in large quantitites in vitro and in vivo 
and that has been considered central to the malignant progression of glial tumors and to the 
immune dysfunction in human patients with glioblastoma (4). This is because TGF-β 
promotes tumor angiogenesis, enhances migration and invasion, and inhibits T cell-mediated 
immune responses. Experimental therapeutic efforts to neutralize TGF-β activity associated 
with glioblastoma include antisense strategies (197) and antagonism by decorin (198). 
Here, we examined the biochemical pathways of TGF-β synthesis and processing in 
malignant glioma cells and asked whether proteases of the subtilisin-like proprotein 
convertase family such as furin are involved in TGF-β maturation and might therefore 
become a target for immunotherapy in these tumors. We find that glioma cells express furin 
mRNA and protein and exhibit FLP activity in a fluorometric enzyme assay. Cellular FLP 
activity does not correlate well with furin protein levels, indicating that this enzyme assay 
detects the activity of other furin-related proteases as well. 
As indicated above, there is an increasing number of subtilisin-like proprotein convertases 
which are now designated SPC1-8 and which are candidate enzymes for TGF-β processing 
(182). There were also significant differences in the levels of released furin and the levels of 
FLP activity in the supernatant among the cell lines (Fig. 5.3). A definite physiological role 
of released furin has not been characterized. However, previous studies have postulated a 
role for furin release in the processing of cellular substrates (199). The present study suggests 
that the release of furin may play a crucial role in creating an immunosupressive 
microinvironment in human gliomas via enhanced TGF-β processing. 
We confirm that the synthesis and release of large levels of TGF-β1 and TGF-β2 are a feature 
of cultured glioma cell lines (Fig. 5.2). Numerous previous studies have confirmed that 
glioblastoma cells produce TGF-β in vivo, too (reviewed in (147)). Here, we identify one or 
more furin-like proteases as the enzyme(s) responsible for TGF-β activation in glioma cells 
(Fig. 5.4). Furin has so far been characterized as a TGF-β1-processing enzyme in cell-free 
systems (120). For the first time ever, we show that furin inhibitors abrogate TGF-β1 
processing in intact cells and extend these observations to the processing of TGF-β2, too. 
The present study does not allow firm conclusions as to whether FLP activity is 
pathologically elevated in glioma cells and thus primarily responsible for the high level of 
TGF-β release from human gliomas in vivo. In contrast to other cell types (179), TGF-β 
 107
appears not to promote furin mRNA expression or activity to enhance its own release in a 
ositive autocrine loop in glioma cells (data not shown). 
 (200). 
X, of conditions associated with 
 
 
 
 
 
 
p
At present, there is little information on the expression and activity of furin-like proteases in 
other cell types in vitro and in vivo (200). Our study indicates that differences in furin 
expression or FLP activity alone do not account for most of the variation in the levels of TGF-
β1 or TGF-β2 that are processed and released in a panel of human glioma cell lines. Further, 
the phenotype obtained after targeted disruption of the furin gene in mice revealed that furin is 
probably not the only pathway that regulates the processing of TGF-β family members
Yet, the effects of the synthetic pseudosubstrate furin inhibitor, dec-RVKR-cmk (Fig. 5.4) and 
the antitrypsin derivative, PDX (Fig. 5.5), demonstrate that furin may be a suitable target to 
reduce TGF-β bioactivity associated with glioma cells. Of note, since subtilisin-like 
proprotein convertases other than furin may be chiefly responsible for the inhibition of TGF-β 
processing observed here, inhibition of furin alone may not be sufficient for successful 
immunotherapy of malignant glioma. Thus, the present study defines a novel strategy for the 
pharmacotherapy or somatic gene therapy, e.g., using PD
pathological levels of TGF-β bioactivity, including glioblastoma. 
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VI. MICA/NKG2D-mediated immunogene therapy of experimental gliomas 
A related manuscript has been published in Cancer Research, 2003 Dec 15;63(24):8996-9006 
his project is based on previous work from my colleague Dr. Manuel Friese who also carried 
ut most of the experiments. Dr. Alexander Steinle generated and supplied MICA and MICB-
pecific antibodies. Yasmin Breithardt and Brigitte Frank provided expert technical 
ssistance. Dr. Ulrike Naumann generated the adenoviral constructs, Dr. Hans-Jörg Bühring 
as responsible for the cell sorting. I contributed to this project by establishing the syngeneic 
urine astrocytoma SMA-560 mouse glioma model, which served and still serves as a 
recious immunological read out tool for glioma immunotherapy approaches in our 
boratory, further I planned and characterized the immunological animal experiments 
gether with Manuel Friese. 
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Introd
lioblastoma, the most frequent malignant primary brain tumor, carries a poor prognosis, 
ith a median survival after resection, radiotherapy and chemotherapy of 12 months (201). 
he lack of effective immune responses to glial tumors inside the CNS has been attributed to 
e immune-privileged status of the brain conferred by the blood-brain barrier, the lack of 
onventional lymphatics and the local release of immunosuppressive factors (132, 202, 203). 
owever, both lymphocytes and macrophages infiltrate malignant gliomas, indicating the 
otential for lymphocyte homing and presentation of processed tumor antigens (132).  
KG2D is a C-type lectin-like homodimeric receptor expressed by human NK, γδ T and 
D8+ αβ T cells (204). In the mouse, NKG2D expression is found on NK cells, activated 
D8+ T cells and LPS-stimulated macrophages (205). Ligation of NKG2D may be a critical 
ctivating pathway to provide tumor surveillance (206-208). NKG2D interacts with ligands 
at are not constitutively, but inducibly expressed, including human MICA and MICB, 
istant cell stress-inducible homologs of MHC class I (209-211). The tissue distribution of 
IC molecules is highly restricted to intestinal epithelia, but they are frequently expressed in 
pithelial tumors (210, 212). A second family of human NKG2D ligands (NKG2DL), 
esignated UL16-binding proteins (ULBP)1, ULBP2 and ULBP3, has been characterized 
13-215). Although no murine MIC molecules have been found, there are mouse orthologs 
f ULBP, the retinoic acid early inducible gene-1 products (RAE-1). The minor 
istocompatibility antigen H60 is another murine NKG2DL (205, 216-218). H60 and RAE-1 
re upregulated on tumor cells and in response to genotoxic stress and induce tumor immunity 
06-208). 
ctivation of NK and effector T cells is inhibited by interactions of MHC class I antigens on 
ck of MHC class I antigen expression on neurons (226, 227). 
uction 
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αβ and γδ T cells. These inhibitory NK cell receptors include isoforms of the killer cell 
immunoglobulin (Ig)-like receptors (KIR) and Ig-like transcript/leukocyte Ig-like receptors 
(ILT/LIR) that interact with HLA-A, -B, -C or -G antigens, and a heterodimer formed by the 
C-type lectin like CD94 and NKG2A that interacts with HLA-E (57, 219-222). Since a 
decrease or loss of MHC class I antigen expression may accompany neoplastic 
transformation, NK cells represent a natural defense to sense and selectively eliminate 
abnormal cells (223-225). This NK-mediated cytolytic activity must be down-regulated in the 
brain to prevent autoimmune damage because of low expression levels of MHC class I 
antigens on glial cells and a la
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Material and methods 
versity 
Total RNA was prepared using RNAeasy (Quiagen, Hilden, Germany) and 
A 
AGGATGTCTTGTGAG-3’; antisense, 5’-TGAGGGTGGTGGCTGTGGCCCTGA-3’ (327 
 
Cell lines and transfectants. The human Sv-FHAS astrocytic cell line was provided by D. 
Stanimirovic (Institute of Biological Sciences, National Research Council of Canada, Ottawa, 
Canada). The human malignant glioma cell lines were provided by Dr. N. de Tribolet (Centre 
Hospitalier Universitaire Vaudois, Lausanne, Switzerland). Primary glioblastoma cells were 
established from freshly resected tumors, cultured in monolayers and used between passages 4 
and 9 (228). The murine glioma cell lines GL261 and SMA-560 were gifts of X. O. 
Breakefield (Harvard Medical School, Boston, MA) and D. D. Bigner (Duke Uni
Medical Center, Durham, NC). The cells were maintained in DMEM supplemented with 2 
mM L-glutamine (Gibco Life Technologies, Paisley, UK), 10% FCS (Biochrom KG, Berlin, 
Germany) and penicillin (100 IU/ml)/streptomycin (100 µg/ml) (Gibco). NKL cells, kindly 
provided by M. J. Robertson (Indiana University School of Medicine, Indianapolis, IN), COS-
7, YAC-1 and K562 cells (ATCC, Rockville, MD) were grown in RPMI 1640 medium 
supplemented with 15% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate and penicillin (100 
IU/ml)/streptomycin (100 µg/ml). Transfections with cDNA clones, RSV.5neo, RSV.5neo-
MICA*01 (209, 210) or RSV.5neo-PatrMIC1 (229) were conducted using FuGENE 6 
(Roche, Mannheim, Germany) and selection with G418 (1 mg/ml). PatrMIC1 is the 
chimpanzee homolog of MICA which show 87% homology and was used as a negative 
control in some experiments (229). Stable positive isolates were identified by flow cytometry 
and, to speed up the selection process sorted using a FACSvantage (Becton Dickinson, 
Heidelberg, Germany).  
RT-PCR. 
transcribed according to standard protocols. The conditions for all standard PCR were: 5 min 
at 95°C, 30 cycles of 1 min at 95°C, 1 min at 65°C and 1 min at 72°C, and 10 min at 72°C, 
using the following PCR primers: H60: sense, 5’-GATGGTACAGACTCTCTAAGTTGT-3’; 
antisense, 5’-CAGACCCTGGTTGTCAGAATTATG-3’ (554 bp); RAE-1: sense, 5’-
ATGGCCAAGGCAGCAGTGACCAAG-3’; antisense, 5’-CACATCGCAAATGCAAAT 
GCAAATAAT-3’ (748 bp); MICA: sense, 5’-GTGCCCCAGTCCTCCAGAGCTCAG-3’; 
antisense, 5’-GTGGCATCCCTGTGGTCACTCGTC-3’ (635 bp); MICB: sense, 5’-
GGCGTCAGGATGGGGTATCTTTGA-3’; antisense, 5’-GGCAGGAGCAGTCGTGAGTT 
TGCC-3’ (690 bp); ULBP1: sense, 5’-CTGCAGGCCAGGATGTCTTGTGAG-3’; antisense, 
5’-TGAGGGTGGTGGCCATGGCCTTGG-3’ (319 bp); ULBP2: sense, 5’-CTGCAGGC
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bp); ULBP3: sense, 5’-CTGCAGGTCAGGATGTCTTGTGAG-3’; antisense, 5’-
GAGGGTGGTGGCTATGGCTTTGG-3’ (321 bp); β-actin: sense, 5’-AGCCATGTAC 
e
 on Ni2+-charged chelating sepharose (BD Pharmingen, Heidelberg, 
T
GTAGCCAT-3’; antisense, 5’-TTTGATGTCACGCACGATTT-3’ (232 bp). 
Generation of monoclonal antibodies. The mouse P815 mastocytoma cell line was 
transfected using FuGENE 6 with full length cDNA of NKG2DL MICA*01, MICA*04, 
MICB*02, ULBP1, ULBP2 or ULBP3, in RSV.5 neo (214). Transfectants were selected with 
G418. BALB/c mice were immunized either with a mixture of MICA*01-, MICA*04-, and 
MICB*02-, or ULBP1-, ULBP2-, and ULBP3- expressing P815 cells. Splenocytes of 
immunized mice were fused with P3X63Ag8.653 myeloma cells. Hybridoma supernatants 
were tested by indirect immunofluorescence using a FACSCalibur (Becton Dickinson) for 
selective binding to P815-NKG2DL transfectants and to COS cells transiently transfected 
with the various NKG2DL cDNAs. Hybridomas producing NKG2DL-specific mAbs were 
subcloned twice and immunoglobulins were isotyped using an isotyping kit (Roche). BAMO-
1 (IgG1) and BAMO-2 (IgG2a) recognize MICA and MICB, AMO-1 (IgG1) is MICA-specific, 
BMO-1 (IgG1) MICB-specific, AUMO-1 (IgG1) ULBP1-specific, BUMO-2 (IgG1) ULBP2-
specific and CUMO-1 (IgM) ULBP3-specific (230). 
Production of soluble mNKG2D in insect cells. Recombinant soluble mNKG2D lacking th  
amino-terminal cytoplasmic region and transmembrane domain was produced in Sf9 insect 
cells (Invitrogen, Karlsruhe, Germany) using the BAC-to-BAC system (Gibco Life 
Technologies, Paisley, UK). The expression construct included an amino-terminal 
FLAG/hexahistidine (214). Soluble mNKG2D was purified from culture supernatant by 
affinity chromatography
Germany) and size-exclusion filtration. 
Monoclonal antibodies and flow cytometry. Cell surface expression of MHC class I 
antigens and NKG2D was assayed with the following monoclonal antibodies: W6/32, IgG2a 
pan anti-HLA-A, -B, -C, -E, -G (Biozol, Echingen, Germany); anti-H-2Kb (BD Pharmingen, 
Heidelberg, Germany); anti-H-2Db (Caltag Laboratories, Hamburg, Germany); M585, IgG1 
anti-NKG2D (kindly provided by Immunex, Seattle, WA). IgG1, IgG2a and IgM isotype-
matched antibodies were used as controls (BD Pharmingen). For the mNKG2D binding 
assays, mAb anti-FLAG M2 (5 µg/ml) (Sigma) was mixed with soluble mNKG2D (3 mg/ml) 
prior to addition to cells. COS-7 cells were transiently transfected with neo-control, MICA*01 
or PatrMIC1. MICA/B and PatrMIC1 expression levels were detected by flow cytometry 
using the mAb AMO-1. Interactions of human MICA*01 and chimpanzee PatrMIC1 with 
mouse NKG2D was analyzed by staining with flagged soluble mouse NKG2D and anti-
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FLAG mAb. Glioma cells were detached using Accutase (PAA, Wien, Austria), preincubated 
in PBS with 2% BSA and incubated with the specific antibody or matched mouse Ig isotype 
(10 µg/ml) as a control for 30 min on ice. Specific binding was detected with PE-conjugated 
monocytes using the LymphoKwik TTM reagent (One 
goat anti-mouse IgG (Sigma). Fluorescence was measured in a Becton Dickinson 
FACScalibur. Specific fluorescence indexes (SFI) were calculated by dividing mean 
fluorescence obtained with specific antibody by mean fluorescence obtained with control 
antibody.  
Adenoviral constructs and transduction. Replication-deficient recombinant adenoviruses 
(Ad5dE1,3) that had the E1A region replaced by the full length MICA*01 cDNA (Ad-MICA) 
were constructed using the AdEasy System, kindly provided by Bert Vogelstein (The Howard 
Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD). 
Recombinant adenoviral particles were produced in 293 cells (ATCC CRL-1573) and 
transgene expression was assessed by RT-PCR. Infection of target cells with recombinant 
viruses was accomplished by exposing cells to different concentrations of adenovirus in PBS 
containing 10% glycerol for 15 min followed by addition of serum-containing medium for 2 
days. 
Purification of PBL and isolation of NK and T cells. PBMC were derived from healthy 
donors by density gradient centrifugation (Biocoll, Biochrom KG) and depletion of plastic-
adherent cells. PBL were cultured on irradiated RPMI 8866 feeder cells in order to obtain 
polyclonal NK cell populations. To further enrich NK cells, PBL were sorted by 
immunomagnetic depletion using Dynabeads (NK Cell Negative Isolation Kit, Dynal, Oslo, 
Norway). CD3- CD56+ cells were used for cytotoxicity assays. To obtain purified T cells, 
fresh PBL were depleted of B cells and 
Lambda Inc., Canoga Park, CA).  
Mouse lymphocyte isolation. Murine NK cells were prepared from splenocytes from CD1-
deficient BALB/c nude mice or VMDk mice. NK cells were positively selected using DX5 
mAb-coupled magnetic beads with the corresponding column system (Miltenyi Biotech, 
Bergisch Gladbach, Germany). Polyclonal mouse NK cells were cultured with mouse IL-2 
(5000 U/ml, Preprotech, London, UK) for at least 10 days before use in cytotoxicity assays. 
Cytotoxicity assay. Cytotoxicity was assessed in 4 h 51Cr release assays in the absence or 
presence of various mAb or soluble mNKG2D. The concentrations for the masking 
experiments were 10 µg mAb/ml and 20 µg/ml for soluble mNKG2D. The 51Cr release assay 
was performed using 2000 51Cr-labeled targets per well. Effector and target cells were 
incubated at various effector:target (E:T) ratios for 4 h. Spontaneous release of 51Cr was 
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determined by incubating the target cells with medium alone. Maximum release was 
determined by adding NP40 to a final concentration of 2%. The percentage of 51Cr release 
was calculated as follows: 100 x ([experimental release – spontaneous release]/[maximum 
release – spontaneous release]). 
T cell reaction against allogeneic glioma cells. To suppress LN-229 glioma cell 
proliferation, the cells were irradiated at 100 Gy. HLA-A2-positive T cells or PBMC 
(105/well) were cocultured with 104 irradiated LN-229 HLA-A2-negative glioma cells in 96 
elease assay. T cells (1 x 106/well) isolated at day 10 after tumor inoculation from 
-6 mice were injected subcutaneously in the right flank with 
 
g, 
.
well plates in triplicates. After 4 days the cells were pulsed for 24 h with [methyl-3H]-
thymidine (0.5 µCi, Amersham, Braunschweig, Germany) and harvested with a cell harvester 
(Tomtec, Hamden, CT). Incorporated radioactivity was determined in a Wallac 1450 
Microbeta Plus Liquid Scintillation Counter. For the priming assays, non-irradiated glioma 
cells were incubated with PBMC or T cells for specific priming and clonal expansion. 
Lymphocytes were harvested on day 5 and used as effectors in a 4 h 51Cr release cytotoxicity 
assay. Mock-transfected LN-229.neo cells or LN-229 cells transfected with MICA*01 or 
PatrMIC1 were used as targets. 
IL-2 r
spleens of vaccinated or control animals were stimulated ex vivo with irradiated SMA-560 
cells (1 x 105). T cell supernatants from triplicate wells were collected and pooled 48 h later. 
IL-2 release was determined by ELISA (R&D Systems, Minneapolis, MN). 
Mice and animal experiments. Athymic CD1-deficient BALB/c nude mice were purchased 
from Charles River Laboratories (Sulzfeld, Germany) and VMDk mice from the TSE 
Research Center (Berkshire, UK). Mice of 6-12 weeks of age were used in all experiments. 
The experiments were performed according to NIH guidelines "Guide for the Care and Use of 
Laboratory Animals". Groups of 4
transfected LN-229 tumor cells, or uninfected or infected SMA-560 glioma cells (1 x 106 
cells) in 0.1 ml of PBS, as indicated. Mice were examined regularly for tumor growth using a 
metric caliper and killed when tumors reached >12 mm diameter. Mice were anesthetized by 
intraperitoneal injection of 7% chloral hydrate before all intracranial procedures. For 
intracranial implantation the mice were placed in a stereotactic fixation device (Stoeltin
Wood Dale, IL) and a burr hole was drilled in the skull 2 mm lateral to the bregma. The 
needle of a Hamilton syringe (Hamilton, Darmstadt, Germany) was introduced to a depth of 3 
mm. Five x 104 LN-229 glioma cells or 5 x 103 SMA-560 cells in a volume of 2 µl PBS were 
injected into the right striatum  The mice were observed daily and sacrificed when developing 
neurological symptoms. 
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Immunohistochemistry. Cryosections (0.7 mm) of SMA-560 gliomas, prepared at day 10 
after glioma cell inoculation, were fixed in acetone and blocked with 2% normal rabbit serum 
and 2% BSA. Tissue sections were stained with antibodies (1:50) to CD8 (53-6.7) (CD8 T 
cells) and CD11b (M1/70) (macrophages/microglia) (BD PharMingen, Heidelberg, Germany). 
A biotinylated anti-rat secondary antibody (Zymed, San Francisco, CA) was used at 1:150. 
Avidin biotin complex was added, and the staining was developed with diaminobenzidine. 
Murine spleens served as positive controls. Normal murine brain served as a negative control.  
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Results 
 
Expression of NKG2DL and MHC class I antigens by human glioma cells. To investigate 
the expression of the NKG2DL MICA, MICB, ULBP1, ULBP2 and ULBP3 by glioma cells, 
12 glioma cell lines, a non-neoplastic astrocyte line, Sv-FHAS and five primary ex vivo 
cultured glioma cells, were assessed by RT-PCR (Fig. 6.1. A,B). 
 
 
Fig. 6.1.A,B NKG2DL expression in human glioma cells. A, B. NKG2DL (MICA, MICB, 
ULBP 1, 2, 3) mRNA expression was assessed by RT-PCR in human glioma cell lines (A) and 
primary glioma cells (B). β-actin was used as a standard. 
 
MICA and ULBP1, 2 and 3 mRNA were expressed by almost all cell lines and most of the 
primary glioma cell cultures. MICB was not detectable in U251MG or U373MG cells and 
several primary glioma cell cultures. In contrast, none of the NKG2DL were detected in Sv-
FHAS cells. We next monitored the cell surface expression of NKG2DL and MHC class I 
antigens using monoclonal antibodies. All glioma cell lines expressed MICA, ULBP2 and 
ULBP3. MICB was expressed by 9 of 12 cell lines while ULBP1 was only detectable for 5 of 
12 cell lines. All of the primary gliomas expressed MICA and ULBP2, and the other 
NKG2DL at various levels (Table 1). MICB was expressed by TU132, TU140 and 203 while 
TU113 and TU 207 did not (Table 1). All cell lines and primary cultures showed high levels 
of MHC class I antigen expression. The non-neoplastic Sv-FHAS cell line did not express 
any NKG2DL, as determined by RT-PCR and flow cytometry. Sv-FHAS cells showed low 
MHC class I antigen expression (Table 1). 
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Cell line 
MHC class I 
(W6/32) 
MICA  
(AMO-1) 
MICB  
(BMO-1) 
MICA/B 
(BAMO-1) 
ULBP1 
(AUMO-1) 
ULBP2 
(BUMO-2) 
ULBP3 
(CUMO-1) 
A172 145 13.0 2.3 11.2 1.8 4.1 1.8 
D247 113 8.2 1.5 6.5 1.0 1.6 1.4 
LN-18 85 6.1 3.6 7.3 1.0 2.4 1.9 
LN-229 215 6.9 2.0 5.2 1.1 5.8 6.7 
LN-308 153 4.7 1.8 5.0 1.1 3.1 2.6 
LN-319 112 9.7 2.2 8.9 1.3 3.7 4.4 
LN-428 129 5.9 1.6 6.3 1.2 3.1 2.2 
T98G 480 12.3 5.0 10.3 1.6 6.7 8.6 
U87MG 351 8.6 2.2 6.4 1.3 5.9 8.4 
U138MG 346 11.7 1.2 11.2 2.4 3.6 3.4 
U251MG 216 14.5 1.0 9.2 1.0 7.6 5.3 
U373MG 358 11.6 1.0 7.0 1.0 11.8 6.0 
Sv-FHAS 90 1.0 1.0 1.0 1.0 1.1 1.2 
TU113 29 4.0 1.0 3.9 1.0 1.7 1.4 
TU203 23 3.8 1.3 3.5 1.3 1.7 1.1 
TU207 38 1.4 1.1 1.4 1.1 1.7 1.1 
TU132 95 6.2 1.4 4.4 1.0 1.3 1.0 
TU140 100 9.1 2.5 7.4 1.3 1.8 1.0 
 
human malignant glioma cell lines, non-neoplastic Sv-FHAS astrocytes and primary glioma 
or cells, suggesting that ectopic MIC expression 
vercomes the inhibitory effect of MHC class I antigens (Fig. 6.2.A,B, lower panels).  
Table 1. Flow cytometric analysis of MHC class I antigens and NKG2DL expression by 
cell cultures. The cells were stained with the indicated mAb or isotype-matched Ig. Expression 
was quantified as SFI values (mean fluorescencespecific mAb/mean fluorescenceisotyp control). 
 
Stable transfection and adenoviral gene transfer of MICA into glioma cells stimulates 
NK cytolytic activity. To determine whether increased NKG2DL expression confers 
additional stimulatory signals for NK cells, we generated stable MICA*01 and PatrMIC1 
(chimpanzee MIC homolog (229)) transfectants of the LN-229 and Sv-FHAS cell lines (Fig. 
6.2. A,B). PatrMIC1 was included in this study to serve as a negative control for the nude 
mouse model in vivo (see below). Enhanced MICA or PatrMIC1 expression rendered cells 
susceptible to lysis by human NKL effect
o
 
 117
 118
Fig. 6.2.A-C. Ectopic MICA*01 and PatrMIC1 expression by glioma cells promote NK cell-
mediated cytolysis. A, B. LN-229 (A) or Sv-FHAS (B) cells transfected with MICA*01 or 
PatrMIC1 were assessed for MICA (mAb BAMO-1) or PatrMIC1 (mAb BAMO-2) expression 
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(filled profiles) as compared to mock-transfectants (neo-control) by flow cytometry. Open profiles 
show the labeling with isotype-matched Ig. The SFI values are indicated in the upper right of each 
panel. (C) LN-229 or TU113 primary glioma cells were infected with Ad-MICA or Ad-dE1 (300 
MOI) and assessed for MICA expression accordingly. In the lower panels of A-C, the cell lines 
were tested as targets for human NKL cells in 51Cr release assays. Data are expressed as specific 
lysis at different E:T ratios. 
 
Similar results were obtained with freshly isolated polyclonal NK cells (data not shown). For 
a gene therapeutic approach, we generated an adenoviral vector encoding MICA*01 (Ad-
MICA). Infection of LN-229, primary glioma cells (Fig. 6.2.C) or other glioma cell lines (data 
not shown) with Ad-MICA resulted in a marked increase in MICA expression. Adenoviral 
MICA gene transfer also promoted NK-mediated cytolysis (Fig. 6.2.C, lower panel). 
 
LN-229.neo transfectants were sensitized to NK cytolysis by treatment with the anti-MHC 
class I mAb W6/32 (Fig. 6.3.A), confirming that classical MHC class I antigens protect LN-
229.neo cells from NK cytolysis. Anti-MICA/B (BAMO-1) or -NKG2D (M585) mAb had no 
effect on cytolysis in LN-229.neo cells. However, these mAb either attenuated (anti-MICA) 
or blocked (anti-NKG2D) the sensitization mediated by anti-MHC class I mAb. The superior 
effect of anti-NKG2D compared with anti-MICA reflects the composition of the system of a 
single receptor (NKG2D) in NK cells, but multiple ligands (MIC and ULBP molecules) 
expressed by LN-229 cells (Fig. 1, Table 1). Soluble mouse NKG2D (mNKG2D) attenuated 
the anti-MHC class I mAb-mediated sensitization as effectively as anti-MICA, suggesting that 
murine NKG2D interacts with some human NKG2DL. NK cytolysis of LN-229.MICA targets 
pre-treated with anti-MICA or anti-NKG2D mAb was reduced (Fig. 6.3.B), demonstrating 
that enhanced cytolysis of LN-229.MICA cells is due to MICA overexpression overruling 
MHC class I antigen inhibitory signals. Similar results were obtained with LN-229.PatrMIC1 
transfectants (Fig. 6.3.C) 
 
Costimulatory functions of MICA-transfected glioma cells. Allostimulation assays were 
performed to analyze whether MICA/NKG2D interactions promote the induction of T cell 
responses. LN-229.MICA or LN-229.PatrMIC1 cells were substantially more potent 
stimulators (3-fold) of T cell proliferation than LN-229.neo cells (Fig. 6.4.A). mAb masking 
f MICA abrogated the augmentation of T cell proliferation mediated by MICA, but had no 
effect when T cells were coincubated with LN-229.neo cells (Fig. 6.4.B). Additional evidence  
o
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targets. The specific lytic activities are given for an E:T ratio of 40:1 (mean ± SD, t-test, ∗ P < 
0.05, ∗∗ P < 0.01, compared with isotype control Ig). 
A2-mismatched T cells. [3H]-thymidine was added on day 4 for 16 h and incorporation was 
measured by liquid scintillation counting. (B) Irradiated glioma cells were preincubated with 
Fig. 6.3.A-C. NKG2DL and MHC class I antigen expression determines NK cytolysis. A-C. 
Different target cell lines were pretreated with control Ig or anti-MICA BAMO-1 mAb, anti-
PatrMIC1 BAMO-2 mAb, anti-MHC class I W6/32 mAb or soluble mNKG2D. NKL effector cells 
were pretreated with control Ig or anti-NKG2D M585 mAb for 30 min before use in 51Cr release 
cytotoxcity assays. LN-229.neo (A), LN-229.MICA (B) or LN-229.PatrMIC1 (C) were used as 
0 10 20 30 40 50
anti-NKG2D
anti-PatrMIC1
anti-MHC I
control IgG
Specific lysis of LN-229.PatrMIC1 [%]
*
**
C
LN-229.neoA
0 10 20 30 40 5
anti-MHC I + mNKG2D
anti-MICA
Specific lysis of LN-229.neo [%]
*
0 10 20 30 40
anti-MHC I + anti-NKG2D
anti-MHC I + anti-MICA
anti-MHC I
anti-NKG2D
control IgG
**
*
**
A
0
**
**anti-NKG2D
anti-MICA
anti-MHC I
control IgG
Specific lysis of LN-229.MICA [%]
B
50
Fig. 6.4.A,B. Modulation of alloreactivity to glioma cells by MICA and PatrMIC1. A. 
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isotype control ab or anti-MICA (BAMO-1) and processed as in A. Data are expressed as cpm ± 
SD (t-test, ∗∗ P < 0.01, compared with LN-229.neo in A or isotype control ab in B). 
 
 
Fig. 6.4.C-E. T cells were incubated with glioma cells, harvested on day 4 and used as 
effectors in a 4 h Cr-release assay at the indicated E:T ratios. 
 
for the costimulatory potential of NKG2D for T cells was obtained by rechallenging primed T 
cells. T cells were primed for 4 days with LN-229.neo, LN-229.MICA or LN-229.PatrMIC1 
cells and then used as effectors against fresh LN-229.neo, LN-229.MICA or LN-
229.PatrMIC1 cells. No target cell lysis was seen when LN-229.neo cells, LN-229.MICA or 
LN-229.PatrMIC1 cells were used as targets for LN-229.neo-primed T cells (Fig. 6.4.C-E). In 
contrast, LN-229.MICA- or LN-229.PatrMIC1-primed T cells efficiently killed LN-229.neo, 
LN-229.MICA or LN-229.PatrMIC1 cells with comparable efficacy, indicating that NKG2D 
ligati cells 
(Fig. 
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MIC ht to 
exam
vivo models. We first tested the physical and functional engagement of MICA*01 and 
PatrMIC1 by mouse NKG2D (mNKG2D). Interaction of MICA*01 and PatrMIC1, 
respectively, with mNKG2D, was assessed by using soluble mNKG2D. COS-7 cells 
transiently transfected with either MICA*01 or PatrMIC1 cDNA stained with the mAb AMO-
1, but only MICA*01-transfected COS cells bound soluble mNKG2D (data not shown). We 
concluded that mNKG2D interacts with human MICA*01, but not with PatrMIC1. PatrMIC1 
differs from MICA and MICB in several positions directly involved in NKG2D interaction, 
which may selectively interfere with binding of mNKG2D (209-211). Accordingly, NK cell 
cytotoxicity assays using polyclonal mouse NK cells as effector cells revealed marked lysis of 
human MICA glioma cell transfectants, but not of mock or PatrMIC1 transfectants (Fig. 
6.5.A), indicating an activation by MICA*01 of the mouse NKG2D receptor. PatrMIC1 
transfectants served hereafter as negative controls in the ensuing nude mice studies. 
The immune stimulatory potential of MICA transfected LN-229 cells for the NK cell 
mediated anti-glioma response in vivo was examined in subcutaneous and intracerebral 
xenograft glioma models in nude mice which have NK cells, but lack T cells. LN-229 glioma 
cells were injected subcutaneously and the tumor sizes were measured every two days. LN-
229. PatrMIC1 cells grew rapidly to form compact tumors whereas LN-229.MICA tumor 
rowth was significantly delayed (Fig. 6.5.B). Tumor volumes differed significantly (t-test, P 
 0.01) from day 17 to the end of the experiment. When LN-229 cells were implanted 
stereo mors 
devel  day 20-21. In contrast, animals 
arrying LN-229.MICA tumors showed significantly prolonged survival (Fig. 6.5.C) (t-test, P 
A expression delays growth of glioma xenografts in nude mice. We next soug
ine the immune-stimulatory capacity of MICA-overexpressing glioma cells in murine in 
g
<
tactically into the brains of nude mice, animals carrying LN-229.PatrMIC1 tu
oped neurological symptoms and had to be sacrificed at
c
< 0.01). Appropriate control experiments disclosed no difference between the proliferation of 
LN-229.MICA and LN-229.PatrMIC1 cell lines in vitro (Table 2). 
 
 
 
 
 
 
 
 Proliferation [cpm] 
 LN-229 SMA-560 
Parental 1802 ± 401  3078 ± 523 
PatrMIC1 (stable) 1766 ± 431 - 
MICA (stable) 1722 ± 386 - 
Ad-dE1 (300 MOI) - 3153 ± 500 
Ad-MICA (300 M
Table 2. MICA gene transfer does not modulate
glioma cell growth as assessed by [3H]-thymidine
incorporation in vitro. [3H]-thymidine incorporation
was measured after 24 h by liquid scintillation
counting. Data are expressed as cpm ± SD. 
OI) - 3122 ± 489 
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Since MICA gene transfer delayed glioma growth, but did not lead to tumor rejection, we 
characterized the glioma cells forming progressive tumors in nude mice. To this end, we 
isolated the tumor cells, which had grown subcutaneously and analyzed the expression of 
MICA and PatrMIC1 by flow cytometry. These experiments yielded two findings which 
support a proficient role for MICA as a potent molecule inhibiting the growth of gliomas. 
First, glioma cells recovered from mice that had received LN-229.PatrMIC1 cells, showed 
unaltered levels of high PatrMIC1 expression before and after tumor inoculation, consistent 
with the failure of PatrMIC1 to interact with mNKG2D (Fig. 6.5.D, left); secondly, all tumor 
cells harvested from mice which had received LN-229.MICA*01 cells were essentially 
devoid of MICA. This is probably due to tumor formation by a small non-MICA expressing 
population among the LN-229.MICA cells (Fig. 6.5.D, right). Endogenous MICA expression 
in LN-229.PatrMIC1 cells was also reduced after glioma cell passaging in vivo: the SFI 
decreased from 2.6 prior to inoculation to 1.4 after inoculation. MHC class I antigen 
expression measured by flow cytometry did not change after MICA transfection or in vivo 
c M A ex ays the growth of subcutaneous and intracerebral human 
glioma xenografts in nude mice. (A) LN-229 transfectants were tested as targets for BALB/c nude 
mice NK cells in a 51Cr release assay. (B) The growth of subcutaneous LN-229.PatrMIC1 or LN-
passaging (data not shown). 
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229.MICA tumors was monitored every 2 days. (C) LN-229.PatrMIC1 (solid line) or LN-
229.MICA*01 (broken line) cells (5 x 104) were inoculated intracerebrally in Balb/c nude mice. 
Survival data for five animals per group are shown (t-test, r  0.59, < 0.01). ( ) At 25 days after 
tumors were analyzed for PatrMIC1 in PatrMIC1 tumors (left) or MICA in MICA tumors (right) 
by flow cytometry. Representative tumor isolates are shown as grey profiles, the preinoculation 
levels as black profiles, and an isotype control as open profiles. 
 
NKG2DL expression by mouse glioma cell lines. We evaluated two syngeneic mouse 
glioma models, SMA-560 cells in VMDk mice (spontaneous tumor) and GL261 cells in 
C57BL/6 mice (3-methylcholanthrene-induced), for a therapeutic trial of MICA gene transfer 
in vivo. The mNKG2DL RAE-1β was prominently expressed by SMA-560 cells while GL261 
showed only a weak expression. H60 was only expressed by SMA-560 and not by GL261 
cells, consistent with the report that C57BL/6 mice do not express H60 (207) (Fig. 6.6.A).  
 
2 P D
injection of tumor cells, the mice were killed, and freshly isolated tumor cells from subcutaneous 
 
Fig. 6.6.A. SMA-560 glioma cells in VMDk mice as syngeneic model for MICA gene transfer. 
(A) Expression of the murine NKG2DL RAE-1β and H-60 mRNA was assessed by RT-PCR. 
YAC-1 cells were used as a positive control. β-actin was used as a standard. 
 
Soluble mNKG2D was more prominently bound by SMA-560 than GL261 cells (Fig. 6.6.B), 
indicating higher expression levels of mNKG2DL in SMA-560 cells. Whereas SMA-560 cells 
expressed both MHC class I antigensH-2Kb and H-2Db which are potential ligands for 
inhibitory Ly49 receptors, GL261 cells showed only low level H-2Db expression (Fig. 6.6.B). 
SMA-560 cells thus resemble the phenotype of human glioma cell lines and were used in 
further animal experiments. When SMA-560 cells were infected with Ad-MICA, MICA 
expression increased in a multiplicity of infection (MOI)-dependent manner: the SFI values 
were 6.6 at 100 MOI, 12.2 at 300 MOI and 22.8 at 1000 MOI (Fig. 6.7.B). Similar to LN-229 
cells, the growth of SMA-560 cells was unaffected by forced MICA expression (Table 2). The 
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(Fig. G2D 
demo e to 
MICA expression. Attenuation of the constitutive lysis of control-infected SMA-560 cells by 
appro 2DL 
like R ve in 
inhib   
 values are indicated 
in the upper right corner of each panel. (C) Uninfected, Ad-dE1 (300 MOI)-infected or Ad-MICA 
Cr release assay, using VMDk NK cells as effectors. Data are expressed as specific lytic 
6.6.C). Blocking experiments with anti-MICA mAb and soluble mNK
nstrated that the increased killing of Ad-MICA infected SMA-560 cells was du
ximately 50% by mNKG2D probably reflects the activation by endogenous NKG
AE-1 and H60 (Fig. 6.6.D). Accordingly, neutralization of MICA was less effecti
iting lysis of Ad-MICA-infected cells than mNKG2D.
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Fig. 6.6.B. NKG2DL and MHC class I antigen expression (H-2Kb, H-2Db) was assessed by 
flow cytometry. The cell lines were stained with soluble mNKG2D/anti-FLAG or the indicated 
mAb (solid profiles) or with isotype-matched control ab (open profiles). SFI
(300 MOI)-infected SMA-560 cells were tested as targets for NK cells isolated from VMDk mice 
in 51Cr release assays at 48 h. (D) Ad-dE1- or Ad-MICA-infected (300 MOI) SMA-560 cells were 
untreated or pretreated with soluble mNKG2D, or control ab or anti-MICA, and tested as targets in 
51
activities at an E:T ratio of 40:1 (mean ± SD, t-test, ∗ P < 0.05, ∗∗ P < 0.01). 
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MICA expression in SMA-560 glioma cells delays tumor growth. To analyse the immune 
stimulatory capacity of MICA-transduced SMA-560 tumor cells in vivo, VMDk mice were 
inoculated subcutaneously with syngeneic tumor cell transductants. There was no difference 
between the in vivo growth of Ad-dE1-infected and uninfected SMA-560 cells. Conversely, 
MICA*01 expression by SMA-560 glioma cells resulted in a substantial delay of tumor 
growth in a MOI-dependent manner (Fig. 6.7.A). Of note, two out of six animals in the groups 
challenged with 300 and 1000 MOI-infected glioma cells, respectively, developed no tumor. 
Irrespective of the initial level of MICA expression prior to inoculation, glioma cells 
harvested from progressive tumors at day 10 after inoculation were devoid of MICA (Fig. 
6.7.B). To address whether prior immunization with glioma cells that express MICA induces 
protective immunity to wild-type glioma cells, mice that had previously rejected MICA-
transduced tumor cells were rechallenged with wild-type SMA-560 cells 10 weeks after the 
first exposure in the opposite flank. Wild-type SMA-560 cells grew progressively in naïve  
 
 
Fig. 6.7. MICA delays SMA-560 glioma growth in
syngeneic mice. A. The growth of subcutaneous tumors
formed by SMA-560 cells infected in vitro with Ad-dE1
(1000 MOI) or Ad-MICA (100, 300 or 1000 MOI) was
monitored every 2 days. Two of 6 animals challenged with
Ad-MICA-infected cells at 300 and 1000 MOI did not
develop a measurable tumor. (B) SMA-560 cells infected
with Ad-MICA at increasing MOI were assessed for MICA
expression before subcutanous inoculation (black profiles).
Open profiles show the labeling with isotype-matched Ig.
Further, glioma cells were freshly isolated from
subcutaneous tumors at 10 days after inoculation and re-
SMA-560
300 Ad-MICA
SMA-560
100 Ad-MICA
4/6
2/6
4/6
2/6
A
B
C
SMA-560
1000 Ad-MICA
analyzed for MICA expression (grey profiles). (C) VMDk
mice that had previously rejected MICA-transduced SMA-
560 cells were inoculated subcutaneously with wild-type
SMA-560 glioma cells in the opposite flank. Primary
exposure preceded the challenge by 10 weeks. 
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VMDk mice, but were rejected by mice that had been exposed previously to the MICA-
transduced tumor cells (Fig. 6.7.C) 
 
Subcutaneous vaccination with MICA-expressing glioma cells after tumor inoculation 
delays tumor growth. To address whether subcutaneous vaccination with tumor cells 
expressing MICA induces protective immunity to pre-established SMA-560 gliomas, mice 
were intracerebral inoculated with SMA-560 wild-type cells and then immunized with 
irradiated wild-type cells or irradiated Ad-dE1 (1000 MOI) or Ad-MICA (1000 MOI) -
infected SMA-560 cells at days 3 and 8 (Fig. 6.7.D). Peripheral vaccination with Ad-MICA-
infected irradiated cells resulted in a significant prolongation of survival with 2 of 6 animals 
still alife and asymptomatic after 90 days (t-test, P < 0.01). NK cells isolated from 
splenocytes from mice vaccinated with Ad-MICA-transduced SMA-560 cells at day 10 
showed a substantially enhanced cytotoxic activity against YAC-1 target cells compared with 
NK cells from animals vaccinat 6.7.E). 
Evidence for T cell stimulation by lated at 
day 10 after tumor cell inoculatio MICA-
infected SMA-560 cells released h 0 wild-
type cells, while no such effect was seen with control-transduced tumor cells (Fig. 6.7.F). 
 
 
Fig. 6.7.D-F. 5 x 103 SMA-560 cells were inoculated intracerebrally in syngeneic VMDk mice 
(day 1). D. At days 3 and 8 the animals were vaccinated subcutaneously with 1 x 106 irradiated 
Ad-dE1- or Ad-MICA-infected (1000 MOI) or uninfected SMA-560 cells. The graph shows 
survival data for 6 animals per group (t-test, P < 0.01). (E, F) At day 10, splenocytes were 
ed with control-transduced SMA-560 cells (Fig. 
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recovered from the differently vaccinated animals and T and NK cells were isolated. (E) NK cells 
were used as effector cells in a 51Cr release assay using YAC-1 cells as targets. (F) Isolated T cells 
were restimulated with irradiated wild-type SMA-560 cells, and IL-2 release was measured by 
ELISA 48 h later. 
 
Fig. 6.8.A-M. Ad-MICA gene transfer promotes immune cell infiltration in the SMA-560 
syngeneic mouse glioma model. VMDk mice were inoculated intracerebrally with SMA-560 
wild-type cells and vaccinated subcutaneously with SMA-560 (A, B, C), SMA-560.Ad-dE1 (D, E, 
F) or SMA-560.Ad-MICA (G, H, I) at days 3 and 8 post-inoculation. Cryosections were generated 
 
To determine the in situ  distribution of glioma-infiltrating immune cells, we analyzed brain 
sections at day 10 post tumor inoculation by immunohistochemistry (Fig. 6.8). Using specific 
mAbs for CD8+ T cells (CD8) and macrophages/microglia (CD11b), we observed an increase 
in number of infiltrating immune cells in SMA-560 gliomas after SMA-560.Ad-MICA 
vaccination compared with SMA-560 or SMA-560.Ad-dE1 vaccinated animals. We were not 
able to stain murine NK cells with the currently available antibodies (231). An antibody 
recognizing Ly-49G2 (4D11) which has been reported to stain murine NK cells in 
immunohistochemistry provided no signal in our hands probably because VMDk mice do not 
express Ly-49G2 (231).  
 128
from brains at day 10 following tumor inoculation and stained with mAb directed against 
macrophages/microglia (A, D, G) or CD8+ T cells (B, E, H), or with isotype-matched control mAb 
(C, F, I). Spleen sections from untreated animals were used as positive controls (J, K, L) 
Magnification for all sections was x 20. (M) Quantification of positively stained cells per visual 
field in glioma sections in x 20 magnification. Each column represents the average number (± SD, 
t-test, ∗∗ P < 0.01) of positively stained cells from at least three different brain sections. 
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Discu
 
This e to 
gliob 2DL 
expressed on glioma cells is overruled by MHC class I molecules which engage inhibitory 
receptors on NK cells. Gene transfer-mediated ectopic expression of MICA on human and 
mouse glioma cells permits their in vitro immune recognition and lysis and in vivo growth 
inhibition despite high level MHC class I antigen expression. These observations provide a 
rationale for MICA-based immunogene therapy of gliomas. 
Malignant transformation of glial cells is associated with an NKG2DL expression, this is, of 
MICA/B and ULBP molecules, at the cell surface (Fig. 6.1.A,B, Table 1). However, the NK 
cell inhibitory potential of MHC class I antigens expressed on human glioma cells masks the 
activating signals of NKG2DL. The interaction of effector NKG2D with endogenous tumor 
MIC and ULBP molecules promotes NK cell-mediated tumor cell lysis in vitro when MHC 
class I antigens are masked (Fig. 6.3.A). NK cell-mediated tumor cell lysis was also achieved 
when MICA expression was enhanced via plasmid transfection or adenoviral gene transfer 
(Fig. 6.2 and 6.3.B) (225). NKL cells do not express the FcγRIII (CD16) (232) which 
mediates antibody-dependent cellular cytotoxicity (ADCC), ruling out that the lysis seen in 
the presence of mAbs is due to ADCC. Thus, glioma cells out-balance activating ligand 
expression by inhibitory MHC class I antigens and prevent NK cell lysis. This concept is 
supported by a highly significant correlation between MHC class I antigen expression and 
NKG2DL expression on human glioma cells when the SFI values for the NK cell inhibitory 
MHC class I antigens were correlated with a sum score of the SFI values for MICA, MICB, 
ULBP1, 2 and 3, (t-test, r2 0.6523, P 0.0015). 
One way of immune escape for glioma cells may be the expression of MHC class I antigens at 
a level that allows sufficient binding of NK inhibitory receptors and escape from NK-
mediated killing. High expression of MHC class I antigens in human glioblastomas in vivo 
has been confirmed by several studies (233, 234). MHC class I down-regulation, conversely, 
is a hallmark of many peripheral cancers and decreases the susceptibility of tumor cells to 
lysis by cytotoxic T cells (224, 235). Possibly only those glioma cells which show an 
upregulation of MHC class I antigens expression to compensate for the acquisition of 
activating NKG2DL expression during malignant transformation will survive. This selection 
may render tumor cells more vulnerable towards T cell-dependent elimination through tumor-
associated antigen detection (224, 235). Since the brain lacks specific brain-associated 
lymphoid tissue, antigens which are introduced directly into the brain parenchyma exclusively 
ssion 
study investigates the potential of NKG2DL to promote an immune respons
lastoma. We show that NKG2D-mediated NK cell triggering induced by NKG
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elicit transient innate inflammatory immune responses, but no adaptive immunity (236-240). 
owever, if immunization is elicited by injecting the identical antigen outside the brain, the 
e levels of activating NKG2DL 
intracerebral implantation of wild-type tumor 
H
adaptive immune system becomes primed, and antigenic epitopes anywhere within the brain 
will be recognized as targets of either activated effector T cells, B cells or antibodies (236, 
238, 240). This immunological peculiarity may explain high expression levels of MHC class I 
antigens on glioma cells which could effectively present tumor-associated antigens to primed 
T cells. Since intracerebral T cell priming is not found, the MHC class I antigens may only 
serve to suppress NK cell activation by NKG2DL.  
The highly lethal nature of glioblastoma suggests that th
expressed by glioma cells are too low to induce anti-tumor immunity. Thus, we concluded 
that immunity to gliomas may be boosted by engineering cells expressing high levels of 
activating NKG2DL. We noted that MICA gene transfer induces NK and T cell responses to 
glioma cells in vitro (Fig. 6.2-4) and delays growth in a human xenograft and syngeneic 
mouse glioma model in vivo (Fig. 6.5-7). In this model, the in vivo selection for low MICA 
expressing glioma cells strikingly demonstrated the NK cell activating potential of the 
NKG2D/NKG2DL system (Fig. 6.5.D, 6.7.B). Previously it was shown that ligation of 
NKG2D on NK and T cells can promote subsequent T cell immunity to parental tumors which 
lack NKG2DL, although T cell priming was NK cell-independent (207). However, a similar 
study did not detect such T cell-mediated memory against the parental tumor in mice (206). 
Our data support that NKG2D engagement costimulates human CTL responses since prior 
immunization with tumor cells expressing the NKG2DL MICA induces protective immunity 
against a challenge with wild-type glioma cells in mice that had previously rejected MICA-
transduced glioma cells (Fig. 6.7.C) (207, 241). Finally, the peripheral vaccination with 
irradiated Ad-MICA-infected cells after the 
cells delayed the growth of syngeneic gliomas and promoted immune activation in the NK 
and T cell compartments (Fig. 6.7.E,F, 6.8). NKG2DL expression and consequent activation 
of NK cells and T cells may thus provide a novel therapeutic approach for the treatment of 
human gliomas. If the magnitude of the effect achieved with peripheral vaccination, this is, a 
median prolongation of survival from 27.5 in control animals to 46 days in SMA-560.Ad-
MICA vaccinated animals, with 2 of 6 animals (33%) alive and asymptomatic after 90 days 
(Fig. 6.7.D), could be transferred into the human situation, this would be a major advance, 
compared, e.g., with all chemotherapy trials performed in the recent 20 years (160). 
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Summary 
 
The immune system is essential in guarding the body against pathogens and tumor cells. 
Immunity has many facets, the dichotomy separating innate and adaptive immunity in the last 
decades, nowadays emerges as evolutionary consecutive with interdepending pathways and 
continuative receptor evolution. The complexicity of the somatic rearrangement of TCR genes 
guarantees virtually infinite variability in the specificity of TCRs expressed on naïve T cells, 
i.e. costimulated via CD27/CD70 interaction, but relies on the body’s rapid innate defense 
MA-560 
mors. The tumorigenicity of CD70-expressing glioma cells was  altogether abrogated when  
GF-β signalling was blocked. Moreover, mice surviving the s.c. CD70 glioma challenge 
mechanisms where receptors with consistent PRR recognise PAMP transmitting valuable 
signals to the adaptive immune system, i.e. via TLR, activated by ssRNA. Thus it is not 
astonishing that TLR are accounted as the interface between innate and adaptive immunity 
(242). It actually becomes clear that the innate arm of immunity links with its adaptive 
counterpart in tumor immune surveillance also via NK cells, i.e. with NKG2D as a receptor of 
an activatory pathway. Proteomic analysis of unactivated and activated human NK cell 
membrane-enriched fractions demonstrated that activated NK cells can efficiently stimulate T 
cells, since NK cells upregulate MHC class II molecules and multiple ligands for TCR 
costimulatory molecules (243). Combining these findings with our improved understanding of 
cancer biology has helped to understand how to configure immunological strategies against 
the “hallmarks of cancer” (244). Encounter the escape of immune surveillance and the 
immunosuppressive properties of glioma cells (chapter 1), i.e. by TGF-β, are the major 
challenges in our laboratory and were the main topics in my Ph.D. work. 
 
In chapter 2 we describe the approach of overcoming immunosuppression by stimulating the 
immune system via CD70 (CD27 ligand) which promotes the expansion of primed 
lymphocytes by enhancing cell survival. Surprisingly, we had previously observed that CD70 
aberrantly expressed on human glioma cells promoted immune cell apoptosis and inhibited 
alloreactive lysis (109). In the mouse system we found that the ectopic expression of CD70 in 
mouse glioma cells enhanced apoptosis of T, B and NK cells in coculture, but nevertheless 
promoted glioma cell lysis by NK cells in vitro. In nude mice, CD70 expression in SMA-560 
gliomas delayed their growth upon s.c. or intracerebral (i.c.) inoculation, suggesting a role for 
CD70/CD27-dependent NK cell activity in tumor surveillance. In syngeneic 
immunocompetent mice, CD70 allowed the rejection of s.c. and i.c. implanted S
tu
T
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subsequently also rejected wild-type glioma cells administered i.c.. Similarly, CD70-
xpressing GL-261 gliomas were rejected in syngeneic C57BL/6 mice while glioma growth 
eradication of solid 
mors. 
proliferation. PBL or purified T cells, cocultured with TGF- -releasing LN-308 glioma cells 
e
was restored in CD27-/- mice, suggesting that the CD70/CD27 interaction recruited a tumor-
specific T cell repertoire and induced tumor-specific memory. Altogether, these observations 
indicate that the net effect of aberrant CD70 expression in gliomas was immune stimulatory 
rather than immune paralytic and encourage its application in tumor immunotherapy. 
 
Activating the immune system on the basis of activatory information at the level of innate 
immunity being transduced to adaptive immunity were the efforts described in chapter 3. 
Stabilized synthetic RNA oligonucleotides (ORN) and protected messenger RNA (mRNA) 
such as protamine-condensed mRNA were recently discovered to be immune stimulatory 
through their recognition by TLR7 and TLR8. We tested whether these danger signals would 
be capable of triggering anti-tumor immunity when injected locally into an established tumor 
as it has been shown for other danger signals. Using the mouse glioma tumor cell line SMA-
560 in syngeneic VM/Dk mice, we showed that intra-tumor injections of protamine-
stabilized mRNA induced tumor regression and lasting anti-tumor immunity. Residual RNA-
injected tumors showed CD8 infiltration. Injections of protamine-protected mRNA and intra-
tumor injection of naked mRNA also resulted in anti-tumor immunity. RNAs are labile 
molecules with a short half live. They do not trigger side effects such as splenomegaly in 
treated mice. These observations indicate that mRNAs are potent and safe danger signals that 
are relevant in the context of active immunotherapy strategies for the 
tu
 
As one of the major aspects in tumor immune escape mechanisms, TGF-β 
immunosuppression and its abrogation is one of the most pursued aims in our laboratory. In 
chapter 4 we characterized the effects of a novel TGF-βRI kinase inhibitor, SD-208, on the 
growth and immunogenicity of mouse SMA-560 and human LN-308 glioma cells in vitro 
and the growth of, and immune response to, intracranial SMA-560 gliomas in syngeneic 
VM/Dk mice in vivo. SD-208 inhibited the growth inhibition of TGF-β-sensitive CCL64 
cells mediated by recombinant TGF-β1 or TGF-β2, or of TGF-β-containing glioma cell 
supernatant, at an EC50 of 0.1 µM. SD-208 blocked autocrine and paracrine TGF-β signalling 
in glioma cells as detected by the phosphorylation of Smad2 or TGF-β reporter assays and 
strongly inhibited constitutive and TGF-β-evoked migration and invasion, but not viability or 
β
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in the presence of SD-208, exhibited enhanced lytic activity against LN-308 targets. The 
release of IFN-γ and TNF-α by these immune effector cells was enhanced by SD-208 
whereas the release of IL-10 was reduced. SD-208 restored the lytic activity of polyclonal 
NK cells against glioma cells in the presence of recombinant TGF-β or of TGF-β-containing 
glioma cell supernatant. The oral bioavailability of SD-208 was verified by demonstrating 
the inhibition of TGF-β-induced Smad phosphorylation in spleen and brain. Systemic SD-
08 treatment initiated three days after the implantation of SMA-560 cells into the brains of 
g 
ll 
lines express furin mRNA and protein, exhibit furin-like protease activity and release active 
furin into the cell culture supernatant. FLP activity was not modulated by exogenous TGF-β or 
by neutralizing TGF-β antibodies. Exposure of LN-18 and T98G glioma cell lines to the furin 
inhibitor, dec-RVKR-cmk, inhibited processing of the TGF-β  and TGF-β  precursor 
s and consequently the release of mature bioactive TGF-β molecules. Ectopic 
xpression of PDX, a synthetic antitrypsin analog with antifurin activity, in the glioma cells 
 
 
stimulate tumor immunity mediated by NK and CD8+ T cells. In chapter 6 we report that 
human glioma cells express the NKG2D ligands MICA, MICB and members of the ULBP 
family constitutively. However, glioma cells resist NK cell cytolysis due to high MHC class I 
antigen expression. Plasmid-mediated or adenovirus-mediated (Ad-MICA) overexpression of 
2
syngeneic VM/Dk mice prolonged their median survival from 18.6 to 25.1 days. Histological 
analysis revealed no difference in blood vessel formation, proliferation or apoptosis. 
However, animals responding to SD-208 showed an increased tumor infiltration by NK cells, 
CD8 T cells and macrophages. These data define TGF-βRI kinase inhibitors such as SD-208 
as promising novel agents for the treatment of human malignant glioma and other conditions 
associated with pathological TGF-β activity. 
 
Subtilisin-like proprotein convertases such as furin are thought to mediate TGF-β processin
and thus enhance its bioavailability. In chapter 5 we report that human malignant glioma ce
1 2
molecule
e
inhibited FLP activity, TGF-β processing and TGF-β release. Thus, subtilisin-like proprotein
convertases may represent a novel target for the immunotherapy of malignant glioma and other
cancers or pathological conditions characterized by enhanced TGF-β bioactivity. 
 
The failure of conventional cancer therapy renders glioblastoma an attractive target for 
immunotherapy. Tumor cells expressing ligands of the activating immunoreceptor NKG2D 
MICA in glioma cells enhanced their sensitivity to NK and T cell lysis in vitro and markedly 
delayed the growth of subcutaneous and intracerebral LN-229 human glioma cell xenografts 
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in nude mice, and of SMA-560 gliomas in syngeneic VM/Dk mice. Glioma cells forming 
progressive tumors after implantation of stably MICA-transfected human LN-229 cells have 
lost MICA expression indicating a strong selection against MICA expression in vivo. 
Rejection of MICA expressing SMA-560 cells in VMDk mice resulted in protective immunity 
to a subsequent challenge with wild-type tumor cells. Finally, the growth of syngeneic 
intracerebral SMA-560 tumors was inhibited by the peripheral vaccination with Ad-MICA-
infected irradiated tumor cells, and vaccination resulted in the immune cell activation in the 
NK and T cell compartments in vivo. These data commend MICA immunogene therapy as a 
novel experimental treatment for human malignant gliomas. 
 
In my Ph.D. research I have thus explored several novel approaches aiming at engaging
immune surveillance via direct activation of adaptive immunity or by more indirect ways via
innate pathways and at an improved unders
 
 
tanding of the immune-paralysing capacities of 
lioma cells. While the connections between these various aspects of glioma biology may not 
surveillance is mediated by immune effector cells that selectively kill cancer cells. Activated T 
and NK attack their targets by the expression of death ligands (245, 246) and by secretion of 
cytotoxic granules (87, 247) and thus seek to activate both the death receptor and the 
intracellular apoptotic pathway. An apoptosis-resistant target cell is therefore less susceptible 
to immune-mediated lysis. Sensitization of tumor cells for apoptotic stimuli could therefore 
vide a source 
f antigens that can be taken up and presented by professional APC, resulting in an anti-tumor 
g
be apparent at first sight, there are good reasons for taking a combined look at the complex 
interactions of innate and adaptive immunity and tumor immunology. Tumor immune 
enhance the efficacy of ongoing anti-tumor immune responses. Further, activation of the 
costimulatory pathways, e.g. using CD70 transgenes or ssRNAs may be beneficial when the 
tumor may strike back and induce apoptosis in tumor-infiltrating lymphocytes by various 
mechanisms, including the expression of CD95/FasL, HLA-G or TGF-β (140, 248-250). 
Finally, therapeutic induction of apoptosis via these mechanisms is thought to pro
o
immune response. The mounting of a productive anti-tumor immune response may be 
prevented by immune-inhibitory signals sent out by the tumor itself. Therefore, a 
costimulation-based reduction of large tumor masses may require the simultaneous relief of 
tumor-dependent immunosuppression in order to be followed by a productive immune 
response that can finally clear residual glioma cells dispersed in the brain.  
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Whether the emerging concepts outlined in this Ph.D. thesis have the potential to improve 
current glioma treatments will, of course, have to be explored in further models. Thus, the 
present work finally was driven by what is expressed by Camille Flammarion’s woodcut 
from: "L'Atmosphère, et la Météorologie populaire", Paris 1888”, which gives a symbolical 
description of the myth of the destruction of the ancient world view by the Copernican 
Revolution and the ensuing loss of the central position of man in cosmos. 
 
 
Man penetrating the celestial spheres reminds me of how encouraging it is to find out a new 
immunological tool, knowing how far it is from being transferred from “bench to bedside”, 
imposingly documented by this woodcut: “how deep is the urge (…) to break the familiar 
horizon, and how independent it is from the question of its practical realisability”. 
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Zusammenfassung 
 
Das Immunsystem schützt unseren Körper vor Pathogenen und Tumorzellen, als Spezialfall. 
Die Immunität hat viele verschiedene Facetten, wobei die in den letzten Jahrzehnten 
propagierte Zweiteilung der angeborenen und adaptiven Immunität heute vielmehr als 
evolutionär aufeinander aufbauend, mit voneinander abhängigen Signaltransduktionspfaden 
und ontogenetisch verwandten Rezeptoren, angesehen wird. Die Komplexität der somatischen 
Rekombination der TCR-Gene ermöglicht eine nahezu unendliche Variabilität der Spezifität 
von TCR. Diese werden auf naiven T-Zellen exprimiert. Diese Zellen können u.a. durch 
kostimulatorische Interaktionen via CD27/CD70 stimuliert werden, sind aber von einer 
schnellen Antwort der angeborenen Immunität abhängig. Rezeptoren mit konsistenten PRRs 
erkennen PAMP und leiten Signale an das adaptive Immunsystem weiter. Die Familie der 
TLR spielt hier eine wichtige Rolle. In dieser Arbeit waren vor allem die Interaktionen der 
TLR7-9 mit ihren jeweiligen Liganden bei der Abwehr von Tumorzellen von Bedeutung. Es 
ist deshalb nicht erstaunlich, dass die TLR als Schnittstelle zwischen angeborener und 
daptiver Immunantwort angesehen werden (242). Bei der Immunüberwachung des Körpers 
ind nicht nur wie bisher bekannt T- und B-Zellen, sondern auch NK-Zellen beteiligt, die z.B. 
tion dieser 
Befunde mit unserem verbesserten Verständnis der Tumorbiologie hilft uns zu verstehen, wie 
wir immunologische Strategien konfigurieren müssen, um den Mechansimen, die einen 
Tumor kennzeichnen, etwas entgegenzusetzen können (244). Gliomzellen entziehen sich der 
Immunüberwachung durch immunsuppressive Mechanismen. Dabei werden das angeborene 
und adaptive Immunsystem, u.a. TGF-β-vermittelt supprimiert. Die Überwindung solcher 
immunsuppressiver Mechanismen waren die Hauptpunkte meiner Doktorarbeit. 
 
In einem Ansatz wurde versucht, diese Immunsuppression durch Stimulation des 
Immunsystems über CD70 (CD27 Ligand) zu durchbrechen, welches die Expansion 
geprimter Lymphozyten dadurch unterstützt, dass es deren Überlebensrate erhöht. 
Interessanterweise konnten wir in früheren Untersuchungen feststellen, dass aberrant auf 
Gliomzellen exprimiertes CD70 die Apoptose von Immunzellen begünstigt und die 
alloreaktive Lyse inhibierte. Dennoch fanden wir heraus, dass die ektope Expression von 
a
s
über den aktivatorischen Rezeptor NKG2D aktiviert werden. Proteomanalysen von 
angereicherten nicht aktivierten und aktivierten NK-Zellmembranen zeigten, dass aktivierte 
NK-Zellen T-Zellen sehr effizient stimulieren können, da sie MHC-Klasse II-Moleküle und 
multiple TCR-kostimulatorische Liganden  hochregulieren (243). Die Kombina
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CD70 auf murinen Gliomzellen in einer Langzeit-Kokultur mit T-, B- und NK-Zellen zu 
iner erhöhten Apoptoserate dieser Immunzellen führte. Während einer kurzen 
Noch nicht 
bgeräumtes, RNA-behandeltes Tumorgewebe zeigte eine Infiltration durch CD8-T-Zellen. 
e
Kokultivierung in einem Lyseassay wurden jedoch auch die Gliomzellen von NK-Zellen 
lysiert. In Nacktmäusen verzögerte eine CD70-Expression auf SMA-560-Gliomzellen deren 
subkutanes und intrakranielles Wachstum, was eine Beteiligung der CD70/CD27-abhängigen 
NK-Zellaktivität bei der Immunüberwachung gegen Tumorzellen suggeriert. In syngenen 
immunkompetenten Mäusen vermittelt CD70 eine Abstoßung von subkutan und intrakraniell 
implantierten SMA-560-Tumoren. Die Tumorigenität der CD70-exprimierenden Gliomzellen 
wurde durch eine Blockade des TGF-β-Signaltransduktionsweges unterbunden. Zudem 
stiessen Mäuse, die subkutane CD70-exprimierende Tumoren abgestossen hatten, später 
selbst intrakraniell implantierte Wildtyp-Gliomzellen ab. Gleichermassen wurden CD70-
exprimierende GL-261-Gliome in syngenen C57BL/6-Mäusen abgestossen, während das 
Gliomwachstum in CD27-/- Mäusen wiederhergestellt werden konnte. Dies suggeriert, dass 
die CD70/CD27-Interaktion ein Tumor-spezifisches T-Zellrepertoire und Tumor-spezifisches 
immunologisches Gedächtnis induziert hat. Zusammengefasst zeigen diese Beobachtungen in 
vivo einen deutlichen immunstimulatorischen Beitrag von CD70, dies ermutigt zu einer 
Anwendung von CD70 in zukünftigen Immuntherapien. 
 
Auf eine andere Weise haben wir versucht, das adaptive Immunsystem indirekt über eine 
Aktivierung der angeborenen Immunität zu stimulieren. Vor Kurzem wurde die 
immunstimulatorische Bedeutung von stabilisierter, synthetischer RNA und geschützter 
Boten-RNA (mRNA), wie auch Protamin-kondensierter RNA, mit deren Rezeptoren TLR7 
und TLR8, erkannt. Wir haben überprüft, ob diese Danger-Signale anti-Tumor-Immunität 
vermitteln können, wenn man sie lokal in einen bereits etablierten Tumor injiziert, so wie es 
für andere Danger-Signale bereits gezeigt wurde. Die intratumorale Injektion von Protamin-
stabilisierter mRNA bewirkt einen Tumorrückgang und eine anhaltende anti-Tumor-
Immunität in unserem syngenen SMA-560-Gliom-VM/Dk-Mausmodell. 
a
Injektionen von Protamin-geschützter mRNA und intra-Tumor-Injektionen von nackter 
mRNA führten ebenfalls zu einer anti-Tumor-Immunität. Da RNA-Moleküle sehr instabil 
sind und eine kurze Halbwertszeit besitzen vermitteln sie auch keine unerwünschten 
Nebenwirkungen wie etwa Splenomegalien oder eine Verminderung von Immunzellen in 
Mäusen. Diese Beobachtungen prädestinieren mRNAs als potente und nebenwirkungsfreie 
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Danger-Signale im Kontext einer aktiven immuntherapeutischen Strategie gegen etablierte 
Tumoren. 
 
Die Immunsuppression durch TGF-β ist einer der grundlegensten Mechanismen, durch die 
Tumoren einer Immunüberwachung entkommen, die Aufhebung dieser Immunsuppression 
ist eines der Hauptziele in unserer Arbeitsgruppe. In unseren Arbeiten beschreiben wir einen 
neuen TGF-βRI-Kinase-Inhibitor, SD-208, seinen Effekt auf Wachstum und Immunogenität 
von murinen SMA-560 und humanen LN-308 Gliomzellen in vitro und das Wachstum und 
die Immunantwort auf intrakraniell inokulierte SMA-560-Gliome in syngenen VM/Dk-
Mäusen in vivo. SD-208 hebt die TGF-β-vermittelte (rekombinantes TGF-β1 oder TGF-β2, 
oder TGF-β-haltiger Gliomzellüberstand) Wachstumsinhibition von TGF-β-sensitiven 
CCL64-Zellen mit einem EC50-Wert von 0.1 µM auf. Dabei blockiert SD-208 autokrine und 
parakrine Signaltransduktionswege in Gliomzellen, was durch die Phosphorylierung von 
Smad2 und in TGF-β-Ρeporter-Assays gezeigt wurde. Weiterhin wurde auch die konstitutive 
und TGF-b-evozierte Migration und Invasion stark gehemmt, die Viabilität und Proliferation 
jedoch nicht beeinflusst. PBL oder aufgereinigte T-Zellen zeigten eine erhöhte lytische 
Aktivität gegenüber LN-308-Targetzellen, wenn sie mit TGF-β-sezernierenden LN-308-
liomzellen in der Anwesenheit von SD-208 kokultiviert wurden. Die Freisetzung von IFN-γ 
und TNF-α durch Immuneffektorzellen wurde durch SD-208 erhöht, wohingegen die 
Freisetzung von IL-10, das als immuninhibitorisch gilt, reduziert wurde. SD-208 war in der 
Lage, die lytische Aktivität polyklonaler  NK-Zellen gegenüber Gliomzellen in Anwesenheit 
von rekombinantem TGF-β oder von TGF-β-haltigem Gliomzellüberstand 
wiederherzustellen. Die orale Bioverfügbarkeit von SD-208 wurde durch die Inhibition einer 
TGF-β-vermittelten Smad-Phosphoryierung in der Milz und im Gehirn gezeigt. Eine 
systemische Gabe von SD-208 verlängerte die mittlere Überlebensspanne von VM/Dk-
Mäusen, die mit syngenen, intrakraniell 3-Tage-präimplantierten SMA-560 Zellen  inokuliert 
wurden, von 18,6 auf 25,1 Tage. Histologische Untersuchungen ergaben keine Beeinflussung 
auf die SD-208-Behandlung ansprachen, eine Erhöhung an Tumor-Infiltration durch NK-
+ β
 
G
der Blutgefäßbildung, Proliferation oder Apoptose durch SD-208. Jedoch zeigten Tiere, die 
Zellen, CD8 -T-Zellen und Makrophagen. Diese Daten beschreiben TGF- RI-Kinase-
Inhibitoren wie SD-208 als vielversprechende neue Agenzien zur Behandlung humaner 
maligner Gliome. 
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Es wird vermutet, dass TGF-β durch Subtilisin-ähnliche Proprotein-Konvertasen wie Furin
prozessiert wird. Hum
 
ane maligne Gliomzelllinien exprimieren Furin-mRNA und -Protein, 
eisen Furin-ähnliche Protease-Aktivität auf und sezernieren Furin in den Extrazellulärraum, 
 
 
 
 
d 
 
 
 
 
 
 
 in vivo. Diese Daten legen die MICA-Immunogentherapie als eine neue 
xperimentelle Behandlungsstrategie für humane maligne Gliome nahe. 
 
w
respektive den Zellkulturüberstand. Die Furin-Aktivität wurde durch die exogene Zugabe von
TGF-β oder  neutralisierendem TGF-β Antikörper nicht verändert. Die Freisetzung von
bioaktivem TGF-β und die Prozessierung von TGF-β1 und TGF-β2 wurde in den
Gliomzelllinien LN-18 und T98G durch den Furin-Inhibitor dec-RVKR-cmk verhindert. Die
ektope Expression von PDX, einem synthetischen Antitrypsin-Analogon mit anti-Furin-
Aktivität, hemmt die Furin-Aktivität in Gliomzellen, wie auch die TGF-β-Prozessierung un
die TGF-β-Freisetzung. Demnach könnten Subtilisin-ähnliche Proprotein Konvertasen ein
neues Zielmolekül für die Immuntherapie maligner Gliome und anderer Krebsarten so wie
anderer Erkrankungen mit erhöhter TGF-β-Bioaktivität darstellen. 
 
Das Versagen der herkömmlichen Standardkrebstherapien beim Glioblastom lässt dieses als 
einen attraktives Modelltumor der Immuntherapie erscheinen. Tumorzellen, die den Liganden 
des aktivatorischen Immunrezeptors NKG2D exprimieren, stimulieren die Tumorimmunität, 
die durch NK- und CD8+-T-Zellen vermittelt wird. Humane Gliomzellen exprimieren die
NKG2D-Liganden MICA, MICB und Mitglieder der ULBP-Familie konstitutiv. Jedoch 
widerstehen Gliomzellen einer NK-Zell-vermittelten Zytolyse aufgrund einer hohen 
Expression von MHC-Klasse I-Molekülen. Die transgene Überexpression von MICA durch 
Plasmide oder Adenoviren (Ad-MICA) in Gliomzellen erhöht deren Sensitivität gegenüber 
NK- und T-Zell-Antworten in vitro und verzögert das Wachstum subkutaner und 
intrazerebraler humaner LN-229-Gliomzellen in einem Nacktmaus Xenograft- und einem 
syngenen SMA-560-VM/Dk-Maus-Modell. Gliomzellen, die progressive Tumoren nach einer 
Inokulation stabil MICA-transduzierter humaner LN-229-Gliomzellen bilden, verlieren ihre
MICA-Expression vermutlich durch einen starken Selektionsdruck in vivo. Die Abstossung 
MICA-exprimierender SMA-560-Zellen in VM/Dk Mäusen führte zu protektiver Immunität, 
selbst nach einer anschliessenden Reexposition mit Wildtyp-Tumorzellen. Abschliessend 
wurde das Wachstum syngener intrakranieller SMA-560-Tumoren untersucht. Das Wachstum
dieser Tumoren wurde nach einer peripheren Vakzination mit Ad-MICA-infizierten
bestrahlten Tumorzellen gehemmt und führte zu einer Immun-Aktivierung in den NK- und T-
Zellkompartinenten
e
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Während meiner Doktorarbeit habe ich an verschiedensten neuen Ansätzen zur Therapie 
maligner Gliome mitgewirkt. Diese basierten nicht nur auf der Wiederherstellung einer Tumor-
Immunüberwachung durch direkte Aktivierung der adaptiven Immunantwort, sondern auch auf 
Mechanismen der angeborenen Immunität, die schliesslich auch zu einer Aktivierung der 
adaptiven Immunität führten. Während die Verbindungen zwischen diesen verschiedenen 
Aspekten der Gliombiologie nicht sofort ersichtlich sind, ist es dennoch unumgänglich, sich 
mit den komplexen Zusammenhängen zwischen angeborener und adaptiver Immunantwort und 
der Tumorimmunologie zu befassen. Die Tumor-Immunüberwachung wird von 
Immuneffektorzellen vermittelt, die selektiv apoptotischen und nicht-apoptotischen Zelltod in 
Krebszellen induzieren können. Werden diese Zellen jedoch in ihren Mechanismen 
supprimiert, etwa durch TGF-β, so können Mechanismen die zu einer Erhaltung eines T-
Zellpools, z.B. nach einer Aktivierung durch CD70, dienen, dennoch eine Immunantwort 
rzeugen, die es erlaubt bereits etablierte Tumoren zu vernichten.  Weiterhin können 
 
e
Aktivierungsprozesse induziert werden, die der angeborenen Immunität angehören, wie es die 
Toll-ähnlichen Rezeptoren 7 und TLR8 durch einen Kontakt mit ihrem Liganden, der
Einzelstrang-RNA, oder MICA als Ligand von NKG2D, vermögen. Jedoch können Tumoren 
auch diesen Mechanismen dadurch entgegenwirken, dass sie in Lymphozyten Apoptose 
induzieren, etwa durch CD95/FasL-Expression oder diese immunsupprimieren durch HLA-G 
oder TGF-β (140, 248-251). Schliesslich führt die Abstossung von Tumorgewebe zu einer 
Quelle von Antigenen, die von professionellen Antigen-präsentierenden Zellen, wie es DC 
sind, aufgenommen und präsentiert werden können (252-256).  
 
Ob die in dieser Doktorarbeit aufgezeigten Konzepte das Potenzial haben, die bestehenden 
Gliom-(Immun)-therapien zu verbessern, muss in weiteren Modellen untersucht und 
verifiziert werden. Deshalb möchte ich die der vorliegenden Arbeit zugrundeliegende 
Motivation mit einem Holzschnitt von Camille Flammarion’s beschreiben, "L'Atmosphère, et 
la Météorologie populaire", Paris 1888”: dieser Holzschnitt stellt den Mythos von der 
Zertrümmerung des antiken Weltbildes durch die Kopernikanische Revolution und dem 
darauffolgenden Verlust der zentralen Stellung des Menschen im Kosmos symbolisch dar. 
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Der Mensch durchbricht die Himmelssphären erinnert mich daran, wie ermutigend es ist ein 
neues immunologisches Werkzeug zu entdecken und wie fern dessen Umsetzung in die 
alltägliche Praxis einer therapeutischen immunologischen Behandlung in der Klinik dennoch 
ist. Dieser Holzschnitt aus dem 16. Jahrhundert dokumentiert eindrucksvoll: „Wie tief der 
Drang (...) zur Durchbrechung des gewohnten Horizontes verwurzelt ist, und wie unabhängig 
er ist von der Frage seiner praktischen Realisierbarkeit”. 
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